Speakers - Sachs Associates

B I O T E C H I N E U R O P E I N V E S T O R F O R U M 

12th Annual 

BIOTECH IN EUROPE 

INVESTOR FORUM 

1st-2nd October 2012 

Hilton Zurich Airport Hotel, Switzerland 

Conference Guide 

www.sachsforum.com 

WELCOME PHARMA LICENSING GROUPS 

SPEAKERS 

PRESENTING COMPANIES SUPPORTING ORGANISATIONS 

ORGANISERS

Welcome 

Sachs Associates are delighted to welcome you to the: 

12th Annual 

Biotech in Europe 

Investor Forum 

1st-2nd October 2012 

Hilton Zurich Airport Hotel, Switzerland 

Sachs Associates are delighted to welcome you to the 12th Annual Biotech in Europe Investor 

Forum. Following the success of previous years, the forum once again provides access to an 

exciting cross-section of venture-funded and small-cap companies with leading investors and 

pharmas. 

This Forum is highly transactional and is comprised of a series of panels and presentations 

from leading investment, pharmaceutical and biotech companies, each one providing an expert 

outlook on growth and investment activity in Europe’s Biotech industry. 

The programme highlights the current issues surrounding the evolving M&A market, the Private 

Equity & Venture Capital environment and a special session on major trends in Partnering. Plus, 

this year’s programme features more than 70 company presentations from a range of publicly 

listed and private life science companies looking to raise finance and/or find partners. 

General Information 

The registration desk will be open from 8am on October 1st and from 8.15am on October 2nd 

although you are welcome to join the event at any time. Please collect a copy of the agenda for 

information on timing and room allocation for each session. 

Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to 

all participants. 

A Networking Lunch will be set up in the Zurich A & B rooms. 

Coffee stations will be set up in the Zurich A & B rooms and the presentation rooms throughout the 

event. 

Request for Presentations 

Please use the agenda to mark off presentations that you are interested in and email your request 

to zoe@sachsforum.com after the conference. We will endeavour to send you the requested 

presentations as soon as we have been granted permission to do so by that specific presenter. 

Please note that we DO NOT have copies of the slides that are shown during the conference. 

next u 


SPEAKERS 


ORGANISERS

Events Diary 

For regular updates, sponsorship, presenting and attending opportunities 

and further information regarding any of our future events please contact 

Zoe Harris on zoe@sachsforum.com 

6th Annual 

European Life Science CEO Forum 

For Partnering & Investing 

5th – 6th March 2013 • Zurich • Switzerland 

Back for its sixth year, this exclusive and highly transactional partnering event is a must for 

companies wishing to meet with their peers, engage with leading investors and forge new 

partnerships. 

Building on the success of this year’s event, the forum will provide an excellent platform to gain 

insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the 

Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants. 

The conference will feature up to 8 presentations by large to mid size pharmaceutical companies 

looking for strategic alliances/partners. 

Do not miss out on this great opportunity to meet emerging companies, leading global investors and 

Big Pharma representatives! 

Annual 

Cancer Bio Partnering Forum 

Promoting Public & Private Sector, Collaboration 

& Investment in Drug Development 

21st – 22nd May 2013 • Boston • USA 

13th Annual 

Biotech in Europe Investor Forum 

30th September – 1st October 2013 • Zurich • Switzerland 


SPEAKERS 

t back 


ORGANISERS

Pharma 

Licensing 

Groups 

represented 

at the 

Forum 

Pharma Licensing Groups 

www.amgen.co.uk 

www.astellas.eu 

www.biogenidec.co.uk 

www.helsinn.com 

www.ipsen.com 

www.jnj.com 

www.menarini-biotech.com 

www.merck.com 

www.merckserono.co.uk/en/index.html 

www.norgine.com 

www.novartisoncology.com 

www.novartisvaccines.com 

www.pierre-fabre.com 

www.roche.com 

www.sanofi.com 

www.nycomed.com 


SPEAKERS 


ORGANISERS

Speakers 

Alexey Eliseev, Managing Director, Maxwell Biotech 

Alexey received his PhD in Chemistry from Moscow State University and MBA from the Sloan School of Management at the 

Massachusetts Institute of Technology. His career includes over 17 years of experience in academia, biotechnology industry 

and venture capital. 

Dr. Eliseev has been working in the United States and Europe since 1992. Following three years of postdoctoral research in 

Germany as an Alexander von Humboldt Fellow and in the US, he joined faculty at the department of Medicinal Chemistry, 

University at Buffalo in 1995 where he was awarded tenure in 2000. In 1999 he co-founded the company Therascope (later 

Alantos Pharmaceuticals) with a number of prominent founders including French Nobel Laureate Jean-Marie Lehn. The 

company used a novel drug discovery technology developed in several academic labs, including Eliseev’s group in Buffalo. 

He joined the company in 2000 and later became Chief Technology Officer of Alantos and President of its US division. Alantos 

was acquired by Amgen in 2007 for $300 million. 

Over the recent years Alexey was involved in starting several biotech companies as a scientist and entrepreneur, including AC 

Immune (Switzerland) and Boston BioCom (US). Alexey has been working with the Russian-based Maxwell Biotech Venture 

Fund as its Managing Director since 2009. He is responsible for international activity of the Fund and has managed numerous 

deals with portfolio companies in the US and Europe. 

Allan Marchington, Partner, Apposite Capital 

Allan is a founder and Partner at Apposite Capital a London based healthcare investor. Allan was formerly at Abingworth 

management and prior to this was a member of Millennium Pharmaceuticals management team as an Senior Vice President 

with responsibility for technology Investments. He also served as Chairman of Millennium Pharmaceuticals in Europe. Allan 

joined Millennium following their acquisition in July 2000 of Cambridge Discovery Chemistry, where he was CEO and founder. 

Allan began his career as a medicinal chemist at Pfizer Central Research. 

Allan is a Board member of the BioIndustry Association, Ambit Biosciences Inc., Ambrx Inc., Anaphore Inc., and Convergence 

Pharmaceuticals Ltd. 

Dr Andreas Caduff, CEO, BioVoition AG 

Andreas was born in 1971 and is a Swiss citizen. He held various positions in the pharmaceutical and medical device 

industry. In his previous position he was serving as CTO of Solianis Monitoring AG, a company focusing on noninvasive 

glucose monitoring. At Solianis, he orchestrated the overall technology and product development, experimental/clinical 

study strategies, regulatory considerations, external technical communication and interaction with the industrial/scientific 

community, regulatory bodies as well as the investor’s community. He is an expert in physiological monitoring techniques 

and involved physiological/metabolic processes, combining the expertise in various fields relevant to the development, 

industrialisation and commercialisation of such technologies. Dr. Caduff is a frequent invited speaker at industrial and 

scientific conferences and meetings on physiological monitoring, mobile Health and related subjects. He has innovated 

numerous patents and co-authored several dozen scientific publications in peer reviewed journals. He holds a BSc degree 

in Chemistry from the University of Applied Science, Winterthur, Switzerland, an MSc degree in Biotechnology and a Ph.D. in 

Biophysics from the University of Teesside, UK and the Hebrew University of Jerusalem, Israel. 

Anne Altmeyer, Executive Director Business Development & Licensing, Novartis Oncology 

Anne is a Vice President in Business Development and Licensing in the Oncology Business Unit at Novartis, USA. Her 

responsibilities are to in-license or acquire Oncology assets that can further strengthen the Novartis Oncology portfolio. In 

this role, she identifies, evaluates, and negotiates transactions for oncology opportunities. She also manages several ongoing 

alliances. 

Anne has over 15 years of experience in the Pharmaceutical Industry working in positions of increasing responsibilities in 

Research, Development, and Business Development and Licensing. Anne joined the Oncology Project Management group of 

Novartis in 2004 as a Project Leader. There she led numerous multidisciplinary Project Teams through the generation and 

implementation of strategies for various compounds in development and on the market. Before joining Novartis, Anne worked 

as a Project Manager at Merck & Co. for close to 4 years and as a Visiting Research Scientist for 2 years. 

Anne received her Ph.D. in Molecular Immunology from Strasbourg University, France. She then performed a postdoctoral 

fellowship at New York University School of Medicine, USA, and subsequently became a Research Associate at Cornell 

University Medical College, New York, USA. In addition to her scientific training, Anne also received a Master in Business 

Administration and a Master in Public Health from the University of Medicine and Dentistry of New Jersey/Rutgers, USA. 

t back :: next u 


SPEAKERS 


ORGANISERS


Arthur Franken, Partner, Gilde Healthcare Partners 

Arthur joined Gilde in 2001. He led the investments in Conatus Pharmaceuticals, FlowCardia (acquired by C. R. Bard), 

Moximed and MTM Laboratories (acquired by Roche). He has been involved in numerous investments and divestments 

including Ablynx (IPO on Euronext), Agendia, uniQure, BG Medicine (IPO on NASDAQ) and Pieris. 

He represents Gilde on the board of Moximed and Symphogen. He served as a board member for FlowCardia (until its trade 

sale to C. R. Bard), MTM Laboratories (until its trade sale to Roche) and observed on the boards of Agendia and AMT (until 

its IPO on Euronext). 

Prior to joining Gilde he gained experience in cardiovascular research at the Leiden/Amsterdam Center for Drug Research 

and TNO. He holds a masters degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch 

national. 

Bassam Damaj, CEO & President, Apricus Biosciences 

Bassam has been the President, Chief Executive Officer and a director since December 2009. Dr. Damaj served as Chairman 

of the Board of Directors from October 2010 to April 2012. He has served as a member of our ad hoc Finance Committee 

since 2010. He is the co-founder of Celltek Biotechnology and served as a director from 1997 until 2000. He is also the 

founder of R&D Healthcare. He is a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific 

Officer and a director of Bio-Quant since its inception in June 2000. He has also served as the Group Leader for the Office 

of New Target Intelligence and a Group Leader for immunological and inflammatory disease programs at Tanabe Research 

Laboratories, U.S.A., Inc., as a senior scientist and member of the senior staff board of the drug discovery department at 

Pharmacopeia Inc., and as a visiting scientist at Genentech Inc., Pfizer Inc. and the National Institutes of Health (NIH). He also 

served as an independent director for CreAgri, Inc. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval 

University and completed a postdoctoral fellowship in molecular oncology from McGill University. 

Dr Benedkt Timmerman, CEO, Genticel 

Benedikt founded Genticel (initially called BT Pharma) in 2001 and is currently CEO of the company. Prior to Genticel, 

Benedikt had a successful career at NOVARTIS (1996 – 2000) and its predecessor company SANDOZ (1991 - 1996). 

In these companies, he held various management positions, including Head of Biotechnology, Sandoz Seeds Eu, Senior 

Director Research & Development of Novartis Seeds – Eu, member of the European Executive Committee and member of the 

corporate Novartis Technology Licensing and Acquisition team. Dr Timmerman is also board member of several organisations, 

including BioMedicalAlliance, a French Biotech Association and Biotech Representative of the Industrials Club of the ‘Cancer 

Pole GSO’ in France. Benedikt is of Belgian nationality, holds a PhD in Molecular Genetics from the University of Ghent, 

Belgium (1986) and an MBA from INSEAD, Fontainebleau, France (1990-1991). 

Bill Blair, BioQuarter 

Bill joined BioQuarter as the Head of Business Creation in April 2011. He is responsible for managing the launch of new 

companies from the BioQuarter portfolio, as well as leading a team of professionals in the development of further new 

businesses based on world-leading medical research from the University of Edinburgh’s College of Medicine and Veterinary 

Medicine and NHS Lothian. 

Prior to joining Edinburgh BioQuarter, Mr Blair was Investment Director at Scottish Widows Investment Partnership (SWIP) 

for eight years where he established and led its venture capital investment programme before setting up his own venture 

capital strategic consultancy business, HVS Advisers. Mr Blair also previously headed up pharmaceutical company research 

for stockbrokers Nomura International, Fleming Securities and Greig Middleton. Before moving into investment, he worked in 

various commercial functions in the pharmaceutical industry for seven years. 

He holds a BSc (Hons) in Biological Sciences and an MSc in Business Administration from Edinburgh University. 



SPEAKERS 


ORGANISERS


Blake M. Paterson, Co-Founder & CEO, Cerecor, Inc. 

Physician-Executive / Entrepreneur with ability to lead drug hunting, translational medicine, product development, registration, 

finance & commercialization operations. Successful company builder with experience in licensing, marketing, strategic 

planning / portfolio management, global clinical research and affiliate operations within small and large organizations. Device 

and therapeutics tech transfer. Proven fundraiser, able to develop and communicate vision throughout the organization and 

in the marketplace. Successful in exploiting biomedical business opportunities in EU, North And South America; trilingual. 

Specialties: Clinical medicine, drug hunting, translational medicine, product development, registration, finance & 

commercialization operations in therapeutics and medical devices. Product licensing, marketing, strategic planning / 

portfolio management, global clinical research and affiliate operations within small and large organizations. Board Certified 

in Anesthesiology (ABA). 

Carina Schmidt, CEO, Athera Biotechnologies AB 

Carina is Chief Executive Officer, Athera Biotechnologies AB (publ), a Karolinska Development portfolio company. 

Ms Schmidt has experience from nearly 30 years in industry, mainly in business development, international marketing and 

product management within the Life Science area. Former management consultant, interim CEO and business advisor to 

several biotech start-ups. During years 1985 to 2000 she has worked with Pharmacia Biotech/Amersham Biosciences (now 

GE HealthCare), founded Grasp Bioscience AB in year 2000 and co-founded BioBusiness Partners Scandinavia in year 2006. 

Board Director in Genovis AB (publ) and Member of the Investment Committe in Innovationsbron AB Region Mitt. Lecturer in 

“Entrepreneurship in Biotechnology” at Umeå University and Umeå Biotech Incubator. 

Carlos Buesa, CEO, Oryzon 

Carlos earned his PhD in Biochemistry from the University of Barcelona in Spain. 

He has produced more than thirty papers and patents internationally, was a member of the cellular signaling research team 

in the Pharmacy Faculty at the University of Barcelona, held an EU post-doctoral fellowship in the Faculty of Medicine at the 

University of Ghent in Belgium, and later became Senior Investigator with the Flemish Institute of Biotechnology (VIB), also 

in Belgium. 

In 2000, he founded Oryzon, one of the strongest-growing biotech companies in Spain, and since 2001 he has served as 

Chief Executive Officer and Chairman of the Board of Directors. 

In addition, he sits on the board of other biotech companies like Neurotech Pharma and Oncnosis Pharma. He has taken the 

executive education programme (PADE) at the IESE Business School. 

Currently he is President of the Association of Catalan Biotechnology Companies CataloniaBio, and he is a member of the 

governing body of ASEBIO and of the Executive Committee of BioRegió de Catalunya, a new regional development model that 

has been set up with the aim of improving people’s quality of life through better coordination of the biotechnology activity 

being carried out in Catalonia. 

Carlos de Sousa, VP Corporate Licensing, Takeda Pharmaceuticals International GmbH 

Carlos is Vice President, Head of Commercial Licensing at Takeda. He was previously Vice President of Corporate Licensing 

at Nycomed, which was acquired by Takeda in 2011. 

Prior to joining Takeda-Nycomed, Dr. de Sousa was Chief Business Officer at Newron Pharmaceuticals SpA in Italy, where he 

was responsible for the company’s growth strategy, including its in- and out-licensing, and mergers & acquisitions activities. 

Before Newron, Dr. de Sousa was Global Head of Business Development and Licensing at Schwarz Pharma AG in Germany 

and prior to that served as Head of Global Negotiations at Novartis Pharma AG, based in Switzerland. At the latter he was also 

European Business Head for the Respiratory and Dermatology Franchise. 

Dr. de Sousa started his career in the pharmaceutical industry with Pfizer in 1989, as Medical Director in Portugal. He then 

joined the Pfizer Corporation in New York, USA, where he was initially appointed International Medical Director and, subsequently, 

Director of Corporate Licensing and Development and Director of Medical and Regulatory Affairs for Latin America. 

Dr. de Sousa earned his M.D. degree from Lisbon University, Portugal in 1983 and his Executive M.B.A. from New York 

University, USA in 2000. 



SPEAKERS 


ORGANISERS


Carlos Paya, CEO, Immune Design Corp. 

Carlos joined Immune Design Corp. in May 2011 as President and Chief Executive Officer. He previously served as President 

of Elan Corporation and led the biotechnology company’s commercial, marketing, clinical, research, and development teams 

from 2008 to 2011. Before joining Elan, Dr. Paya was at Eli Lilly & Company as Vice President, Lilly Research Laboratories 

where he led various therapeutic areas encompassing discovery, clinical development, and the Diabetes and Endocrine 

franchise. Prior to this, Dr. Paya was Professor of Medicine, Immunology, and Pathology, and Vice Dean of the Clinical 

Investigation Program at the Mayo Clinic in Rochester, Minnesota. He received his MD and PhD degrees from the University 

of Madrid and underwent postdoctoral training at the Institute Pasteur, Paris, France. 

Carole Nuechterlein, VP Corporate Licensing, Takeda Pharmaceuticals International GmbH 

Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the 

pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where 

she was General Counsel. 

Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A group. From there, she worked at 

Syntex/Roche in Palo Alto, California focusing on M&A, research collaborations and licensing deals. Due to her background in 

M&A, Carole led the negotiation team for the Roche acquisitions of GlycArt and Therapeutic Human Polyclonals. 

She currently serves as a board observer at Aileron, Alios, Ambit, Ambrx, Conatus, Envoy, Idaho Technology and Nereus. 

She has a BA from Valparaiso University and a JD from University of Michigan. More information on the Roche Venture Fund 

can be found at www.venturefund.roche.com. 

Catherine Pickering, Head of Oncology, Merck Serono 

Specialties: Leading a team of BD professionals focussed in the oncology licensing field. Licesning of preclinical and clinical 

stage products within biotechnology and pharmaceutical companies. 

Technology Transfer within UK Oncology Research Institution for four years. Responsible for protecting and exploition the 

Institution’s IP. 

More recently business development role within Oncology company. 

Chirs Britten, Independent Consultant 

Chris has a scientific background, a PhD in biochemistry and an MBA. Chris has gained huge experience and contacts 

in the Life Sciences market having negotiated a variety of acquisitions, licences, divestments and strategic alliances with 

partners around the world. 

Current activities include advising clients across the spectrum of the Life Science sector, from molecular diagnostics to 

biotechnology, generics to specialty pharmaceuticals and OTC products. 

Christof Boehler, CEO, Pantec Biosolutions 

After finishing his PhD in chemistry at ETH Zurich dealing with bio-polymeric drug release systems, Dr. Christof Böhler moved 

to the United States for a Postdoc at the Salk and Scripps Research Institutes in La Jolla (CA, USA) carrying out bio-medical 

basic research. 

From there he started to work as the head of development for a start up biotech company in Zurich, whose process has 

now been commercialized. Realizing the need to develop his commercial know-how, he moved into product management of 

research chemicals and biologicals at Fluka Chemie AG (a Sigma Aldrich company, Buchs, CH). 

During his Fluka time he completed a postgraduate executive degree in “International Management” at the FH Liechtenstein 

and UBC Vancouver (Canada). His further career involved Business Development Manager Europe and Business Manager 

for Maybridge, a Drug Discovery service company, and finally Marketing Director “Drug Discovery Chemicals” for Acros/ 

Maybridge (Fisher Scientific). 



SPEAKERS 


ORGANISERS


David Slack, Head of Corporate and Business Development, NovImmune SA 

David brings nearly 20 years of senior management and business development experience, and joined NovImmune in 2012. 

David has a track record of innovation in business development, fundraising and in senior management positions at public 

and private biotech as well as large pharmaceutical companies. His deal-making experience encompasses nearly $1 billion 

in corporate partnerships, spin-outs and financings. 

Prior to joining NovImmune, David co-founded and served as Chairman, President and CEO of Kinagen, an innovative next 

generation kinase drug discovery and development company. Under David’s leadership, Kinagen advanced programs and 

established collaborations targeting cancer, inflammatory, fibrotic and ocular diseases, and was sold in 2011. Prior to Kinagen, 

David served as Vice President of Business Development at Isis Pharmaceuticals, where he was responsible for several major 

partnerships and for the GeneTrove functional genomics division. From the “buy side” corporate partnering perspective, 

David served in senior business development positions as Rhône-Poulenc Rorer and Aventis Pharmaceuticals, where he was 

responsible for multiple major strategic partnerships, and served as the business representative to the Genomics Task Force. 

David has played key roles in securing financing for emerging companies and has provided consulting services to a range of 

pharma, biotech and medical device companies as well as investor groups. 

Deborah Harland, General Partner, SR One 

Deborah joined SR One in 2005 to establish the firm’s European investment office. She brings to SR One extensive operational, 

drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and 

business development during her more than 20 year tenure in the pharmaceutical industry. Deborah is currently a member 

of the Board of Directors of Mission Therapeutics Limited, Protaffin AG, Bicycle Therapeutics Limited, Syntaxin Limited, and 

f-star GmbH. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange, 

2007) and Pharmakodex Limited (sold to Orexo) and an observer on the Boards of Ablynx (IPO, Euronext Brussels 2007) and 

7TM Pharma. Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from 

the University of London, and her MBA from Henley Management College. 

Eduardo Bravo, Managing Director & CEO, TiGenix 

Eduardo has more than 20 years experience in the bio-pharmaceutical industry. His professional career includes several senior 

management positions at Sanofi-Aventis, including Vice President for Latin America, where he was in charge of more than 2000 

employees and oversaw sales of more than €1 billion. At Sanofi-Aventis he also held positions such as Marketing and Sales 

Manager for Europe and General Manager for Belgium. He also worked for 7 years in SmithKline Beecham in sales positions 

both nationally and internationally. Mr. Bravo holds a degree in Business Administration and an MBA (INSEAD). Mr. Bravo is cochair 

of the Alliance for Advanced Therapies (AAT) and member of YPO. He is an executive Board member of TiGenix. 

Edwin Moses, CEO, Ablynx 

After completing his post-doctoral research in Germany, Edwin Moses began a commercial career with successful periods 

spent at Amersham International, Enzymatix and Raggio-Italgene. From 1993-2001, first as CEO and later as Chairman, he 

was responsible for the growth of Oxford Asymmetry (OAI) through a series of venture rounds cumulating in a flotation (LSE) in 

1998 at a value of £120 million. This was followed by a sale of the company to Evotec Biosystems in 2000 for £316 million. 

During this period, OAI grew from four people to over 250. Over the past eight years, Edwin has played an important role at 

Board level (primarily as Chairman) in over 15 European life science companies. During this time he has been involved in a 

number of financing rounds, a series of M&A transactions and four IPOs. He has been Chairman of Ablynx since 2004, and 

in 2006 he extended his role as Chairman to include that of Chief Executive Officer. 



SPEAKERS 


ORGANISERS


Eric de La Fortelle, CEO, Delenex Therapeutics 

Eric is CEO of Delenex Therapeutics AG, a Zurich-based biotechnology company focused on biologic medicines delivered 

locally for chronic diseases, and administered systemically for acute diseases. The company is currently focused on 

generating clinical efficacy data in patient studies in three areas: psoriasis, inflammatory bowel disease and acute systemic 

inflammation. It also uses its proprietary PENTRA® platform to generate a full pipeline of highly stable small antibodies that 

have comparable affinity and other drug-like properties to existing antibodies, but superior tissue penetration properties and 

rapid clearance, thus enhancing safety for patients. 

Formerly, Eric was Global Head, External Research and Technologies, for Roche. During six years there, he headed a worldwide 

group with a global mandate to find partners, establish contracts and manage alliances with companies offering innovative 

technologies for every stage of product discovery, development and life cycle. 

Eric is a scientist by training, with contributions in the field of structure-based drug design (determination of 3D structures of 

protein targets by X-ray crystallography). 

He has extensive experience of negotiating Pharma/Biotech alliances (both from the Biotech and the Pharma side). He was 

trained as an engineer and Physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, and an 

MBA from INSEAD. 

Erik van den Berg, CEO, AM-Pharma B.V. 

AM-Pharma is a biopharmaceutical company, engaged in the development of novel human alkaline phosphatase therapeutics 

for unmet needs in severe inflammatory diseases. The Company’s lead programs for this therapeutic enzyme are in Acute 

Kidney Injury and Inflammatory Bowel Disease. 

Strong, positive results from Phase II clinical studies using native bovine alkaline phosphatase demonstrated the efficacy of 

this treatment in patients with Acute Kidney Injury and Moderate-to-Severe Ulcerative Colitis (a type of Inflammatory Bowel 

Disease), thereby providing proof-of-concept for the development of recombinant human alkaline phosphatase. 

AM-Pharma’s proprietary human form of this enzyme has been optimized for treating inflammatory conditions and is being 

produced by cGMP manufacture for preclinical and clinical trial supply and commercialization. 

AM-Pharma discovered that a key function of alkaline phosphatase is to protect organs against inflammation and tissue 

damage. While alkaline phosphatase is found in many cells of the human body, it is present at reduced levels in certain 

diseases including Acute Kidney Injury and Ulcerative Colitis. The Company’s proprietary therapeutics are disease modifying 

therapies and have the potential to be “first-in-class” medicines. 

The Company’s business strategy is to advance its human alkaline phosphatase therapeutics through to Phase II development 

in Acute Kidney Injury, before seeking partners for further clinical development and commercialization. AM-Pharma is currently 

seeking strategic partners for the further development of its therapeutic in Ulcerative Colitis. Founded in 2001, AM-Pharma 

is a private company that is based in Bunnik, the Netherlands. The Company is backed by a strong syndicate of international 

investors and has raised over €55 million equity to date. 

Esteban Pombo Villar, Chief Operating Officer, Oxford BioTherapeutics AG 

Esteban is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 

years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of 

Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept 

in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz 

Neuroscience Research in Basel in 1988. At Sandoz he worked on drug discovery projects as well as leading collaborative 

projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry. 

Francis Marsland, Head of EU Corporate Development, Biogen Idec 

Francis is the Site Leader of Biogen Idec’s International HQ in Zug, Switzerland. As VP, European Corporate Development, 

Francis is responsible for sourcing and transacting European business development and M&A opportunities. Francis advises 

on Biogen Idec’s European Corporate Strategy, Corporate Communications, Investor Relations, and Government Affairs. 

Francis was previously Biogen Idec’s Chief International Counsel. 



SPEAKERS 


ORGANISERS


Frank Grams, VP, Head Alliance Management & Contracting, Sanofi R&D 

Frank joined Sanofi in September 2011 as VP, Head R&D Alliance Management & Contracting. In this function he is leading 

the early stage technology contracting activities and the R&D Alliance Management organization up to POC. 

Before coming to Sanofi he has been working for Roche as Executive Director, Roche Partnering Asia, and as such has 

been instrumental in setting up the Roche Pharma Partnering office in Shanghai starting in 2008. The office has been 

strengthening Roche’s presence in the region from China to Australia. 

Prior to taking up this post, Frank was Global Head, Drug Delivery Partnering, responsible for both the strategic and lifecycle 

management activities related to drug delivery partnering. Frank was a Global Alliance Director from 2002, managing 

pivotal research alliances such as Chugai, Evotec, SGX, Syrrx and Biotie. He has been involved in more than 100 transactions 

including product and technology deals, in- and out-licensing opportunities and also an acquisition. He is also one of the 

initiators of the Greater China Life Sciences Business Plan Competition SEED (www.seedcompetition.com). 

Frank joined the Roche Pharma Partnering team as Head of Opportunity Surveillance in July 2001, having previously worked 

in various research functions in Roche and at Boehringer Mannheim GmbH. 

Frank has a degree in chemistry from the University of Heidelberg and received his Ph.D. with summa cum laude from the 

Technical University of Munich within the group of Nobel laureate Robert Huber (Max-Planck-Institute for Biochemistry at 

Martinsried, Germany). 

Frederic Desdouits, EVP, Global Head Business Development – Market Intelligence, Pierre Fabre 

Frederic is head of Pierre Fabre Group Business Development, Acquisition and Market Intelligence. Prior to join Pierre 

Fabre, Frederic was a Managing Partner at Bionest Partners, a consulting and transaction firm based in Paris and New York 

specialized in healthcare and biotechnology; and the founder Managing Partner of Bionest Partners Finance, a boutique 

specialized in value strategy and fund raising for emerging bio-companies. Before Bionest, Frederic was a partner in charge 

of Pharmaceutical and Biotechnology sectors at Exane BNP-Paribas, an investment company. Before heading for finance, 

Frederic work in research for GlaxoWellcome in France (now GSK), as a consultant for Hoechst in the USA and as a PhD 

student at Rhône-Poulenc in France (now Sanofi). Frederic is graduated from Ecole Polytechnique (Palaiseau), obtained a MS 

in pharmacology, a PhD in Neurosciences, did a post-doc at the Rockefeller University in New York and is a CEFA (Certified 

European Financial Analyst). 

Gerard Plattenburg, CEO, ISA Therapeutics BV 

Gerard holds a degree as a chemist/molecular biologist from the University of Leiden, The Netherlands. He is currently 

managing director of ISA Pharmaceuticals B.V. He is responsible for the overall management and strategic direction of ISA 

Pharmaceuticals. He has more than 20 years senior managerial experience in the biotech industry. Gerard worked for several 

biotech companies such as Pharming and Genpharm (Medarex) prior to founding Prosensa (a Fierce 15 Biotech company), 

which he grew into a generally recognized RNA modulation clinical stage company. 

Graeme Martin, President & CEO, Takeda Research Investment 

Graeme is President and CEO of Takeda Ventures, Inc (TVI), the corporate venture arm of Takeda Pharmaceutical Company, 

Ltd. Since joining Takeda in 2003, Dr Martin has overseen investment of $49mm into 18 early and mid-stage biotechnology 

companies, the result of which has been several strategic relationships with Takeda R&D operations. During more than 30 

years R&D management in multinational Pharmaceutical and Biotech companies in Europe and the USA, Dr Martin has 

pursued scientific enquiry with a passion, resulting in IND submissions for three novel drug candidates one of which, under 

the brand name Zomig®, is marketed worldwide for the acute treatment of migraine. He is the author of more than 85 peerreviewed 

publications and book chapters, obtaining his Bachelor of Science degree in Pharmacology from the University of 

Bath, UK and his doctorate from University College, London, UK. 



SPEAKERS 


ORGANISERS


Hans T. Schambye, CEO, Galecto Biotech 

Hans T. Schambye is a seasoned biotech entrepreneur with extensive experience in drug discovery and development. 

Previously, Dr. Schambye served as the Chief Executive Officer of ReceptIcon from 2006 to 2009 and as the CEO of Gastrotech 

Pharma A/S from 2004 to 2006. Before joining Gastrotech, Dr. Schambye was Director of Biology and Pharmacology and 

Head of Portfolio Management at Maxygen, a US biotech company. Dr. Schambye has co-founded several biotech companies, 

including ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Prior to this Dr. 

Schambye had a successful research career at Stanford University and Copenhagen University within the field of receptor 

biology. Dr. Schambye holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University. 

Harmut Tintrup, Director Marketing & Business Development, CEVEC Pharmaceuticals GmbH 

Harmut is biochemist by training and received his Ph.D. in 1998 from Frankfurt University, Germany. He held various positions 

of increasing responsibility in R&D and Marketing /Sales, starting as a Research Scientist at Artemis Pharmaceuticals GmbH, 

Cologne and later at Exelixis Inc., South San Francisco, USA. Hartmut joined the US subsidiary of amaxa AG (now Lonza 

Cologne AG) in 2004 to support US and global sales in various functions like industrial sales, export and tactical marketing. 

After joining CEVEC in 2010, his main focus are now the european and ROW business development activities and CEVEC’s 

overall marketing strategy. 

Harren Jhoti, President & Director, Astex Pharmaceuticals, Inc. 

Harren has served as Astex Pharmaceuticals president and member of the Board of Directors since July 2011. He cofounded 

Astex Therapeutics in 1999 and was chief scientific officer until November 2007 when he was appointed chief 

executive. Dr. Jhoti was awarded the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery 

by the European Federation for Medicinal Chemistry in 2012 and was also named by the Royal Society of Chemistry as 

“Chemistry World Entrepreneur of the Year” for 2007. He has published widely including in leading journals such as Nature 

and Science and has also been featured in TIME magazine after being named by the World Economic Forum a Technology 

Pioneer in 2005. Dr. Jhoti served as a non-executive director of Iconix Inc. Before starting up Astex Therapeutics in 1999, 

he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999). Prior to Glaxo, 

Dr. Jhoti was a post-doctoral scientist at Oxford University. He received a BSc (Hons) in Biochemistry in 1985 and a PhD in 

Protein Crystallography from the University of London in 1989. 

Harry Welton, VP & CFO, Cytos Biotechnology 

Harry has more than 15 years of international senior executive experience, eleven of which as CFO in biotech companies. 

He joined Cytos in June 2010 as Executive Vice President and Chief Financial Officer. Recently, he successfully restructured 

Cytos and its convertible bonds and raised more than CHF 33 million in equity and debt from an international syndicate of 

investors and through a rights offering. 

Prior to joining Cytos Biotechnology, he was CFO at Nitec Pharma AG in Reinach which merged with the US based Horizon 

Pharma Inc. in order to go public at the US stock market in 2011. From 2001 to 2009, he was CFO at Arpida AG where he 

raised more than CHF 250 million in private equity and public monies including the Initial Public Offering at the SIX Swiss 

Exchange in 2005. Prior to joining Arpida, he was a Director at UBS Warburg in New York following various senior positions 

within the UBS Group. Harry holds a degree in banking and finance, a degree in economics and business administration and 

an MBA (Hons.) from Columbia University, New York. 

Heinz Schwer, Member of Senior Management Team, MorphoSys AG 

Heinz is Senior Director of MorphoSys and currently establishing the company’s corporate venture activities. He joined the 

company in 2010 after he has sold Sloning Biotechnology to MorphoSys. Heinz Schwer co-founded Sloning in 2000 and 

managed the company as Managing Director from 2005 until 2010. In the years before, he held the positions as Chief 

Operating Officer and Head of R&D. Heinz Schwer spent several years as postdoc at the Harvard Institute of Medicine and 

the Dana-Farber-Cancer Institute in Boston. In this time, he has received numerous awards, including a fellowship for his 

research in the field of leukemia disease and the biogenesis of blood platelets. He obtained his Ph.D. in clinical chemistry 

from the University of Regensburg and holds an MBA from Henley Management College in UK. He is also a founding member 

and Vice President of the International Association of Synthetic Biology and an advisory board member of Eucodis Bioscience. 



SPEAKERS 


ORGANISERS


Iain Buchanan, CEO, NOXXON Pharma AG 

Iain was appointed CEO of NOXXON in September 2010 having worked closely with the board of directors since 2007 and 

as a non-executive member of the supervisory board since 2009. He brings to the company over 30 years of commercial 

experience in the pharmaceutical and biotech industries. Iain joined NOXXON from Novexel in Paris where he acted as 

CEO since the Company’s formation in 2004 until its sale to AstraZeneca in 2009. Prior to Novexel, Iain held a variety of 

management positions of increasing responsibility across various companies. These include Vertex Pharmaceuticals (Europe) 

Limited where, as Managing Director, he was responsible for building a Vertex presence in Europe from 1994 to 2004, at Cilag 

A.G. (a division of Johnson and Johnson based in Zug, Switzerland) where he managed the licensee business internationally 

from 1987 to 1994 and at Biogen S.A. in Geneva, Switzerland from 1981 to 1987 where he oversaw commercial activities in 

Europe. Iain began his career in Product Management at Merck Sharp & Dohme (UK) Limited in 1978. 

Iain holds a Bachelor of Science in Physiology from the University of St Andrews, Scotland and is a non-Executive Director of 

Synairgen plc based in Southampton UK. 

Ilka Wicke, Director, Boehringer Ingelheim Venture Fund 

Ilka joined Boehringer Ingelheim in 1996 as head of an interdisciplinary research laboratory specializing in new drug discovery 

approaches. She later joined the Corporate Licensing Division of Boehringer Ingelheim where she over the last 10 years 

gained extensive experience in the evaluation, negotiation and the management of global licensing transactions. 

Subsequently Ilka joined the Corporate Licensing group as head of the business advisory teams for oncology, urology and 

metabolism where she was responsible for the identification and evaluation of pre-clinical and clinical licensing opportunities 

as well as structuring and negotiating technology and licensing agreements. She later joined the transaction group of 

Corporate Licensing where she was responsible for the negotiation and conclusion of a variety of global licensing agreements. 

Ilka has a PhD in organic chemistry from the Johann Wolfgang Goethe University in Frankfurt. Following her graduation she 

spent a year as a postdoctoral fellow at the Sloan Kettering Cancer Center in New York investigating retroviral gene therapy 

approaches to stimulate antitumour responses. 

Jacques Nasstrom, CEO, PledPharma AB 

Jacques has a basic training as Pharmacist with PhD in Pharmacology from Uppsala University, Sweden and a Business 

degree from Stockholm School of Economics. He has 25 years of experience from the pharmaceutical and biotechnology 

industries, including a position as Investment Manager at Karolinska Investment Fund, Stockholm Sweden, and various 

management positions within drug discovery at Astra and AstraZeneca, Södertälje, Sweden and most recently as Director 

of Research & Development at Q-Med AB, Uppsala, Sweden from 2006-2010. Since 2010, Jacques is CEO of PledPharma 

which is a Swedish based specialty pharma company that develops a new medicine, PledOx®, for prevention of the severe 

side effects that patients develop as a consequence of chemotherapy treatment of cancer. 

Jakob Knudsen, CEO, ViroGates A/S 

Jakob assumed his role as CEO of ViroGates in April 2011. Jakob was previously CCO & CFO of Egalet Ltd. a Danish based biotech 

company focusing on development of pain products. Jakob oversaw all commercial operations including IP and Financing, and 

was responsible for entering into multiple commercial collaborations (licensing and feasibility stage agreements). Prior to this 

Jakob was heading the Corporate Business Development function at ALK-Abelló A/S, a Danish biopharmaceutical company. 

Jakob was responsible for ALK’s licensing and M&A deals. Before this Jakob held positions within sales and marketing with 

the company. Jakob is a lawyer by training and he also holds an MBA from Imperial College, UK. 

Jan K Öhrström, CEO, ProFibrix BV 

Jan is CEO and President of ProFibrix BV. Dr Öhrström has 20+ years biotech industry experience from companies in EU and 

the US. He started his career at Novo Nordisk A/S in 1990 and held various positions of increasing seniority within Development 

and Business/Marketing in Denmark and the US. Dr Öhrström joined the Senior Management Team at ZymoGenetics Inc in 

Seattle in 2000, and was part of the Management Team that took the company public (Nasdaq:ZGEN) in 2002. Dr Öhrström 

was responsible for establishing the company’s development and business infrastructure. During his tenure at ZymoGenetics 

Inc, the company submitted its first BLA (RecoThrom©) that was approved in 2008. Dr Öhrström joined ProFibrix in 2008, 

incorporated the company in the US, and in 2011 he was promoted to CEO. He is an MD from University of Copenhagen and 

completed 6 years of clinical practice prior to joining the pharmaceutical industry. 



SPEAKERS 


ORGANISERS


Jason Rushton, Head of Life Sciences Advisory Initiative, Deloitte 

Jason leads the life science focus of Deloitte Corporate Finance in Switzerland. 

He has 20 years of experience in the pharmaceutical sector spanning R&D, management consulting and venture capital. 

Jason began his career in drug discovery with Eli Lilly and then moved to PA Consulting Group where he advised pharmaceutical 

/biotech clients in technical, commercial due diligence and financial transactions. For 10 years Jason was a venture capital 

investor with direct involvement in completing over 30 private life science transactions latterly with the venture capital fund 

of Nestle. 

Jason has been a board member of a number of biotech companies and has firsthand experience of business development 

and licensing. 

Jeremy Warren, CEO, NanoSight 

From a degree in Chemical Engineering from the University of Birmingham, UK, Jeremy worked for Unilever in chemical 

production where he qualified as a chartered engineer. He then set up a successful chemicals manufacturing business in 

Belgium, before completing an MBA at INSEAD in France. After a period in strategy consultancy with Booz.Allen, Warren 

began a series of CEO roles in SMEs centered on developing technology businesses. Warren joined NanoSight in 2005 as 

CEO and was directly involved in development of the company’s multiparameter characterization technology. During the 

last two years emphasis has been on biological nanoparticles, specifically exosomes, with particular interest in the use of 

NanoSight as a platform for their detection and diagnostic application to address a range of unmet need in oncology. 

Johanna Holldack, CEO, Telormedix S.A. 

Johanna has worked in the pharmaceutical industry for more than 20 years, where she has held key positions in both startup 

and large pharma companies. Her experience includes management and executive positions at Behringwerke, Chiron, 

MediGene and Borean Pharma. 

Dr. Holldack has a medical degree from Georg-August-University in Gottingen, Germany and is a Board Certified pediatrician. 

In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche 

Krebshilfe and a research associate at Harvard Medical School. 

John Burt, CEO, PolyTherics 

John joined PolyTherics in November 2010 and brings broad business and corporate development experience to the 

Company. Prior to joining PolyTherics he co-founded Thiakis, with Professor Steve Bloom (Imperial College), which he led as 

CEO through a major financing round in 2006 and ultimately to a very successful sale to Wyeth in 2008. 

John was a board member of Sterix, a joint Imperial College – University of Bath spin-out company which was acquired by 

Ipsen in 2004, and has been an active advisor to early-stage biotech and life sciences companies on strategy, business 

development and finance issues. 

John Trizzino, CEO, ImmunoVaccine Technologies 

John is a senior executive with more than 25 years of experience advancing strategic initiatives for publicly traded biotechnology 

companies, primarily within the vaccine market. Prior to joining Immunovaccine, he was the Senior Vice President at Novavax 

Inc., where he provided strategic direction and successfully negotiated profitable joint venture and licensing agreements, 

including a $179M BARDA contract. Prior to joining Novavax, Mr. Trizzino held senior executive positions at MedImmune 

Inc., which was acquired by AstraZeneca, and ID BioMedical Inc., which is now part of GlaxoSmithKline Inc. He began his 

extensive career in vaccines at Henry Schein Inc. leading commercial marketing efforts and executing a series of successful 

commercialization and distribution agreements. Mr. Trizzino is a graduate of Long Island University and received his master’s 

degree in business administration from New York University’s Leonard N. Stern School of Business. 



SPEAKERS 


ORGANISERS


Juhani Lahdenperä, CEO, Hermo Pharma Oy Ltd 

Juhani as served as the Chief Executive Officer of Hermo Pharma Ltd. since February 2010. 

Mr. Lahdenperä holds a degree in biochemistry from the University of Oulu. Before joining Hermo Pharma Mr. Lahdenperä 

served as a Chief Executive Officer in Plex-Press Ltd., a gene expression analysis technology company, that he co-founded 

in 2006. Thus, he has 5+ years of CEO experience from VC backed organizations. Previously, he held managerial positions 

at the University of Helsinki and Wallac Inc. (Perkin Elmer, Inc.). Some of this work has been published in high-profile journals 

such as Nature. 

Julian Bertschinger-Ehrler, CEO and Co-Founder, Covagen 

Julian is co-founder and CEO of Covagen. After his studies in molecular biology and biochemistry at ETH Zurich, Julian 

Bertschinger joined the group of Prof. Dario Neri at the Institute of Pharmaceutical Sciences ETH Zurich as a Ph.D. student. 

There he co-invented Covalent DNA Display technology. After obtaining his Ph.D. in May 2005, he continued developing 

Covalent DNA Display as a postdoctoral fellow in Prof. Dario Neri’s group. In June 2006, Julian Bertschinger was selected 

from more than 100 applicants as one of the winners of the Venture Leaders Prize founded by the Gebert Rüf Stiftung. This 

enabled him to join a training program in the Boston area (USA) with a course in entrepreneurship at Babson College. 

Katya Smirnyagina, Venture Partner, Alta Partners 

Katya joined Alta in 2002 and focuses on European investment opportunities. She currently represents Alta on the board of 

directors of Cerenis Therapeutics and Kiadis Pharma. She also led Alta’s investment in Ablynx. 

Prior to joining Alta, she worked in business development and finance at Genset, a French genomics-based biotechnology 

company, where she negotiated a number of licensing agreements and strategic partnerships. Prior to Genset, Katya was a 

manager with the Mitchell Madison Group, a global management-consulting firm, from 1997 to 2000. 

She obtained a Ph.D. in Cellular and Molecular Biology from the University of Wisconsin-Madison and received her Bachelor 

of Science in Biochemistry with high honors from Moscow University in Russia. Katya completed her scientific training as a 

post-doctoral fellow at the Department of Microbiology and Immunology at the Stanford University School of Medicine. She 

has co-authored a number of scientific papers. 

Konstantinos Alevizoloulos, CEO, APIM Therapeutics AS 

Konstantinos Alevizoloulos, the current Chief Executive Officer of APIM Therapeutics AS, is a biomedical executive and 

enterpreneur with more than 12 years of corporate experience in the development and commercialization of novel therapeutic 

and diagnostic leads in the biomedical sector. He is also a partner of Ventac Partners SA, an international life science 

consultancy with affiliate offices in the US, Europe and Asia. 

Before joining APIM Therapeutics, Kostas held various executive positions including: CSO of Gerolymatos International SA 

(GR), CEO of Medexis SA (GR), Head of Preclinical R & D of Biovista Inc. (US) and Head of R & D of Apotech SA (CH). Dr. 

Alevizopoulos consults for several biotech companies, Academic Institutes and government associations; he is also a cofounder 

of Zestagen AG (Switzerland) and Casigen Pharma (Hong Kong). Dr. Alevizopoulos received his Biology degree from 

the University of Athens, Greece and his Ph.D. in Molecular Biology from the University of Lausanne, Switzerland. He has 

also conducted post-doctoral studies in the Swiss Institute of Experimental Cancer Research (Switzerland) and the Schering 

Plough Research Institute (USA) specializing in pre-clinical oncology research. Dr. Alevizopoulos is trained in European Patent 

Law (Robert Schuman University of Strasbourg, France). 



SPEAKERS 


ORGANISERS


Lorenza Castellón, Health & Biotech Equity Analyst, Equity Development 

Lorenza is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies 

in Europe and Australia. Prior to joining Equity Development in January 2005 she held similar roles at leading international 

investment organisations. Equity Development brings together investors and companies by means of writing and distributing 

detailed research. We provide the markets with both facts and opinions along with fair valuations based upon diverse and 

appropriate metrics. Over the last decade our brand has become synonymous with quality objective research and we have 

built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA 

approved and boast a cumulative 400 years of experience. Please visit www.equitydevelopment.co.uk for more details and 

examples of our work or contact me. I am the health & biotech analyst and I have many years of experience in the sector 

having worked for leading international investment organisations. 

Ludo Haazen, Chief Medical Officer, PharmaNeuroBoost 

Ludo is Chief Medical Officer at PharmaNeuroBoost (PNB) since 2008. 

He has been directing Global Clinical Research, Development and Medical Affairs activities in different positions since 1995, 

mostly in CNS. 

As such, Ludo directed the Global Development of Durogesic® in chronic pain at JNJ, was involved in the development of 

antidepressants at Roche and JNJ, and assisted TiGenix in having ChondroCelect® approved as the first Advanced Therapy 

Medicinal Product (ATMP) in Europe. 

At PNB, Ludo has been instrumental in designing and directing the Phase I to III clinical development plans in Major Depression 

and Schizophrenia. He also is a registered Qualified Person for Pharmacovigilance. 

Lukas Guenther, Principal, Wellington Partners 

With an international background in clinical medicine and economics, Lukas joined the Wellington Life Science investment 

team in 2007. Prior to joining Wellington, Lukas had worked for six years as a surgeon and researcher specializing in 

organ and cell transplantation at the department of surgery at the Universities of Heidelberg and Freiburg. From 2000 

to 2002, Lukas was a post-doctoral scientist at Harvard University in Boston, where he conducted research in the fields 

of immunology and protective genes. In 2003/2004 Lukas completed a fellowship in clinical islet transplantation at the 

University of Minnesota in Minneapolis, participating in NIH multicenter trials. Lukas studied Medical Sciences in Berlin and 

Cape Town. He holds a summa cum laude doctorate in Medicine from the Humboldt University Berlin and a Global OneMBA 

degree from RSM Erasmus University, Rotterdam. 

Malcolm Weir, Chief Executive Officer, Heptares Therapeutics 

Malcolm has a BSc and PhD in biochemistry and biophysics from Imperial College, London. He was Head of the Biomolecular 

Structure Department and then the Molecular Sciences Division of GlaxoWellcome with responsibility for 300 people 

engaged in target validation and lead discovery. During this time he led the application of structural biology and modelling 

to drug discovery, resulting in the advancement of clinical candidates to a wide range of diseases. He joined the structural 

bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 2000, growing it from the spin-out stage to a 

100-person company. Inpharmatica was sold to Galapagos NV in 2006. He joined MRC Technology in 2006 in order to 

establish Heptares Therapeutics Ltd in July 2007, as co-Founder and CEO. Malcolm was elected Visiting Professor of 

Biochemistry at Imperial College, London in 1997 and is on the Chemistry and Chemical Biology Advisory Boards at the same 

university. He served on the Council of the UK Biotechnology and Biological Sciences Research Council from 2004 – 2011. 

Marcel Tigges, CSO and Co-Founder, BioVersys AG 

Marcel is CSO and co-founder of BioVersys AG. He holds a M.Sc from Ludwig-Maximilians-University Munich and performed 

his PhD studies at ETH Zurich in the group of Prof. Martin Fussenegger. In 2009, he co-founded the BioVersys AG, a 

company performing research and development in the field of antimicrobial resistance. Since then, he is responsible for 

the implementation of synthetic biology derived assay modules into BioVersys`TRIC technology platform and the current 

development of BioVersys`LEAD molecules towards entering clinical phases. 



SPEAKERS 


ORGANISERS


Marcel Zwaal, CBO, DCPrime 

After receiving his MSc in Finance and EMFC degree from VU University in Amsterdam, Marcel Zwaal (1967) has started 

his business career at Philips Electronics. Subsequently he has gained over 10 years of experience in international finance 

and controlling, both in a multinational setting and as an independent consultant. His experience in the field of vaccines and 

biotechnology started when joining Dutch biotech Crucell in 2006 where he has held several senior management positions in 

Business Development and Corporate Finance. He has been responsible for managing Crucell’s recombinant adeno vaccine 

development portfolio and he has concluded several collaborative financing and corporate restructuring deals. After the 

acquisition of Crucell by Johnson & Johnson, Mr. Zwaal has decided to join start-up company DCPrime as Chief Business 

Officer per Jan 1st, 2012. In this role he has been responsible for further developing the company strategy, professionalizing 

the organisation as well as rolling out the partnering and funding approach. Outside of his work he is a sport enthusiast and 

an avid rower and road racing cyclist. 

Markus Goebel, Partner, Novartis Venture Funds 

Markus is Managing Director, Novartis Venture Fund Markus Goebel started his career in the Health Care Industry in 1990. 

An MD by training and certified, amongst others, in hematology/oncology he worked for Farmitalia Germany and later held 

several global positions in R&D, Marketing and Strategy at Roche headquarters, partially in a ww alliance with Amgen. He 

joined Novartis in 2000 and first worked as global head Nervous System BD&L Pharma and later as global head Pharma 

Corporate M&A. In 2004 he joined the Novartis Venture Fund as a Managing Director in the US. Previously he received an 

MD and a PhD from the Ludwig Maximilian’s University in Munich and an MBA from Henley Management College. Markus 

serves on the boards of several Novartis Venture Fund portfolio companies, having exited, amongst others from Sirtris, FoldRx, 

EraGen and Intellikine. 

Markus Hosang, General Partner, BioMedPartners AG 

Markus is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad knowledge 

in strategic and operational aspects of the venture capital business, as well as in pharmaceutical research and in many 

product development and marketing areas, with special expertise in the areas of biotechnologies, strategic alliances, and 

theranostics/diagnostics. Before joining BioMedPartners in 2004, Dr. Hosang was a Venture Partner at MPM Capital, where 

he was co-responsible for their European deal flow, and served on the boards of several European portfolio companies. 

Previously, he was at Roche in Basel, where, for nearly 20 years, he held several senior management positions in the Pharma 

R&D organization, including Vice President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the 

President of Pharma R&D, membership of the Global Board of R&D Directors, Head of Development Projects in Basel and 

Member of the Roche Portfolio Board, and most recently, as a Deputy Head and Chief Scientific Officer of Genetics and 

Integrated Medicine, and a member of the Roche Genetics Executive Committee. 

He obtained his Ph.D. in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University 

Medical School in neurobiology and subsequently at the University of Washington in Seattle in vascular dieseases. Dr. Hosang 

served on the Board of Directors and the Board of Trustees of the Swiss Foundation for Stipends in Medicine and Biology 

(SSMBS) as its Treasurer from 1994-2002. He currently is a member of the boards of Okairos AG, Suppremol GmbH and 

Anergis SA (as interim Chairman of the Board). Earlier he was on the boards of Omrix, Kourion (until its merger with ViaCell), 

IDEA, Atugen, Avontec and Neuraxo. He has published more than 30 articles in peer reviewed journals, and is coinventor on 

several patents. 

Martin Bonde, CEO, EpiTherapeutics ApS 

Martin is a serial entrepreneur, founded and managed several companies in Denmark and the US (Aros Pharma ApS, 

NatImmune A/S, Combio A/S, CelTor Inc., Torsana Biosensor, Osteometer Biotech) 

Martin fronted several successful exits over the last decade (NatImmune A/S to IPC, Combio A/S to Arpida AG, Torsana 

Biosensor A/S to Celtor Inc) as well as significant out-licensing deals, 

He is engaged as board member in Orphazyme ApS (www.orphazyme.com) (Chairman) and Danish Association of Biotech 

Companies (www.danskbiotek.dk) (Chairman). 



SPEAKERS 


ORGANISERS


Martin Welschof, CEO, Opsona Therapeutics Ltd 

Martin is the CEO of Opsona Therapeutics Ltd, a leading immunology drug development company in Dublin focused on novel 

therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases. 

Before Opsona he was the MD & Co-founder of Affitech A/S, a biopharmaceutical company focused on the discovery & 

development of human antibodies, listed on the Nasdaq OMX Copenhagen stock exchange. Affitech AS was transformed 

through a reverse merger in 2009 with Pharmexa A/S, listed on the Copenhagen stock exchange. In 2010 he was a key 

resource in implementing a strategic partnership with the Russian Pharmaceutical IBC Generium (worth up to €24.6m) & 

secured strategic investment from Trans Nova (€20.9m). 

Prior to Affitech AS, he was Director of Technology at Axaron Bioscience AG, Heidelberg, Germany during the Company’s 

start-up phase. During a portion of this period was an expatriate at the parent company, LYNX Therapeutics Inc., Hayward, 

California, contributing to the process development of LYNX massive parallel cloning & sequencing technologies. 

Matthias Steger, Global Head Research & Technology Partnering, Roche 

Matthias is Global Head Research & Technology Partnering at Roche; he holds a PhD in Medicinal Chemistry from the 

University of Sussex, UK, and an MBA from the University of St Gallen, Switzerland. 

Prior to joining Roche in his current role, Dr Steger was a Pharma/Biotech analyst at the investment bank Kepler Equities 

and was Head of Chemical Technologies at Axovan, a biotech company which was subsequently acquired by Actelion, Basel, 

Switzerland. He began his career in the pharmaceutical industry at Roche in 1999 as Laboratory Head in Medicinal Chemistry.. 

Mike Romanos, CEO, Crescendo Biologics 

Mike is CEO and founder of Crescendo Biologics, an innovative transgenic antibody fragment company based in Cambridge, 

UK. He has 25 years’ biotech and pharmaceutical industry experience in biologic and NCE drug discovery across most 

therapeutic areas, starting with Wellcome Biotech in the 1980s. 

Previous to his current role, Mike held leadership positions for over 10 years in GlaxoSmithKline R&D, building and managing 

global Discovery organisations that made a major impact in targets, technology and pipeline projects. In particular, Mike 

established GSK’s antibody lead discovery capability which generated a pipeline of in-house monoclonal antibodies, several 

of which are in clinical development. 

Mike holds a degree in Natural Sciences from Cambridge University, a PhD in Molecular Virology from Imperial College, and 

undertook postdoctoral research in Virology at the MRC’s National Institute for Medical Research and in Yeast Biotechnology 

at Leicester Biocentre. He is currently a panel member of the MRC’s Developmental Pathway Funding Scheme, which funds 

translational studies through preclinical and early clinical development, and a Fellow of the Society of Biology. 

Naveed Siddiqi, Partner, Phase4 Ventures Limited 

Naveed is a Partner of Phase4 Ventures with over 11 years experience of investing in healthcare companies in US, Europe 

and Asia. Naveed worked for Nomura and was actively involved with many of Nomura Phase4 Venture’s private investments 

including Pharmion and Paratek. He has taken Board observer roles on the Boards of several companies. Prior to joining 

Nomura’s healthcare investment business, he spent 5 years advising management teams and companies on buy-outs, cross 

border M&A, private and public company offerings in biotechnology and other sectors whilst at Nomura and EFG Group. Naveed 

holds a degree in Medicine from Guy’s Hospital, London and worked in the UK’s National Health Service as a doctor. He is also 

qualified as a chartered accountant whilst at KPMG and holds a Diploma in Company Direction from the Institute of Directors. 



SPEAKERS 


ORGANISERS


Paul Higham, Managing Director, immatics Biotechnologies 

Paul was appointed as CEO of immatics in August 2008. Previously, he served as Director Commercial Development at Ark 

Therapeutics Group plc where he was responsible for commercial strategy and all business development activities. In addition, 

he was in charge of establishing the operations and gene-based medicine production facilities of Ark Therapeutics in Finland. 

Prior to joining Ark Therapeutics in 2001, Paul Higham worked as International Commercial Vice President for GI, Metabolic 

and Pain at GlaxoWellcome plc from 1996 to 2001, where he covered all aspects of business development, strategic 

marketing and sales. From 1985 to 1996, after completing his studies in Applied Biology, he held various sales and marketing 

positions of increasing responsibility with Bayer AG and eventually became General Manager of Bayer Pharmaceuticals for 

Sweden and Denmark. 

Patrik Frei, CEO, Venture Valuation 

Patrik is founder and CEO of Venture Valuation AG, Switzerland. Patrik graduated from the Business University of St. Gallen and 

completed his Ph.D thesis (”Assessment and valuation of high growth companies”) at the Swiss Federal Institute of Technology, 

EPFL Lausanne. Prior to forming Venture Valuation, Patrik was CFO of a logistic company and worked for several international 

corporations: LeCroy (Geneva, New York), Hans Merensky Holding (South Africa) and Swatch Group – EM Microelectronic 

(Marin). Patrik is a board member and one of the original founders of ineo, a holding company of the Swiss dental implant VCbacked 

firm Thommen Medical and a board member of Ophthalmopharma, a Swiss based biotech ophthalmology company. 

Patrik’s articles have been published in a number of scientific journals including “Nature Biotechnology”, “Chimia” and other 

business publications (“Starting a Business in the Life Sciences: From Idea to Market” and “Building Biotechnology: Starting, 

Managing, and Understanding Biotechnology Companies”). He has also lectured at Seoul National University, South Korea and 

Danube University Krems, Austria and presented at numerous Valuation workshops around the world. More recently, Patrik was 

named as one of the 20 most influential people in the Swiss Life Sciences Industry by Bilan, a Swiss Business Journal along 

with other noteworthy individuals such as Ernesto Bertarelli, Daniel Vasella and Henry B. Meier. 

Specialties: Finance, valuation, merger and acquisition, reporting of high growth companies in the VC and private equity area. 

Peter E. Burckhardt, CEO, EVA the Basel Life Sciences Start-up agency 

Peter plays an important role in supporting innovation in Northwestern Switzerland. His main focus is life sciences start-ups. 

Peter is CEO of “EVA the Basel Life Sciences Start-up agency”. This company was founded in 1996 with the aim to support 

life sciences start-ups with coaching, access to a high value network and providing seed money. In addition he is CEO of the 

BASEL INCUBATOR, which he helped to establish 2 years ago. The BASEL INCUBATOR is a joint venture of the University of 

Basel, the University of Applied Sciences of Northwestern Switzerland (FHNW) and the Canton of Basel-Stadt. To complement 

his activities, Peter is the president of the BioValley Business Angel Club, the only Business Angel’s Club in Switzerland focusing 

entirely on life sciences / MedTech. Peter has a PhD in chemistry from the University of Basel and joined Ciba-Geigy / Novartis 

1984 as a research chemist. Throughout his professional career he had managerial positions with worldwide responsibility in 

technical development, regulatory affairs, manufacturing, production and communication and was the CEO of the subsidiary 

of a sector of Novartis in Germany. He joined EVA in 2006. 

Peter Stein, Chairman & CEO, Norgine 

Peter is the Chairman and Chief Executive and principal shareholder of Norgine, an independent specialty pharmaceutical 

company with operations throughout Europe. 

Prior to joining Norgine in 1987, Peter was a co-founder and Vice President of Invitron Corporation, a contract biomanufacturer 

formed as a spin-off from the Monsanto Company. He started his pharmaceutical career with Centocor. 

Peter holds BA and MA degrees in Chemistry from Harvard University and an MBA from Stanford University. 


WELCOME 

PHARMA LICENSING GROUPS 

SPEAKERS 


ORGANISERS


Piers Morgan, CFO, uniQure BV 

Piers joined uniQure’s predecessor company AMT in December 2009 as Chief Financial Officer. He has over ten years 

experience as CFO with biotechnology companies, including Phytopharm plc, BioAlliance Pharma SA, and Arrow Therapeutics 

Ltd. Prior to this period, he gained ten years experience in investment banking, working in Mergers & Acquisitions, and Equity 

Capital Markets with Close Brothers and Ernst & Young Corporate Finance. He qualified as a Chartered Accountant in London 

with PricewaterhouseCoopers. 

Remy Luthringer, Venture Partner, Index Ventures 

Remy joined the Index Ventures life science team as Chief Medical Officer in 2010. After spending some years in clinical 

psychiatric practice and getting in parallel a master degree in functional explorations and computer engineering, Remy 

obtained a PhD in Neurosciences and another in Clinical Pharmacology. 

Prior to joining Index Ventures, Remy was the CEO of one of the most recognized research institute in neurosciences. Thus 

he was involved in several European grants and research programs focusing on development and validation of biomarkers/ 

surrogate endpoints. The latter of these can be implemented in drug development programs with the purpose of reducing the 

attrition rate and failures in the CNS space and also an early readout of the potential of a molecule as early as Phase I/IIa. 

Remy is the author of about 50 publications, served on advisory boards of biotech as well as pharmaceutical companies and 

was involved in the development of more than 150 CNS active molecules. 

Riccardo Braglia, CEO, Helsinn Healthcare S.A 

Riccardo has a degree in Business Economics with specialization in Business Management. 

He is HELSINN GROUP’s Chief Executive Officer and Entrepreneur; Managing Director and Member of HELSINN HOLDING’s 

Board of Directors, Switzerland and Executive Committee for HELSINN GROUP’s strategic management; Managing Director 

of Helsinn Healthcare, Switzerland; Managing Director of Helsinn Advanced Synthesis, Switzerland; Member of Helsinn Birex 

Pharmaceuticals’ Board of Directors, Ireland; and Chairman of Helsinn Therapeutics’ Board of Directors, USA. 

His main role and functions are to focus on fundamental operational strategies such as high level business development, 

relationships with pharmaceutical industry, financial, political and regulatory institutions, other stakeholders, public relations 

and communication internal and external to the Group, as well as final control of Helsinn Group’s business trend. 

Riccardo is a Board Member of Thorne Research, USA; Member of Management Committee of Chamber of Commerce, 

Industry and Handicraft of Canton Ticino, Switzerland; Board Member of American School in Switzerland; and Chairman of 

WS Fashion Holding Switzerland. 

Richard Godfrey, CEO, BerGenBio 

Richard is an industrial pharmacist; originally trained as a scientist, his career developed through R&D, supply chain, sales & 

marketing, since 1999 he has served as Managing Director, CEO, and NED in life science companies. He has worked in UK, 

Germany, Switzerland and USA for Eli Lilly, Catalant, DCC, Reckitt Benckiser and SwissCaps. 

During his career Mr. Godfrey has led and been involved in the development and life cycle management of broad range of 

products and technologies, including Zydis, Vegagel, Cyclosporin, Zyprexia, Cialis, Advil and Temgesic. 

He has successfully grown businesses organically, secured funding and executed substantial merger, acquisition and 

divestment transactions in UK, Switzerland, Germany and Romania and USA. In 2008 Mr. Godfrey relocated with his family to 

Bergen Norway and in 2009 led the formation and spin out of BerGenBio from the University of Bergen. 



SPEAKERS 


ORGANISERS


Richard Goodfellow, CEO, Scancell 

Richard has over 30 years international experience in the pharmaceutical industry, in Big Pharma and with Biotech companies. 

During his time at Astra, he oversaw the launch of Losec and other key products internationally. Thereafter, he held the post of 

Director of Licensing and New Business Development at Scotia Pharmaceuticals, where he was involved with the company’s 

flotation on the London Stock Exchange and successfully negotiated numerous deals. 

In addition to co-founding Scancell’s ImmunoBody cancer vaccine business, Dr Goodfellow was also a co-founder of Paradigm 

Therapeutics, a Cambridge based functional genomics company and was a former Director of Enact Pharma plc. 

Robert Burns, CEO, 4-Antibody 

Robert is CEO at 4-Antibody and is an experienced biotech business leader previously at Affitech A/S and Celldex Therapeutics 

Inc., both antibody discovery and development companies. 

Dr Burns joined 4-Antibody following the successful repositioning and refinancing of Copenhagen listed and Oslo-located 

Affitech A/S (AFFY, NASDAQ OMX). Prior to his time at Affitech, he was CEO at Celldex Therapeutics Inc. (CLDX, NASDAQ) 

during the critical period of Celldex’s emergence from Medarex through to its eventual reverse merger into NASDAQ-listed 

Avant Immunotherapeutics. 

Before his role at Celldex, Dr Burns was at the Ludwig Institute for Cancer Research in New York, where he played leadership 

roles in the spin-out of several successful companies including Piramed in the UK. Prior to that he was Commercial Director at 

both Oxford Glycosciences, UK and British Biotech, UK; and previously AbT, Cambridge Mass.; and CIBA-Corning Diagnostics. 

Dr Burns is also non-executive Chairman of Haemostatix, an early stage UK company specialising in haemostasis blood clotting 

products and also serves on the board of Oncos Therapeutics Oy, a Finnish developer of novel cancer therapies based on next 

generation oncolytic viruses. 

Rolf Guenther, CEO, Bicycle Therapeutics 

Rolf has over 25 years of pharmaceutical industry experience with an extensive background in drug development, biologics 

and speciality pharmaceuticals. Since 2004 he has served as CEO and COO of Affimed, a monoclonal recombinant antibody 

company, and has successfully developed its clinical product portfolio in oncology. He previously held the position of VP and 

General Manager of the Critical Care business unit of Aventis Behring, which he joined as VP Global Clinical Research in 1996, 

and was responsible for successful drug approvals in the US and Europe. 

Dr. Günther is a trained physician in critical care medicine. He received his MD and his PhD in Physical Chemistry from the 

University of Mainz, Germany. He completed an Executive Development Program at the University of Pennsylvania’s Wharton 

School of Business. 

Rolf Witte, CEO, PSites Pharma GmbH 

Rolf has over 25 years experience in finance and law and has consulted many companies on financial and legal matters. 

Dr. Witte has a thorough knowledge of the public funding in Germany and has been successful in raising capital for a number 

of biotech companies. 



SPEAKERS 


ORGANISERS


Rudi Neirinckx, CEO, Ennar Pharma 

Rudi is an experienced pharmaceutical industry executive, with a record of invention, being the author of over 100 scientific 

publications and more than a dozen patents. He worked in most aspects of the pharmaceutical business, i.e. research, clinical 

development, licensing, business development, etc. in the diagnostic as well as the therapeutic side of the business. After an 

academic career in Nuclear Medicine and Radiology he headed up the R&D operations of Amersham International (UK) and 

Serono (Geneva), but also was responsible for reorganizing the M&A Department of Merck KGaA, where he made numerous 

license and M&A deals, including a deal with Imclone Systems. He founded an OTC Company (Agys Pharma, Belgium), based 

on his invention of an effective treatment of dental sensitivity and was COO of a Generics Company (PAR Pharmaceuticals, 

USA), which he helped turn around. He also was CEO of atugen, a Berlin high-tech start-up, before he became a full-time 

consultant to the President of Altana Pharma. Subsequently he has exclusively worked on the psoriasis project, which is now 

handled at Ennar Pharma AG. 

Sarah Holland, Global Head, Strategic Partnering, Roche Partnering 

Sarah Holland is the Global head, Strategic Partnering for Roche Partnering based in Basel, Switzerland. Her team’s 

projects include broad strategic landscapes of M&A and late stage opportunities, transactional support for all pharma M&A 

transactions, initiatives to generate income through divestments, spin-outs and strategic partnerships, and development and 

delivery of creative deal structures to address key business needs. In 2010 the team acquired world-wide rights to danoprevir 

from Intermune and supported the acquisition of Marcadia Biotech. Since joining Roche in 2005, Sarah has held various 

responsibilities in business development, such as Global Head of CNS Partnering, and has led projects in a range of disease 

areas, including the Plexxikon deal on b-raf inhibitors. 

Prior to joining Roche, Sarah was Global Brand Director at AstraZeneca for a hormonal agent for breast cancer during US 

and EU launch. She held various commercial and strategic roles over her ten years there, including Global Strategic Planning 

Manager for early compounds, Pricing Strategist and Health Economist. Before AstraZeneca, she held local and international 

sales and marketing roles in diagnostics, biotech and pharmaceutical companies. 

Sarah gained her MBA from Manchester Business School, where she was a Visiting Fellow until 2004, and her D.Phil and first 

degree at Oxford University. 

Scott Cuthill, Director, Corporate Business Development Team, Ipsen 

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen’s ambition is 

to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 

four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, 

the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patientdriven 

platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The 

Group has total worldwide staff of close to 4,500 employees. 

Simon Nebel, Managing Partner, Aravis 

Since joining Aravis in 2001, Simon has participated in the financing of a number of life science companies and the M&A 

transactions of a number of Aravis portfolio companies. Most recently he was a co-founder of Aravis Energy I LP, the first Swiss 

Limited Partnership focused on renewable energy. 

Before joining Aravis, Simon was a group strategist at UBS (London, Basel and Zurich), where he coordinated and worked on 

business planning and modelling. This included developing a Biotechnology Venture Capital business proposal for UBS Capital. 

He is currently a board member of MarinoMed, ImVision and MerLion Pharmaceutical SA and Leading Swiss Renewable 

Energy AG as well as an observer on the board of Anaphore (USA), and a former member of the board of directors of Borean 

Pharma (Denmark) and secretary of the board of Evolva (Switzerland). 

Simon holds a PhD in Biophysics from the Biocentre of the University of Basel (1996) and an MBA with distinction from the 

London Business School (2001). 



SPEAKERS 


ORGANISERS


Søren Moller, Managing Investment Director, Novo A/S 

Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology 

in 1997 from the Technical University of Denmark for a project on molecular microbiology. In addition to his PhD, Søren has 

academic training as postdoctoral fellow at Stanford University School of Medicine. 

Prior to joining Novo Seeds, Søren served as global manager of Bioinformatics and Genomics at Novozymes. Before 

Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S where he was responsible for development of microRNA 

based products for life science research, pharma services and diagnostics. In 2007 Exiqon completed an IPO on NASDAQ 

OMX Copenhagen raising 400 mio DKK to develop and commercialize life science and diagnostic products. Previously, Søren 

worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk. 

Since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark). Søren 

serves on the board of directors of Denator AB, a Swedish based biotech company. 

Stephanie Leouzon, Senior Advisor, Torreya Partners 

Stephanie is a Senior Advisor at Torreya Partners, a life sciences advisory boutique. 

She has worked in Health Care Investment Banking since 1989, participating in over 65 transactions in the biotechnology, 

pharmaceutical and speciality pharmaceutical sectors. 

She has advised clients on a number of strategic transactions, valued at over $70 billion, and she has been involved in 

financing transactions to provide over $7 billion to healthcare clients. 

Prior to joining Credit Suisse in 1998, Stephanie’s experience included working in Health Care at Lehman Brothers, JP Morgan 

and Salomon Brothers (now Citigroup). Stephanie earned an M.B.A. degree from the Darden Graduate School of Business at 

the University of Virginia in 1989 and a B.A. degree, cum laude, from Mount Holyoke College in 1985. 

Thomas Kronbach, CEO, BioCrea GmbH 

Thomas is CEO of BioCrea, a drug discovery company in Radebeul, Germany, which is creating first-in-class drugs from 

concept to drug candidate. Tom established BioCrea as a Management buy-out of assets from Biotie Therapies in 2010. 

Previously, Tom was CSO of Biotie Therapies, CSO and founder of elbion and had various positions at Asta Medica, AWD and 

Goedecke. 

Tom has initiated, negotiated and fostered partnerships with Boehringer Ingelheim, Wyeth/Pfizer and GlaxoSmithKline. Tom 

holds a Ph.D. from the University of Tubingen, Germany, was a Post Doctoral Fellow at the University of Basle, Switzerland and 

a Research Associate at The Scripps Clinic and Research Foundation in La Jolla, CA. 

Tim Haines, Partner, Abingworth Management 

Tim has more than 25 years of international management experience in the life sciences industry including significant 

expertise in medical devices. Before joining Abingworth in 2005, he was Chief Executive of the Abingworth portfolio company, 

Astex Therapeutics. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, 

Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe. At 

Abingworth, he identifies and creates new businesses and provides support for existing companies within the Abingworth 

portfolio. He is or has been a board member of the following portfolio companies: Astex Therapeutics, Powdermed (acquired 

by Pfizer), IMI, Stanmore Orthopedic, Fovea (acquired by sanofi-aventis), KSpine, XCounter (AIM) and Chroma Therapeutics. 

Tom Johnston, CEO, Mucosis BV 

In his role he has global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate 

partnerships and other strategic alliances. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of 

Science degree in Computer Science from Arcadia University. 



SPEAKERS 


ORGANISERS


Wilder Filford, Principal, Torreya Partners 

Wilder is the founding partner of Torreya Partners Europe, the London branch of Torreya Partners, an international advisory 

firm assisting Life Science companies with M&A, licensing, alliances, financings and other transactions. Dr. Fulford has had 

a long career advising healthcare companies of all kinds around the globe. After completing his PhD in molecular biology at 

the Rockefeller University in 1986, he worked for a few years as a venture capitalist, before embarking on a career as an 

M&A advisor. He has run healthcare M&A or coverage groups in New York and London at Salomon Brothers, Merrill Lynch, 

Bank of America and (most recently) Deutsche Bank. He has participated in close to 100 financing and M&A transactions 

with an aggregate value in excess of $100 billion. Torreya Partners has a full team in London, and about a dozen mandates 

in execution. 

Willem van Weperen, CEO, to-bbb 

Willem obtained an MSc degree in biomedical sciences from Utrecht University, and an Executive MBA degree from NIMBAS 

/ Bradford University. He began his professional career in clinical research at GSK and joined Genzyme in 1994 in various 

European clinical, sales & marketing positions. From 2004 to 2006 he was globally responsible for marketing of the genetic 

disease business unit in Genzyme’s worldwide headquarters in Cambridge, MA and in 2006 he moved back to lead the 

Genzyme Netherlands organization in Naarden. In 2009 Willem joined the to-BBB team as their CEO to help develop their 

break-through brain delivery platform for patients with CNS diseases. Willem is member of the Advisory Boards of the Leiden 

BioScience Park, VenGen life science start-up management and Rabobank Leiden. 



SPEAKERS 


ORGANISERS

CONTACT 

Robert F Burns, PhD 

Chief Executive Officer 

ADDRESS 

Hochbergerstrasse 60c 

Basel 

CH4057 

TELEPHONE 

+41 61 633 22 60 

EMAIL 

robert.burns@4-antibody.com 

4-Antibody 

www.4-antibody.com 

COMPANY PROFILE 

4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology 

platform. The Company is making this technology available to pharmaceutical partners and is also using it to 

generate a proprietary pipeline of antibody therapeutic drugs initially in the immune check point target area in 

oncology. 4-Antibody is a private company with strong, commercially-experienced leadership located in Basel, 

Switzerland and Jena, Germany 

MANAGEMENT 

Robert F Burns, PhD, CEO 

Marc van Dijk, PhD, CTO 

Luis Martin-Parras, PhD, Head R&D Germany 

Andreas Richter, CFO 



SPEAKERS 


ORGANISERS

CONTACT 

Edwin Moses 

Chairman and 


ADDRESS 

Ablynx nv 

Technologiepark 21 

9052 Zwijnaarde 

Belgium 

TELEPHONE 

+32 (0)9 262 00 00 

FAX 

+32 (0)9 262 00 01 

EMAIL 

edwin.moses@ablynx.com 

info@ablynx.com 

YEAR FOUNDED 

2001 

Ablynx 

www.ablynx.com 

FINANCIAL SUMMARY 

(€ million) H1 2012 H1 2011 % change 

Revenues 16.6 12.8 30% 

R&D income 15.6 12.0 30% 

Grants 1.0 0.8 25% 

Operating expenses 30.6 33.8 (9%) 

R&D 25.9 28.9 (10%) 

G&A 4.7 4.9 (4%) 

Other operating income/(expense) (0.4) – – 

Operating result (14.4) (21.0) 31% 

Finance income (net) 0.8 0.8 0% 

Net result (13.6) (20.2) 33% 

Net cash burn (7.3) (23.3) (69%) 

Cash at June 30 76.5(1) 92.6 (17%) 

(1) Including €2.7 million in restricted cash 


Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel 

class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human 

diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has 

approximately 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has 

ongoing research collaborations and significant partnerships with major pharmaceutical companies, including 

Boehringer Ingelheim, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More 

information can be found on www.ablynx.com. 

MANAGEMENT 

Edwin Moses, Chairman and Chief Executive Officer 

Josi Holz, Chief Medical Officer 

Eva-Lotta Allan, Chief Business Officer 

Andreas Menrad, Chief Scientific Officer 

Wim Ottevaere, Chief Financial Officer 



SPEAKERS 


ORGANISERS

CONTACTS 

Rostislav Raykov 


Robert Andrade 

Chief Financial Officer 

ADDRESS 

68 TW Alexander Drive 

PO Box 13628 

Research Triangle Park, 

NC 27709 

TELEPHONE 

(919) 636-4530 

Rostislav Raykov, 

(919) 636.5144 

Robert Andrade 

(919) 636.5013 

FAX 

(919) 890-0490 

EMAIL 

adherex@adherex.com 

rraykov@adherex.com 

andrader@adherex.com 

Adherex 

www.adherex.com 


Cash @ 06/30/12 – $3.6 million 

The Company doesn’t anticipate the need for further funding until data becomes available from the enrolling 

Phase II trial next year. 


Business Summary 

• Adherex is a biopharmaceutical company focused on cancer therapeutics, which is publicly traded in both the 

United States and Canada (TSX:AHX, OTC: ADHXF). 

• Adherex has principally focused its resources on eniluracil. The Company believes eniluracil might enhance 

and expand the therapeutic spectrum of activity of 5-FU, reduce the occurrence of a disabling side effect 

known as hand foot syndrome and allow 5-FU to be given orally. 

• The new clinical plan is led by Dr. Thomas Spector, the principal inventor of the eniluracil / 5-fluorouracil 

cancer treatment while working at Burroughs Wellcome Laboratories 20 years ago. 

Clinical Trial 

• The Company’s Phase 2 clinical trial for Metastatic Breast Cancer compares the oral regiment of Eniluracil + 

5-Fluorouracil (5 FU) and Leucovorin versus Capecitabine (Xeloda®). 

• The comparative study intends to enroll 140 patients at approximately 20 clinical sites in the United States and 

Russia with enrollment anticipated to be completed in the fourth quarter of 2012. As of August 10, 2012 the 

Company had enrolled 134 patients. It plans to enroll 80 patients in the eniluracil/5-FU/leucovorin arm and 60 

in the capecitabine arm. 

• The primary endpoint of the trial is progression-free survival. The secondary endpoints include the overall 

toxicity (including hand-foot syndrome), antitumor response rate, disease control rate, duration of response, 

and time-to-treatment response. Patients receiving eniluracil (40 mg)/5-FU (30 mg/m2) /leucovorin (30 mg) 

are treated once per week for three consecutive weeks per month. Patients receiving capecitabine are treated 

with 1000 mg/m2 every 12 hours for 14 days every three weeks. 

Target Market 

• O ver 500,000 patients in North America and millions worldwide use iv-5FU. 

• Breast cancer is the second leading cause of cancer related death among women, according to the National 

Cancer Institute. In 2010, NCI estimated that 207,090 women were diagnosed with breast cancer, while 

39,840 women likely died from the disease. 

MANAGEMENT 

Rostislav Raykov, Chief Executive Officer 

Robert Andrade, Chief Financial Officer 

Dr Thomas Spector, Chief Scientific Officer 



SPEAKERS 


ORGANISERS

CONTACT 

Erik van den Berg 


ADDRESS 

AM-Pharma B.V. 

Rumpsterweg 6 

3981 AK Bunnik 

The Netherlands 

TELEPHONE 

+31-30-2289222 

FAX 

+31-30-2289220 

EMAIL 

office@am-pharma.com 

YEAR FOUNDED 

2001 

AM-Pharma B.V. 

www.am-pharma.com 


Raised a series D financing round of EUR 29.2 million in September 2011. 


AM–Pharma is a biopharmaceutical company developing novel recombinant human alkaline phosphatase 

therapeutics for inflammatory diseases, including Acute Kidney Injury (AKI) and Ulcerative Colitis (UC). 

MANAGEMENT 

Erik van den Berg, MSc, MBA, CEO 

Jacques Arend, MD, VP Clinical Development 

Steve Connor, BSc, VP Preclinical Development 

Peter Verwayen, VP Finance 

Andrea van Elsas, PhD, VP Research 



SPEAKERS 


ORGANISERS

CONTACTS 

Vincent Charlon PhD, 

CEO 

Zoltan Czigler MBA, 

Finance Director 

ADDRESS 

BioPole III 

Route de la Corniche 9B 

CH-1066 Epalinges 

Switzerland 

TELEPHONE 

+41 21 651 9220 

FAX 

+41 21 651 9221 

EMAIL 

info@anergis.ch 

YEAR FOUNDED 

2001 

Anergis SA 

www.anergis.ch 


CHF 18M round March 2011. 


ANERGIS SA is a Swiss-based biopharmaceutical company specializing in the discovery and development 

of novel ultra-fast specific immunotherapy (also known as “SIT” or “desensitization”) products. Allergy is the 

most prevalent and the fastest growing chronic condition in the industrialized world with over 300 million 

people affected. Current SIT remains underused due to its long duration (3-5 years of treatment) and safety 

risks. ANERGIS develops ultra-fast and safe SIT treatments for allergic patients, which can achieve induction 

of tolerance to the allergen in few injections only. ANERGIS possesses a unique know-how and the exclusive 

rights to the technology of Contiguous Overlapping Peptides (“COPs”) developed jointly by the University of 

Lausanne, Switzerland (UNIL), the Federal Institute of Technology (EPFL) and the Centre Hospitalier Universitaire 

Vaudois (CHUV). Because ANERGIS COPs are long peptides they present the advantage of being recognized 

and processed by the antigen presenting cells of the immune system using similar mechanisms as the original 

allergen. This feature, combined with the fact that the COPs reproduce – in separate molecules – the full 

amino acid sequence of the allergen, and that overlapping sequences guarantee that all linear epitopes are 

present, ensures the high immunogenicity of the COPs. In the past years, ANERGIS has studied proprietary COPs 

targeting bee venom and birch pollen allergies both in animals and in humans. These studies have confirmed the 

excellent safety (no immediate allergic reaction) and expected immunogenicity (production of specific antibodies 

and cytokines against the original allergen) of ANERGIS COPs. 

MANAGEMENT 

Vincent Charlon, CEO 

20+ years global clinical development and management experience 

• LS Pharma International, CEO 

• Hesperion, CEO 

• Hoffmann-La Roche, Clinical Director 

Christophe Reymond, CSO 

20+ years biology, immunology, patents and start-up experience 

• Anergis, CSO/COO 

• Dictagène, CSO 

• Assist Professor University Lausanne 

François Spertini, Medical Expert 

20+ years medical practice and research in immunology and allergy 

• Assoc. Prof. and Chief Allergy/Immunology 

• Lausanne University Hospital (CHUV) 

• President & founder of Anergis 

Zoltan Czigler, Finance Director 

MBA Insead, MSc 

• Business and Finance consultant 

• Director Finance Kuros Biosurgery AG 

• Investment and finance manager, VI Partners 

Jean-Paul Rohmer, Business Development 

20+ years biotech, pharma business and commercial management 

• IDEFI Gestion, Managing Director 

• Stallergenes, GM & CEO 

• Eli Lilly France, Head Pharma Division 



SPEAKERS 


ORGANISERS

CONTACT 

Kostas Alevizopoulos PhD 


ADDRESS 

APIM Therapeutics AS 

c/o NTNU Tech Transfer AS 

Sem Sælandsvei 14 

Kjemiblokk 1, 3etg 

N-7491 Trondheim 

Norway 

TELEPHONE 

+41 78 752 7002 

EMAIL 

contact@apimtherapeutics.com 

kalevizo@apimtherapeutics.com 

YEAR FOUNDED 

Founded in 2009 as a spin out 

from the Norwegian University 

of Science and Technology in 

Trondheim (NTNU), Norway. 

APIM Therapeutics AS 

www.apimtherapeutics.com 


Venture Capital Financed. 

Current investors include: • Sarsia Seed • Birk Venture • Ro Invest • Norsk Innovasjonskapital AS 


APIM Therapeutics AS is a Norwegian biotech company set to develop and commercialize novel anti-cancer 

therapies potentiating chemotherapy-induced responses in cancer cells. 

We offer a unique physiological intervention point targeting a cellular “hub” protein called Proliferating cell 

Nuclear Antigen (PCNA). PCNA acts a master regulator of replication, repair, cell cycle control and apoptosis, 

ultimately controlling responses to pathological (cancer) and pharmacological (chemotherapy) stress in cells. 

ATX-101, the company’s current preclinical lead, features a novel PCNA-interacting Stress Switch Peptide 

Motif termed APIM. This motif, being incorporated in peptide sequence, interferes with several cellular defense 

systems dealing with stress resulting in both hypersensitivity to chemotherapy and direct induction of apoptosis 

in selected cancer cells. 

Overall, ATX-101 has shown potent preclinical efficacy including single agent activity and potentiation of the 

action of >15 clinical drugs in vitro (cisplatin, melphalan, bleomycin, cytarabine, decitabine, dasatinib, vorinostat, 

bortezomib and others) as well as proof-of-efficacy in animal models of blood cancer and solid tumor indications. 

Currently, ATX-101 is being developed as a novel candidate drug for various oncology indications. 

MANAGEMENT 

Kostas Alevizopoulos Ph.D., Chief Executive Officer 

Marit Otterlei Ph.D., Chief Scientific Officer 



SPEAKERS 


ORGANISERS

CONTACTS 

Dr Bassam Damaj 

Chairman, President & CEO 

Ed Cox 

VP Corporate Development & IR 

ADDRESS 

6330 Nancy Ridge Dr., Suite 103 

San Diego, CA 92121 

U.S.A. 

TELEPHONE 

(858) 222-8041 

FAX 

(858) 866-0482 

EMAIL 

bdamaj@apricusbio.com 

ecox@apricusbio.com 

YEAR FOUNDED 

1987 

Apricus Biosciences, Inc. 

www.apricusbio.com 


NASDAQ: APRI 

Shares Out: 19.6M* 

Fully-diluted Shs: 22M* 

Float: 16M* 

Cash position $10.2M* 

Share-price $5.26** 

Marketcap ~$105M** 

Ave. Daily volume ~320k** 

2010 Revenues ~$5M 

*As of March 31, 2011, **As of June 24, 2011 


Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets innovative treatments 

that help large patient populations across numerous, high-demand therapeutic classes. The Company has 

four approved products and has developed a strong pipeline of multiple late-stage product opportunities. With 

commercial operations in both the U.S. and Europe (France), Apricus Bio generates revenues and growth from 

sales of its commercial products and by out-licensing, in certain territories, its pipeline products and NexACT® 

technology. 

Apricus Bio’s growth strategy is to acquire, develop, and commercialize new products through strategic 

partnerships. The Company currently has commercial partnerships with multiple large pharmaceutical companies 

including Novartis, Abbot Laboratories, Takeda, Sandoz, Warner Chilcott and Bracco, and co-promotes multiple 

products in France. 

Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on the NASDAQ under the ticker 

symbol APRI. 

MANAGEMENT 

Dr Bassam Damaj, Chairman, President and Chief Executive Officer 

Steve Martin, Senior Vice President and Chief Financial Officer 

Edward Cox, Vice Corporate Development and Investor Relations 

Randy Berholtz, Executive Vice President, General Counsel and Secretary 



SPEAKERS 


ORGANISERS

CONTACTS 

Harren Jhoti, PhD 

President & Director 

Timothy Enns 

Senior Vice President – 

Corporate Communications & 

Marketing 

ADDRESS 

US Corporate Office 

4140 Dublin Blvd., Suite 200 

Dublin, CA 94568 

European Office 

436 Cambridge Science Park 

Cambridge, CB4 0QA, UK 

TELEPHONE 

US: +1 925.560.0100 

UK: +44 (0) 1223 226200 

FAX 

US: +1 925.560.0101 

UK: +44 (0) 1223 226201 

EMAIL 

Tim.Enns@astx.com 

YEAR FOUNDED 

1991 

Astex Pharmaceuticals, Inc. 

www.astx.com 


• $121 M in unrestricted cash, cash equivalents and marketable securities (current & non-current) 

as of 6/30/12 

• Up to $70.0 M in projected 2012 DACOGEN® royalty revenue 

• Significant potential product milestones plus future royalty revenues 


Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics 

with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating 

de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed 

Dacogen® (decitabine) for Injection and receives significant royalties on global sales. 

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com. 

MANAGEMENT 

Officers 

James S.J. Manuso, PhD, MBA, Chairman & CEO 

Harren Jhoti, PhD, President and Director 

Mohammad Azab, MD, MSc, MBA, Chief Medical Officer 

Martin Buckland, DPhil, MBA, Chief Business Officer 

Michael Molkentin, CPA, CFO & Corporate Secretary 

Senior Management 

Timothy Enns, Senior Vice President, Corporate Communications and Marketing 

Lyn Leaper, EPA, PhD, Senior Vice President, Intellectual Property 

Michael McCullar, PhD, MBA, Senior Vice President, Business Development 

David Rees, PhD, Senior Vice President, Medicinal Chemistry 

Neil Thompson, PhD, Senior Vice President, Biology 



SPEAKERS 


ORGANISERS

CONTACT 

Carina Schmidt 


ADDRESS 

Fogdevreten 2A 

17165 SOLNA 

SWEDEN 

TELEPHONE 

+46 8 508 847 44 

Carina Schmidt 

+46 76 1938 190 

EMAIL 

info@athera.se 

c.schmidt@athera.se 

YEAR FOUNDED 

2002 

Athera Biotechnologies AB 

www.athera.se 


Current shareholders, including Karolinska Development AB (publ), Baltic Sea Foundation and KCIF Coinvestment 

Fund AB, have invested nearly €17 m in the company. 

Athera is currently in discussion with investors to raise €10 m to fund the Phase I clinical trial of PC-mAb. 

Athera plans to partner the program with pharma partners at the end of Phase I trial. Current shareholders have 

committed to invest up to 1/3rd of the current financing need. 


PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, 

phosphorylcholine (“PC”), and will be indicated for secondary prevention to improve outcome after acute 

coronary syndrome (“ACS”). Low endogenous levels of antibodies to phosphorylcholine (“anti-PC”) have been 

linked to a higher incidence of secondary events as well as a markedly increased mortality after the coronary 

event. This program is in IND-enabling studies and the IND is expected in 2013. 

To enhance clinical success by properly selecting the target population, Athera has developed a proprietary 

companion diagnostic CVDefine® kit to identify patients with low anti-PC levels in need of receiving PC-mAb 

therapy. The kit is CE-approved. 

Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory bio-therapeutics 

and companion diagnostics for the prevention and treatment of cardiovascular disease (“CVD”). The Company 

initiated its current program, harnessing breakthrough innovations made at the world-renowned Karolinska 

Institute. The company currently has a proprietary pre-IND program, PC-mAb, supported by an approved 

proprietary companion diagnostic kit. 

MANAGEMENT 

Athera is managed by a team of senior professionals from the pharmaceutical and diagnostics industries in 

a semi-virtual organization. The core team is led by CEO, Carina Schmidt. Ms. Schmidt has nearly 30 years 

industrial experience, mainly in business development and management, international marketing and product 

management within the biotech area. During 15 years she has worked with Pharmacia Biotech/Amersham 

Biosciences (now GE HealthCare). Later she founded Grasp Bioscience and co-founded BioBusiness Partners 

Scandinavia, where positions included management consultant, interim CEO and business advisor to several 

biotech start-ups. 

In Nov 2011, a new Scientific Advisory Board was formed in Athera, which includes Professors Peter Libby, 

Maarten Simoons, Lars Wallentin and Ulf de Faire. 



SPEAKERS 


ORGANISERS

CONTACTS 

Dr José de Chastonay 

Chief Marketing Officer 

Bachem Holding AG 

Markus Schwaller 

Business Development Manager 

Bachem AG 

ADDRESS 

Hauptstrasse 144 

4416 Bubendorf 

Switzerland 

TELEPHONE 

+41 61 935 2323 

FAX 

+41 61 935 2325 

EMAIL 

sales.ch@bachem.com 

YEAR FOUNDED 

1971 

Bachem 

www.bachem.com 


1. Half-Year Year 

2012 2011 

Sales (in MCHF) 76.2 145.8 

EBITDA (in MCHF) 19.8 33.2 

EBIT in % of sales 13.9% 10.2% 

Net income (in MCHF) 7.1 9.4 

Net income in % of sales 

Earnings per share 

9.3% 6.5% 

(EPS – in CHF) 

Number of employees 

0.53 0.70 

(in full-time equivalents) 649 671 


Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma 

and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and 

complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for 

research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem 

works on a global scale and holds a leading position in the field of peptides. 

MANAGEMENT 

Board of Directors 

Dr h.c. Peter Grogg, Honorary Chairman 

Dr Kuno Sommer, Chairman 

Dr Thomas Burckhardt, Secretary 

Nicole Grogg Hötzer 

Dr Jürgen Brokatzky-Geiger 

Prof Dr Hans Hengartner 

Dr Rolf Nyfeler 

Corporate Executive Commitee 

Dr Thomas Früh, CEO 

Stephan Schindler, CFO 

Dr Daniel Erne, CTO 

Dr José de Chastonay, CMO 



SPEAKERS 


ORGANISERS

CONTACT 

Mr Richard Godfrey 


ADDRESS 

BerGenBio AS 

Jonas Lies vei 91 

5009, Bergen, 

Norway 

TELEPHONE 

+47 917 86 304 

EMAIL 

Richard.Godfrey@bergenbio.com 

YEAR FOUNDED 

2009 

BerGenBio AS 

www.bergenbio.com 


Private Company: – Revenue generating 

– VC funded 

– Series A 2011 $10m 

Investors: • Sarsia Seed Fund • Investinor Fund 

Capital plans: – Series B Q4 2012. 


BerGenBio`s mission is to develop novel therapeutics against emerging targets for advanced cancer. 

The company has a deep understanding of the tumor microenvironment and mechanisms of action that result in 

epithelial-to-mesenchymal transition (EMT), the formation of cancer seeding (stem) cells and drug resistance. 

The company is built on proprietary CellSelect technology platform used to identify and validate novel drug 

targets and de-risk and accelerate the development of novel therapeutic candidates. 

BerGenBio has a pipeline of clinical and preclinical candidates. The company is simultaneously developing 

biomarker and PD assays as companion diagnostics for its pipeline of drug leads. 

With its headquarters in Bergen Norway, BerGenBio has established a fully integrated in vitro & in vivo research 

and development infrastructure and a drug discovery and clinical development team in UK. 

PIPELINE 

BGB324 First in class, highly selective Axl inhibitor. Poised to enter Ph1 Q1`13. 

BGB109 mAb inhibitor of Axl. Preclinical candidate at LO stage 

BGB002 Undisclosed target, discovery stage 

TECHNOLOGIES 

CellSelectRNAi Identify novel targets missed by other methods 

CellSelectImaging in vivo & in vitro imaging and recovery of cells 

CellSelectScreening High throughput in vitro assays and screening 

CellSelectModeling Advanced in-vitro and in-vivo models 

CellSelectRegulated Genetic dose response treatment/disease models 

MANAGEMENT 

Prof James Lorens, CSO – (James.Lorens@bergenbio.com) 

Dr David Micklem, CTO – (David.Micklem@bergenbio.com) 

Dr Longen Zhou, Director of Cancer Biology 



SPEAKERS 


ORGANISERS

CONTACT 

Liz Hudson 

Office Manager 

ADDRESS 

Meditrina Building 

Babraham Research Campus 

Cambridge 

CB22 3AT 

TELEPHONE 

+44 1223 497415 

FAX 

+44 1223 832177 

EMAIL 

liz.hudson 

@bicycletherapeutics.com 

YEAR FOUNDED 

2009 

Bicycle Therapeutics Limited 

www.bicycletherapeutics.com 


Funded by £3.95m seed investment with four blue chip investors: 

• Atlas Ventures • Novartis Venture Funds • SR One • SV Life Sciences 


Bicycle Therapeutics is a biotechnology company based at the Babraham Research Campus in Cambridge, UK 

developing a novel technology which uses biological selection methods to identify molecules which combine 

features of small molecular weight drugs and and biopharmaceuticals. The technology allows the identification 

of highly constrained peptides with high potency and selectivity against the target of interest. Bicycle peptides 

have properties that overcome many of the deficiencies of previous generations of peptide based drugs and 

the Bicycle libraries offer a vast diversity with which to interrogate target space. Bicycle technology is based on 

the work performed at the MRC Laboratory of Molecular Biology in Cambridge by the scientific founders of the 

company, Prof Christian Heinis and Sir Gregory Winter. The company was founded in July 2009 and received 

initial seed funding from Atlas Venture and Novartis Venture Fund who were subsequently joined by SVLS and SR 

One to complete the seed phase syndicate. 

MANAGEMENT 

Dr Rolf Guenther, CEO 

Dr John Tite, CSO 



SPEAKERS 


ORGANISERS

CONTACTS 

Tom Kronbach, PhD 


Viktor Viehweg 


ADDRESS 

BioCrea GmbH 

Meissner Strasse 191 

01445 Radebeul 

Germany 

TELEPHONE 

+49 351 4043 3374 

Tom Kronbach 

+49 351 4043 3332 

Viktor Viehweg 

+49 351 4043 3252 

FAX 

+49 351 4043 3216 

EMAIL 

infobiocrea@biocrea.com 

tom.kronbach@biocrea.com 

viktor.viehweg@biocrea.com 

YEAR FOUNDED 

2010 

BioCrea GmbH 

www.biocrea.com 


Private Company, initial funding by Biotie Therapies, which has a minority stake. 


biocrea discovers and develops novel drugs for the treatment of debilitating CNS diseases such as schizophrenia 

or Huntington’s disease. 

The company’s team has an exceptional track record in the development of CNS drug candidates and has 

partnered extensively with major pharmaceutical companies such as Boehringer-Ingelheim, Pfizer, Wyeth and 

GlaxoSmithKline. biocrea is based in Radebeul, Germany. 

MANAGEMENT 

Dr Thomas Kronbach, Chief Executive Officer 

Viktor Viehweg, Chief Financial Officer 

Dr Martin Gunthorpe, Chief Scientific Officer 

Prof Simon Ward, Executive Vice President Chemistry & Development 



SPEAKERS 


ORGANISERS

CONTACTS 

Dr Marcel Tigges 

Chief Scientific Officer 

Dr Marc Gitzinger 


Patrick Burgermeister 

Advisor 

ADDRESS 

BioVersys AG 

c/o Technologiepark Basel 


CH-4057 Basel 

Switzerland 

TELEPHONE 

+41 61 633 22 50 

+41 61 633 22 51 

FAX 

+41 61 633 22 59 

EMAIL 

info@bioversys.com 

marcel.tigges@bioversys.com 

Marc.gitzinger@bioversys.com 

Patrick.burgermeister@eisei.ch 

YEAR FOUNDED 

2010 

BioVersys AG 

www.bioversys.com 


Seed Round: CHF 2.5 million (2011) 

Series A: CHF 12 million expected for end 2012 


BioVersys is a privately held Swiss bio-pharmaceutical company located in Basel that focuses on research and 

development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and 

restore the efficacy of approved antibiotics. 

BioVersys has developed a proprietary multi-level screening technology to identify small chemical molecules that 

interfere with bacterial transcriptional regulators. These Transcription Regulator Inhibitory Compounds (TRICs) are 

able to switch off bacterial resistance at a genetic level and thus reactivate ineffective antibiotics. 

Currently, the company has identified active TRIC molecules acting against gram negative and gram positive 

pathogens. In collaboration with the INSERM Lille the company also follows a program directed against multi 

drug resistant Tuberculosis 

MANAGEMENT 

Dr Marc Gitzinger, co-founder and CEO 

Dr Marcel Tigges, co-founder and CSO 



SPEAKERS 


ORGANISERS

CONTACTS 

Andreas Caduff, PhD 


Mark Talary, PhD 

Chief Technical Officer 

ADDRESS 

Technoparkstr. 1 

8005 Zurich 

Switzerland 

TELEPHONE 

+41 44 515 61 71 

+41 79 677 41 79 

FAX 

+41 44 515 61 71 

EMAIL 

andreas.caduff@biovotion.com 

YEAR FOUNDED 

2011 (taken over IP and technology 

from former Solianis) 

BioVotion AG 

www.biovotion.com 


BioVotion is currently raising a CHF5.5M Series B round for product finalization, further clinical testing, regulatory 

approval, production ramp-up and initial market launch. Revenue generation is expected within 12 to 18 months. 

Revenues in the European COPD market, the first of several addressable markets, should reach around CHF30M 

by 2016. Cash break-even is envisaged for late 2015. 


BioVotion AG is a Swiss based medical device company, providing solutions for continuous, non-invasive 

physiological monitoring. The BioVotion Vital Sign Monitoring (VSM) platform is a mobile, standalone wearable 

monitor of vital sign parameters supported by integrated cloud services for data exchange and analysis. It is 

directed towards patients with chronic conditions featuring BioVotion’s patient-friendly, wearable monitoring 

concept. 

The company holds internationally recognised know how in a number of fields, relevant to provide sensor 

technology and device development for continuous and non-invasive physiological monitoring, embedded into 

mHealth environments. 

MANAGEMENT 

BioVotion AG is a Swiss medical device company established by leading and experienced experts in the field of 

sophisticated, wearable monitoring. 

Andreas Caduff, PhD, Chief Executive Officer 

Mark Talary, PhD, Chief Technical Officer 



SPEAKERS 


ORGANISERS

ADDRESS 

Boehringer Ingelheim Venture Fund 

Backoffice 

Binger Strasse 173 

55216 Ingelheim am Rhein 

GERMANY 

TELEPHONE 

+49 6132 77 8740 

EMAIL 

Venture 

@boehringer-ingelheim.com 

YEAR FOUNDED 

April 2010 

Boehringer Ingelheim 

www.boehringer-ingelheim-venture.com/ 

Financial Summary 

Total fund volume: €100 Mio 

• Initial investment at an early stage of company’s life 

• Follow-on investments in pace with the company’s progress 

• Staged investments of up to €10 mio over company’s lifetime 


Okairos is a clinical stage vaccine company. 

www.okairos.it 

AMP Therapeutics is engaged in the discovery and commercialization of new medicines for the treatment of 

severe bacterial infections predominantly caused by drug-resistant Gram-negative bacteria. 

www.amp-therapeutics.com 

Inserm Transfert Initiative (ITI) is a life-sciences seed and pre-seed VC fund backed by the French government as 

well as by private investors including several major international pharmaceutical groups. 

www.it-initiative.fr 

Promethera Biosciences’ mission is to develop an allogenic cell therapy approach to treat inborn metabolic liver 

diseases. 

www.promethera.com 

MANAGEMENT 

Dr Michel Pairet, Senior Vice President, Head of the Borhringer Ingelhiem Venture Fund 

Dr Ilka Wicke, Director, Investment Manager of the Borhringer Ingelheim Venture Fund 

Dr Martin Heidecker, Director, Investment Manager of the Borhringer Ingelheim Venture Fund 

Dr Knut Elbers, Director, Investment Manager of the Borhringer Ingelheim Venture Fund 

Dr Frank Kalkbrenner, Director, Investment Manager of the Borhringer Ingelheim Venture Fund 



SPEAKERS 


ORGANISERS

CONTACTS 

Dr Blake Paterson 

Co-Founder & CEO 

Mr John Dierkes 

Advisor 

ADDRESS 

2400 Boston Street, Suite 324 

Baltimore, MD 21224 

TELEPHONE 

410-522-8707 

FAX 

410-327-4084 

EMAIL 

bpaterson@cerecor.com 

jdierkes@cerecor.com 

YEAR FOUNDED 

2011 

Cerecor Inc. 

www.cerecor.com 


Pre-revenue 

Funding 

Series A US$ $23.4MM 

May 2012 


Cerecor Inc. is a Maryland-based biopharmaceutical company focused on the discovery, development and 

commercialization of prescription pharmaceuticals whose primary site of activity is in the human nervous system. 

Our mission is to commercialize neuroscience discoveries at Johns Hopkins Medical Institutes (“JHMI”) and our 

founders include world class and highly successful biotechnology investors, scientists and operational experts. 

Our current product opportunities are in cough and schizophrenia, developed under research grants made by the 

Company to various laboratories and research institutes at JHMI. 

MANAGEMENT 

Our management and advisory teams have extensive pharmaceutical product development and 

commercialization experience, with excellence in formulation, clinical development, registration, business 

development and brand management. Members of our management and advisory boards have been involved 

in the development of many different drugs, including the neuroscience blockbuster (>$1B annual revenues) 

products Lyrica®, Cymbalta® and Neurontin®. Our advisory boards and management team possess over 200 

years of academic, pharmaceutical, biotechnology and specialty pharmaceutical experience. 

Blake M Paterson, MD, Co-Founder & CEO 

Reza Mazhari, PhD, VP Drug Discovery & Development 

Sharon Rowland, PhD, VP Regulatory Affairs & Quality 

Karen Krumeich, VP Finance 

John Kaiser, VP Commercialization & Business Development 



SPEAKERS 


ORGANISERS

CONTACT 

Jeroen Rovers, MD PhD 


ADDRESS 

PO Box 85696 

2508CJ Den Haag 


TELEPHONE 

+31 6 52662000 

EMAIL 

j.rovers@ceronco.nl 

YEAR FOUNDED 

2011 

Ceronco Biosciences 

www.ceronco.nl 


Privately funded, First financing round ongoing 


Ceronco Biosciences is a start-up company established recently. It is developing new drugs to fight cancer 

based on the short-chain sphingolipid (SCS) technology discovered in a collaborative research project at the 

Netherlands Cancer Institute (NKI) and Erasmus MC. 

Proof of principle has been established in combining the SCS-technology with doxorubicin in highly relevant 

animal models. Addition of the SCS leads to increase in uptake of doxorubicin, specifically in cancer cells, and 

subsequently a significant reduction in tumor growth and increase in overall survival. At the same time no 

increase in severity of expected side effects or new side effects were noted. 

Ceronco is now taking this first product (CB001) into clinical trials, with expected start of the first clinical trial 

early 2013. 

Technology 

A major barrier for uptake of chemotherapeutic drugs is the cellular membrane of a cancer cell. A new class of 

short-chain sphingolipids (SCS) has been identified which insert themselves into the cellular membrane and lead 

to catalysis of drug-membrane translocation. This results in increased uptake of a large variety of amphiphilic 

chemotherapeutic drugs. 

Tumor Cell Membrane Modulation using the SCS-technology is a novel and unique method to increase the 

efficacy of chemotherpaeutic drugs. 

Products 

CB001: GluCer-enhanced liposomal doxorubicin 

CB002: SCS-enhanced mitoxantrone 

MANAGEMENT 

Jeroen Rovers, Chief Executive Officer 



SPEAKERS 


ORGANISERS

CONTACT 

Wolfgang Kintzel 


ADDRESS 

Gottfried-Hagen-Str. 62 

51105 Koeln 

Germany 

TELEPHONE 

+49 221 460208 00 

FAX 

+49 221 460208 01 

EMAIL 

kintzel@cevec.com 

YEAR FOUNDED 

2001 

Cevec Pharmaceuticals GmbH 

www.cevec.com 


Since 2009 CEVEC successfully markets its cell based technology for protein and antibody production. The 

company has attracted 14 Mio. EUR venture capital in several venture rounds up to now. Lead investors include 

Creathor Venture and NRW.Bank 


The CAP vaccine business case: 

CEVEC commercializes an innovative platform technology for the production of vaccines and biopharmaceuticals 

in human cell lines. 

CEVEC’s CAP cells hold high promise for a best-in-class production system for viral vaccines, such as hCMV, 

Influenza and others, as shown by a recent case study. Compared to leading other cellular production systems 

(like MDCK) CAP demonstrated outstanding results in view of virus yield, extreme short production cycles and 

minimal media consumption. CEVEC’s CAP system is suspension based and serum free offering the best starting 

point for new vaccine production approaches with excellent upscaling possibilities. Being the only remaining 

independent supplier for human production cell lines, the company sets out to repeat the growth story of Crucell 

B.V., recently acquired by Johnson & Johnson for 2.4 Bn US$. 

Feasibility studies further demonstrated CAP being a versatile virus production platform with a broad 

susceptibility for various human-pathogenic human viruses. Commercially significant targets include hCMV, RSV, 

Influenza, Polio, Measles, AAV, Adenoviruses, Lentiviruses and others. Several lead projects have been identified 

and planned, including the first human platform for hCMV, together with its partner Vaccine Project Manager, 

Hannover, Germany. 

CEVEC is underway to close another 7-10 Mio. EUR venture round. This investment will be used to push the 

vaccine lead projects, such as hCMV within 3 years to clinical phase I/IIa results and manage a broad roll-out of 

its vaccine production technology in order to maximize its company exit value by 2015. Venture investors are still 

invited to participate in an exciting low-risk and high return growth story. 

MANAGEMENT 

Wolfgang Kintzel, CEO 

Dr Rainer Lichtenberger, Managing Director, CFO/COO 

Dr Gudrun Schiedner, CSO 

Dr Nicole Faust, VP Development & Services 

Gary Boch, VP BD North America 

Dr Hartmut Tintrup, Dir. BD Europe & ROW 



SPEAKERS 


ORGANISERS

CONTACTS 

Dr Julian Bertschinger 


Dr Dragan Grabulovski 


Dr Fabian Buller 

Director Business Development 

ADDRESS 

Covagen AG 

Wagistrasse 25 

Schlieren, 8952 

Switzerland 

TELEPHONE 

+41 44 732 46 60 

FAX 

+41 44 732 46 64 

EMAIL 

info@covagen.com 

YEAR FOUNDED 

2007 

Covagen AG 

www.covagen.com 


Investors: • Novartis Venture Fund • Edmond de Rothschild Investment Partners • Ventech 

• Seroba Kernel Life Sciences • MP Healthcare Venture Management 


Covagen is a privately held company pioneering the commercialization of Fynomers and bispecific Fynomerantibody 

fusions (FynomAbs) as next generation protein drugs to address unmet medical needs in inflammatory 

diseases and cancer. Fynomers are small binding proteins that can be engineered to bind to any antigen of 

interest. Because of their excellent biophysical properties, Fynomers can be readily fused to therapeutic proteins 

such as antibodies to create bispecific FynomAbs. FynomAbs have novel modes of action as they can engage 

simultaneously with multiple antigens or multiple binding sites on the same target. At the same time, FynomAbs 

maintain the advantageous drug-like properties of antibodies such as excellent stability and long half-life. 

Covagen’s lead program is a bispecific TNF/IL-17 inhibitor (in preclinical development) for the treatment of 

inflammatory diseases such as psoriasis, psoriatic arthritis and rheumatoid arthritis. 

MANAGEMENT 


Frank Walsh, Executive Chairman 

Ray Hill, Franz Hefti, Anja König, Gilles Nobécourt, Mounia Chaoui, Jon Hepple, Julian Bertschinger 

Scientific Advisory Board 

Greg Winter, Ulrich Feige, Thierry Hercend, Christoph Heusser, Christoph Lengauer 



SPEAKERS 


ORGANISERS

CONTACT 

Mike Romanos PhD 


ADDRESS 

Meditrina Building 260 

Babraham Research Campus- 

Cambridge 

CB22 3AT 

TELEPHONE 

+44 1223 497143 

FAX 

+44 1223 497141 

EMAIL 

mromanos 

@crescendobiologics.com 

YEAR FOUNDED 

2009 

Crescendo Biologics Limited 

www.crescendobiologics.com 


Funding to date: GBP 7.7m 

Investors: • Sofinnova Partners • Babraham Bioscience Technologies • Avlar BioVentures • Rainbow Seed Fund 


Crescendo Biologics has developed a novel antibody fragment discovery platform which generates fully human 

VH fragments by immunisation of a transgenic mouse. 

The company’s strategy is to utilise the platform in the key value areas for the smallest and most robust antibody 

fragments, especially in topical products and bi-specifics. It intends to exploit its unique capabilities to create 

differentiated medicines both through its in-house pipeline and through strategic partnerships. 

The Crescendo mouse platform was conceived at the Babraham Institute, Cambridge, by Dr Marianne 

Bruggemann, a pioneer in the field who was the first to engineer transgenic mice to produce human antibodies. 

It is based on the generation of human heavy chain antibodies by transgenic mice, analogous to similar 

antibodies produced naturally in llamas. However in this case they are fully human and provide candidate-quality 

VH fragments directly. VH fragments are the smallest portions of immunoglobulin that retain target specificity and 

potency and, compared to whole antibodies, have properties more akin to small molecules, making them highly 

attractive therapeutic agents. 

The company benefits from a management team that is highly experienced in all aspects of antibody platforms, 

antibody discovery and development, and the support of a syndicate of experienced life science investors led 

by Sofinnova Partners. It is based at the Babraham Research Campus and maintains strong links with the 

Babraham Institute and the antibody science community in Cambridge. 

MANAGEMENT 

Mike Romanos PhD, CEO 

Matthew Roe, Chief Business Officer 

Amanda Bettison, Head of Business Operations 

Clive Dix PhD, Chairman 



SPEAKERS 


ORGANISERS

CONTACT 

Guus Scheefhals, 


ADDRESS 

Padualaan 8 

3584 CH Utrecht 


TELEPHONE 

+31 30 253 2668 

FAX 

+31 30 253 7131 

EMAIL 

g.scheefhals@crossbeta.com 

YEAR FOUNDED 

2005 

Crossbeta Biosciences B.V. 

www.crossbeta.com 


Stabilizing oligomers and targeting toxic oligomers is the basis for Crossbeta’s oligomer drug discovery 

platforms which are accessible for partnering in therapeutics areas such as Alzheimer´s, Parkinson’s, Huntington 

and Diabetes Type 2. 

In our Alzheimer program we have recently completed a high throughput screening campaign with 100,000 

compounds resulting in the selection of 5 hit classes with >50% neutralizing effect on oligomer-induced 

neurotoxicity. 

Stable oligomers can also be used as reference in biomarker assays. 

MANAGEMENT 

Guus Scheefhals, Chief Executive Officer 

Martijn Gebbink, Chief Scientific Officer 



SPEAKERS 


ORGANISERS

CONTACT 

Harry Welten, MBA 


ADDRESS 

Cytos Biotechnology AG 


CH-8952 Schlieren 

TELEPHONE 

Direct phone: +41 44 733 4646 

Mobile: +41 79 750 1564 

FAX 

Direct fax: +41 44 733 4702 

EMAIL 

harry.welten@cytos.com 

YEAR FOUNDED 

1995 

CYTOS Biotechnology AG 

www.cytos.com 


Cash and cash equivalents per June 30, 2012: CHF 36.1 mln 


Cytos Biotechnology is dedicated to the discovery, development and commercialization of a novel class of 

medicines – called Immunodrugs. 

Immunodrugs are therapeutic vaccines intended for use in the treatment and prevention of common chronic 

diseases which afflict millions of people worldwide. 

The Company’s lead program is CYT003, a novel allergen-independent Immunodrug with disease-modifying 

potential in Phase II clinical development for allergic asthma, and with potential to treat a broad range of different 

allergies. 

MANAGEMENT 

Dr Thomas Hecht, Executive Chairman 

Dr Frank Hennecke, EVP Product Development 

Dr Philipp Müller, EVP Clinical Development 

Harry Welten, MBA, Chief Financial Officer 



SPEAKERS 


ORGANISERS

CONTACT 

Marcel Zwaal 

Chief Business Officer 

ADDRESS 

Galileiweg 8 

2333 BD Leiden 


TELEPHONE 

+31 71 332 2626 

Marcel Zwaal 

M: +31 6 11757250 

EMAIL 

info@dcprime.nl 

m.zwaal@dcprime.nl 

YEAR FOUNDED 

2007 

DC Prime 

www.dcprime.nl 


DCPrime is a Dutch biotech company which has developed a novel approach to cancer vaccines. The company’s 

unique platform technology consists of sustainable dendritic progenitor cells (DCOne) and a proprietary 

method to expand these and to create functional mature dendritic cells (DC). 

These cells, in some indications loaded with cancer antigens for targeted treatment, are used as standardized, 

off-the-shelf, therapeutic products that can stimulate the patient’s immune system in a specific manner. The 

platform combines the power of DC-based vaccines with the advantages of allogeneic stimulation of the immune 

system, and the simple logistics of off-the-shelf products. 

MANAGEMENT 

Dr Ada Kruisbeek, CSO/CEO 

Mr Marcel Zwaal, CBO 

Dr Sandra van Wetering, COO 



SPEAKERS 


ORGANISERS

CONTACT 

Barbara Stiefel 

Office Management 

ADDRESS 


CH-8952 Schlieren 

Switzerland 

TELEPHONE 

+41 44 730 51 80 

Barbara Stiefel 

+41 44 730 51 80 

FAX 

+41 44 730 51 81 

EMAIL 

info@delenex.com 

YEAR FOUNDED 

2009 

Delenex Therapeutics AG 

www.delenex.com 


Series A (CHF 30.2 Mio) closed May 2011. 


Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibodies for 

(i) topical administration in severe chronic conditions, and 

(ii) systemic administration in acute diseases. 

Its proprietary compound class, PENTRA® antibodies, are highly tissue-penetrant. 

The company is focused in immuno-inflammation, and within this in three specific areas: dermatology, GI and 

acute inflammation. 

Three PoC clinical projects are currently active 

1. antibody-containing ointment for topical administration in plaque psoriasis 

2. antibody-containing gel for topical administration in Crohn’s fistulas (entry indication for IBD) 

3. intravenous administration for Behçet’s Disease (entry indication for acute inflammation) 

Two clinical trials have already met their endpoints 

a. Proof of mechanism in psoriasis patients (safety and exploratory efficacy) 

b. Systemic safety in healthy volunteers 

MANAGEMENT 

Eric de La Fortelle, Chief Executive Officer 

Thomas Jung, Chief Medical Officer 

Titus Kretzschmar, Chief Scientific Officer 

Jakob Schlapbach, Chief Financial Officer 



SPEAKERS 


ORGANISERS

CONTACT 

Stavros Therianos (speaker) 


ADDRESS 

Chemin de la Vuillette 4 

CH-1000 Lausanne 25 

Switzerland 

TELEPHONE 

+41 21 989 2000 

FAX 

+41 21 989 2001 

EMAIL 

stherianos@diagnoplex.com 

YEAR FOUNDED 

2005 

Diagnoplex SA 

www.diagnoplex.com 


CHF 15 million in series “A” 


We are a dedicated and multi-disciplinary team united in bringing true innovation to personalized cancer care. 

Using our unique molecular workflow and state-of-the-art biostatistical tools, we develop blood-based cancer 

diagnostic tests. Our initial focus is on systematic screening for colorectal cancer. This is an area of increasingly 

urgent and unmet medical need as a result of an ageing population, and one that represents an estimated 

market opportunity of $3.5 billion. 

Diagnoplex lead product, Colox, is a convenient and non-invasive blood test developed for the systematic 

screening of colorectal cancer (Colorectal cancer). The gene signature underlying Colox detects early and 

advanced disease stages with outstanding results and reliability. 

SCIENTIFIC FOCUS 

Cancer, RNA Therapeutics, Preclinical 

MANAGEMENT 

Lothar Wieczorek, Ph.D., Executive Chairman 

Lothar Wieczorek has been at the forefront of the development of medical devices and products in the US and European 

Pharmaceutical and Diagnostics industries throughout his 30-year career, where he has held senior positions in R&D, Business 

Development, Strategic Planning and Medical Affairs. 

Stavros Therianos, Ph.D. Chief Executive Officer 

Stavros Therianos is one of the principal founders of Diagnoplex and has been with the company since 2005. Stavros is 

a consummate entrepreneur who brings his talent and passion to Diagnoplex science and business activities. Prior to the 

founding of Diagnoplex, he was an assistant professor at the University of Rochester Medical Center, USA. 



SPEAKERS 


ORGANISERS

CONTACTS 

Ana Martinez 

Assistant 

Juan Ruiz 

Chief Operating Officer and 

Chief Medical Officer 

Fernando Terron 

Business Development 

ADDRESS 

Avda Pio XII, 22 Office 2 

CP 31008 Pamplona. 

Navarra 

Spain 

TELEPHONE 

+34 94 828 7600 

FAX 

+34 94 818 0500 

EMAIL 

amartinez@dignabiotech.com 

jruiz@dignabiotech.com 

fterron@biolty.com 

YEAR FOUNDED 

2004 

Digna Biotech, S.L. 

www.dignabiotech.com 


Capital raised to date in excess of 30 M€. 

Currently interested in raising an additional 20 M€ 


DIGNA Biotech is a private biotechnology company headquartered in Pamplona (Spain), with offices in Madrid 

and Pennsylvania (USA). It was founded in 2004 as a spin-off of the University of Navarra. The firm currently has 

a pipeline of 9 products at different stages of development in 3 therapeutic areas: Inflammatory/Autoimmune, 

Cardiovascular and Liver diseases. 

Digna Biotech is seeking private funding to spin out a new biotech company to conduct Phase IIb and Phase III 

trials of its more advanced candidate, a cytokine inhibitor for the treatment of patients with Systemic Sclerosis 

and Localized Scleroderma. The product (Disitertide) has already completed Phase I, Phase IIa and open-label 

extension (OLE) clinical trials under a topical formulation in patients with systemic sclerosis. Orphan drug 

designation by both FDA and EMA has been granted in the two indications. 

MANAGEMENT 

Pablo Ortiz, MD, PhD, CEO. – (portiz@dignabiotech.com) 



SPEAKERS 


ORGANISERS

CONTACT 

Ahmed Abdelaziz 


ADDRESS 

Ingolstädter Landstraße 1, 

Building 60W D-85764 

Munich-Neuherberg, 

Germany 

TELEPHONE 

Office: +49 89 3187 2954 

Mob: +49 157 7688 7277 

FAX 

Fax: +49 89 3187 4584 

EMAIL 

Ahmed.abdelaziz@eadmet.com 

YEAR FOUNDED 

2010 

eADMET GmbH 

www.eadmet.com 


The company was founded in 2010 and received GO-Bio phase II funding (as well as exclusive rights to all 

developments funded by GO-Bio phase I) that supports the company until Q1 / 2013. In 2011, eADMET received 

additional funding from High-Tech Gründerfonds and Bayern Kapital that brought the total funding of dilutive and 

non-dilutive capital to € 1.45 million. 


eADMET GmbH is a technology-driven company with a strong focus on the informatics solutions and consultancy 

services in the life science area, in particular ADMETox properties prediction, QSAR & QSPR modeling, 

interpretation and data integration. eADMET is located in Munich, Germany, and employs strong partnerships 

with chemoinformatic service providers worldwide. eADMET is a leader in providing chemical software platforms 

and web applications for the biotechnology and pharmaceutical industries and creates leading edge crossplatform 

solutions to power modern collaborative chemoinformatics. 

MANAGEMENT 

Ahmed Abdelaziz, CEO 

Wolfram Teetz, CEO 

Igor Tetko, CSO 



SPEAKERS 


ORGANISERS

CONTACTS 

Dr Rudi D Neirinckx 


Dr Peter Burckhardt, 

Board Member 

ADDRESS 


CH-4057 Basel 

Switzerland 

TELEPHONE 

061 283 8485 

FAX 

061 283 8486 

EMAIL 

rudi_neirinckx@hotmail.com 

YEAR FOUNDED 

2010 

Ennar Pharma AG 


The company is financially supported by an investment by EVA- a Basel based venture capital company and by 

the private funds of the founder. 


Ennar Pharma was founded in July 2010 to develop a better and safer topical treatment for mild-to-moderate 

psoriasis. Patents, protecting the technology, have been granted in Europe and the USA. The company is 

financially supported by an investment by EVA- a Basel based venture capital company- and uses a network 

of strategic partners to develop the production of EGF and develop a suitable cream-based pharmaceutical 

product. Producers for the cGMP production of high-quality EGF(epidermal growth factor) and for a stable 

cream formulation of the active ingredient have been contracted and a Proof-of-Concept trial is running at the 

Dermatology Clinic of the University of Zurich. The trial, which is carried out with mild-to-moderate psoriasis 

patients, aims to establish the validity of the mode-of-action proposed for the EGF-based topical formulation and 

test an optimised formulation for clinical efficacy and safety. Results of the trial are expected in Q1 2013. 

MANAGEMENT 

Dr Rudi D Neirinckx, Chief Executive Officer 

Dr Peter Burckhardt, Board Member 



SPEAKERS 


ORGANISERS

CONTACT 

Pierre Belichard 


ADDRESS 

Enterome 

94-96 Avenue Ledru-Rollin 

75011 Paris - France 

TELEPHONE 

+33 17 577 2786 

Pierre Belichard 


+33 68 153 9633 

EMAIL 

belichard@enterome.com 

YEAR FOUNDED 

2011 

Enterome 

www.enterome.com 


A round €7m 

Seventure 

Lundbeckfond 

Omnes 

Shire 


Enabling Diagnostic Solutions for gut microbiota-related diseases. 

Paris-based Enterome is a privately owned stratified medicine company, dedicated to the development of 

innovative diagnostic products based on recent progress in metagenomics of the human intestinal microbiota. 

Our intestine harbors an incredible number of bacteria, the gut microbiota, encoding 150-fold more genes than 

our own genome. Each individual has his own personal and unique microbiota, with a large diversity between 

individuals. The contribution of the gut microbiota in health and diseases is undisputed, and recent studies 

demonstrated major alterations of the gut microbiota composition in patients with metabolic and inflammatory 

bowel diseases 

Enterome’s objective is to identify biomarkers in metagenomic signatures, translate them into diagnostic tools 

and validate them vs. clinical outcomes. 

Current portfolio comprises four diagnostic products, the most advanced to be marketed in 2014 

MANAGEMENT 

Pierre Belichard, CEO 

Marie-Laure Bouttier, COO 

James Clark, CTO 

Rodolphe Clerval, CBO 

Pierre Rimbaud, CMO 



SPEAKERS 


ORGANISERS

CONTACT 

Martin Bonde, PhD, BComm 


ADDRESS 

Ole Maaloesvej 3 

2200 Koebenhavn N 

Denmark 

TELEPHONE 

+45 2025 3560 

EMAIL 

mb@epitherapeutics.dk 

YEAR FOUNDED 

2008 

EpiTherapeutics ApS 

www.epitherapeutics.dk 


Raised $ 12.2 mill from 5 investors • Novo Seeds • Seed Capital • Lundbeckfond Ventures • Astellas Venture 

• Merck Serono Venture. 


EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics 

conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University 

of Copenhagen. 

EpiTherapeutics’ development programs are focused on enzymes involved in the regulation of transcription in 

cancer – current programs target histone demethylases and methyltransferases. Subsequent developments may 

identify other potential clinical indications outside oncology. 

In December 2010, EpiTherapeutics signed a drug discovery collaboration with Abbott Laboratories. 

EpiTherapeutics employs 25 FTE and is headquartered in Copenhagen. 

MANAGEMENT 

Martin Bonde, PhD, BComm, Chief Executive Officer 



SPEAKERS 


ORGANISERS

CONTACT 

Hans Schambye, MD PhD 


ADDRESS 

Ole Maaloes Vej 3 

DK-2200 Copenhagen 

Denmark 

TELEPHONE 

+45 26 37 37 26 

EMAIL 

hs@galecto.com 

YEAR FOUNDED 

2011 

Galecto Biotech 

www.galecto.com 


Galecto Biotech is a newly founded company, focused on developing novel drugs for the treatment of fibrosis, 

inflammation and other serious human diseases. The company’s products target galectins, a group of proteins 

that play important roles in many disorders. Galecto Biotech’s high potency galectin inhibitors may open new 

treatment possibilities for many patients. The company is led by top-level scientists and biotech executives. 

Galecto Biotech is located in Medicon Valley in close proximity to the founders’ research groups. 

MANAGEMENT 

Hans Schambye, MD PhD, CEO 

Prof Tariq Sethi, B.Sc., M.A., Ph.D., FRCP, CSO 

Prof Ulf Nilsson, PhD, Head, Med Chem 

Prof Hakon Leffler, MD PhD, Head, Immunology & Biology 



SPEAKERS 


ORGANISERS

CONTACT 

Benedikt Timmerman 


ADDRESS 

GENTICEL 

516 Rue Pierre et Marie Curie 

31670 Labege 

FRANCE 

TELEPHONE 

+33 (0)5 61 28 70 60 

FAX 

+33 (0)5 61 28 70 69 

EMAIL 

btimmerm@genticel.com 

YEAR FOUNDED 

2001 

Genticel 

www.genticel.com 


Raised EUR 27.5 Mio, of which EUR 8 Mio in subsidies and revenues), in private, VC-backed Seed-, A- and 

B-rounds. 

Key investors: 

• Edmond de Rothschild Investment Partners 

• IdInvest (Kurma Biofund) 

• CDC Entreprises (Innobio) 

• AMUNDI Private Equity 


Genticel is a biotechnology company focused on developing multivalent vaccines against Human Papillomavirus 

(HPV) infections, which are the known cause for several cancers including cervix carcinoma. 

Genticel’s proprietary vector technology platform, the recombinant Adenylate Cyclase protein vector (CyaA), has 

the potential to be used for a broad range of vaccine applications as it allows the insertion of large antigens by 

recombinant DNA technology. This vector is the only system that naturally targets specific antigens directly to 

and into the cytosol of antigen-presenting cells, leading to a potent and long lasting cellular immune response. 

ProCervix, Genticel’s lead investigational product has been successfully tested in combination with an 

established adjuvant in a clinical phase I study. It is a proprietary, first in class HPV16/18 vaccine for the 

treatment of already infected women with normal cytology or low-grade precancerous lesions, i.e. women who 

have not yet developed high-grade cervical lesions or cancer. ProCervix is designed to eliminate HPV16 and/ 

or 18 infected cells and to provide protection against re-infection. The Phase Ib trial (n=47) displayed no dose 

limiting toxicity and no patient drop-out. The two intradermal injections 6 weeks apart have generally been well 

tolerated with transient vaccine-related reactions. No treatment-related Serious Adverse Effects were reported. 

ProCervix induced a dose-dependent immune response as well as viral clearance in a substantial proportion of 

patients as compared to placebo. IND filing for phase II is scheduled for H1/2013. 

Heptarvix, complementing Genticel´s HPV pipeline, is a preclinical stage, multivalent HPV vaccine candidate 

which is designed to provide protection against up to seven oncogenic HPV types. It is based on an adapted 

proprietary CyaA vector (Vaxiclase). 

Genticel intends raising additional capital to conduct a PoC Phase 2 trial with ProCervix and advance Heptarvix 

up to end of preclinical development. 

MANAGEMENT 

The management team has jointly 60 years of experience in Pharma & Life Science Industry: 

Dr Benedikt Timmerman, MBA, PhD, Founder and CEO 

Dr Marie-Christine Bissery, PhD, PharmD, CSO 

Mr Martin Koch, MBA, Ing., CFO 



SPEAKERS 


ORGANISERS

CONTACT 

Roberto De Ponti 

Head of Corporate Business 

Development 

ADDRESS 

Helsinn Healthcare SA 

Via Pian Scairolo, 

6912 Lugano-Pazzallo 

Switzerland 

TELEPHONE 

+41 91 985 21 21 

Roberto De Ponti 

Direct line: +41 91 985 21 21 

FAX 

+41 91 993 21 22 

EMAIL 

info-HHC@helsinn.com 

rp@helsinn.com 

YEAR FOUNDED 

1976 

Helsinn 

www.helsinn.com 


Helsinn Group’s 2011 Total Net Turnover: CHF 300.2M – EUR 243.9M 

Helsinn Group’s 2011 Total Assets: CHF 436.1M – EUR 359.2M 

Helsinn Group’s R&D Investments in last 5 years: CHF 298.5M 

Helsinn Group’s Staff: Total = 455 

Switzerland = 277 

Ireland = 141 

USA = 37 


Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating 

subsidiaries in Ireland and the United States. Helsinn’s business model is focused on the licensing of 

pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn Group 

in-licenses early-to-late stage new chemical entities, completes their development through the performance 

of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and 

attains their market approvals worldwide. Helsinn’s products are out-licensed to its network of local marketing 

and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists 

and supports by providing a full range of product and scientific management services, including commercial, 

regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished 

products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s 

GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. 

Further information on Helsinn Group is available at www.helsinn.com. 

MANAGEMENT 

Dr Gabriele Braglia, Founder & Chairman 

Dr Riccardo Braglia, Helsinn Group CEO, Board Member & US Chairman 

Dr Luigi Caletti, Group Chief Financial Officer, Board Member & US Board Member 

Dr Giorgio Calderari, Group General Manager & Chief Operating Officer & US Board Member 

Dr Roberto De Ponti, Senior Director, Head of Corporate Business Development 

Dr Andrea Meoli, Chief Commercial Officer 

Dr Sergio Cantoreggi, Chief Scientific Officer 

Dr Matteo Missaglia, Senior Director, General Counsel, Corporate Legal Affairs 

Dr Daniele Bonadeo, Senior Director, Head of Corporate Technical 

Dr Paolo Guainazzi, Local General Manager, Chemical Business, Helsinn Advanced Synthesis 

Dr William Mann, Local President & CEO & Board Member US Pharma Business, Helsinn Therapeutics (U.S.), Inc. 

Dr Padraig Somers, Local General Manager, Pharma Business, Helsinn Birex Pharmaceuticals, Ireland 



SPEAKERS 


ORGANISERS

CONTACT 

Malcolm Weir 


ADDRESS 

Heptares Therapeutics Ltd 

BioPark 

Broadwater Road 

Welwyn Garden City 

Hertfordshire AL7 3AX 

TELEPHONE 

+44 (0)1707 358 629 (dl) 

+44 (0)7968947268 (m) 

FAX 

+44 (0)1707 35840 

EMAIL 

malcolm.weir@heptares.com 

YEAR FOUNDED 

2007 

Heptares Therapeutics Ltd 

www.heptares.com 


$40M venture finance to date from Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund and 

Takeda Ventures. 


Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of 

receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, 

leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based 

discovery. Our partners include Shire, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad 

pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease, 

Parkinson’s disease, schizophrenia, depression, chronic insomnia, addiction, migraine and diabetes. 

Our in-house pipeline is led by our selective muscarinic M1 programme for cognition in Alzheimer’s disease 

and Schizophrenia, which is in preclinical development and slated for Phase 1 studies in 2013. Our adenosine 

A2a antagonist candidate, licensed to Shire, is also in development for neurological disorders. Further discovery 

programmes include oral GLP-1 agonists for T2DM, driven by our proprietary first-ever Family B crystal 

structure, and CGRP antagonists for prophylaxis and treatment of migraine. 

The Heptares technology platform represents a unique GPCR capability in the industry today, opening up new 

possibilities for both small molecule and antibody therapeutics across the GPCR target universe. Heptares 

is the first and only company transforming GPCRs, which are typically highly unstable when removed from 

cellular membranes, into stabilised receptors or StaRs®. StaRs® enable GPCR structures in their natural 

pharmacological conformations to be determined, thereby overcoming a major historical barrier to structurebased 

GPCR drug discovery. Heptares has also invented Biophysical Mapping, which provides superior 

elucidation of GPCR-ligand interactions, and has engineered new fragment-based and in silico technologies 

specifically tailored to GPCR lead discovery and optimisation. These technology breakthroughs, coupled with 

deep expertise in GPCR chemistry and biology, form the nucleus of a powerful and fully-integrated drug 

discovery platform. 

To learn more about the Heptares pipeline and technology platform, please visit www.heptares.com 

MANAGEMENT 

Dr Malcolm Weir, Co-Founder and CEO 

Dr Fiona Marshall, Co-Founder and CSO 

Dr Barry Kenny, CBO 

Dan Grau, President 

Dr Miles Congreve, Head of Chemistry 

Dr David McGibney, CMO and Head of Development 



SPEAKERS 


ORGANISERS

CONTACT 

Juhani Lahdenperä 


ADDRESS 

Hermo Pharma Ltd. 

Viikinkaari 4 

00790 Helsinki 

Finland 

TELEPHONE 

+35 85 0366 9502 

EMAIL 

lahdenpera@hermopharma.com 

YEAR FOUNDED 

2008 

Hermo Pharma Ltd 

www.hermopharma.com 


Not publicly available. 


Hermo Pharma Ltd is a clinical stage biopharmaceutical company discovering and developing cuttingedge 

therapeutic products and approaches for currently untreatable medical needs in the field of neurology. 

Company’s headquarter is located in Helsinki, Finland. The company outsources the majority of operational R&D 

tasks to external vendors, while controlling the key technology assets and strategic partnerships. 

The company’s R&D programs are based on scientifically innovative concepts. These concepts are being 

developed by the company through preclinical and clinical Phase II proof-of-principal trials and after that Hermo 

Pharma will seek partnerships to support Phase III trials and market its products worldwide. Currently Hermo 

Pharma’s product development focus is on novel disease-modifying treatments for amblyopia in adults and 

Parkinson’s disease. 

Amblyopia in Adults. The project is currently in Phase IIa clinical trials and the results seems very promising. 

Company is expecting to out-license this product latest in early 2014. 

Parkinson´s Disease. Company is currently finalizing the pre-clinical proof-of-concepts studies with the support 

of M.J.Fox Foundation financing. The therapy is based on the neuroprotective and restorative effects provided by 

the CDNF protein. The clinical strategy includes of testing of intracrainial delivery platform to treat the patients. 

The current data looks very promising and the company is expecting to proceed into the IND enabling Toxicology 

phase during year 2013. 

MANAGEMENT 

Juhani Lahdenperä, CEO 

Henri Huttunen, CSO 

Sigrid Booms, Head of Clinical Development 


Jonathan Knowles, 

Timo Veromaa, 

Ari-Pekka Laitsaari, 

Henri Huttunen 

Jyrki Mattila 

Scientific Advisory Board 

Eero Castrén 

Mart Saarma 

Mary Baker 

Seppo Kaakkola 

Lamberto Maffei 

Heikki Rauvala 

Pekka Männistö. 



SPEAKERS 


ORGANISERS

CONTACTS 

Mr Paul Higham 


Mr Rainer Kramer 

Director & Head of Business 

Development 

ADDRESS 

immatics biotechnologies GmbH 

Paul-Ehrlich-Straße 15 

72076 Tuebingen 

Germany 

TELEPHONE 

+49 7071 5397-0 

FAX 

+49 7071 5397-900 

EMAIL 

partnering@immatics.com 

info@immatics.com 

YEAR FOUNDED 

2000 

immatics biotechnologies GmbH 

www.immatics.com 


2004/2005: € 14 mn Series A 

2007: € 40 mn Series B 

2010: € 54 mn Series C 

non equity funding total: € 4 mn 


immatics is a biopharmaceutical company dedicated to the development of innovative cancer 

immunotherapeutics. 

immatics ’ proprietary technology for the identification of tumor-associated pep¬tides (TUMAPs) enables the 

development of novel anti-cancer vaccines for multiple cancer indications. immatics is currently developing 

IMA901 for the treatment of renal cell carcinoma in Phase III and IMA910 (in Phase II) for the treatment of 

colorectal carcinoma (CRC). 

For third product, IMA950, for the treatment of malignant glioma (brain cancer) immatics has entered into two 

clinical studies. Further product candidates are currently in pre-clinical development. The furthest advanced of 

which are for gastric and lung cancer. 

immatics was founded in 2000 as a spin-off from the Institute of Immu¬nology at the University of Tuebingen 

(Prof. Hans-Georg Rammensee) and is based in Tuebingen and in Munich, both in Germany. 

MANAGEMENT 

Paul Higham, CEO 

Rainer Kramer, CBO 

Harpreet Singh, CSO 

Carsten Reinhardt, CMO 



SPEAKERS 


ORGANISERS

CONTACT 

Carlos Paya 


ADDRESS 

1124 Columbia Street suite 700 

Seattle, WA 98104 

TELEPHONE 

206-826-7910 

FAX 

206-682-0648 

EMAIL 

carlos.paya@immunedesign.com 

YEAR FOUNDED 

2008 

Immune Design 

www.immunedesign.com 


Since 2008 Immune Design has raised $52M from venture capital funding. 


Immune Design is a privately held biotechnology company based in Seattle, Washington and formed in 2008 

to bring together some of the world’s leaders in the field of immunology, and their technologies, to develop 

therapeutic vaccines for the treatment of infectious and malignant disease. The company’s scientific founders 

are Dr. David Baltimore (Past President of Caltech, Rockefeller University, and the Whitehead Institute and the 

Co-Recipient of the 1975 Nobel Prize in Physiology or Medicine), Dr. Steven Reed (Past Co-founder and CSO 

of Corixa and Founder/CEO of the Infectious Diseases Research Institute), and Dr. Larry Corey (President and 

Director of the Fred Hutchinson Cancer Research Center and Professor of Medicine and Laboratory Medicine at 

the University of Washington). To date Immune Design has raised approximately $52 million from The Column 

Group, Alta Partners, Versant Ventures, and Proquest. 

Immune Design leverages its unique vaccine technologies to precisely control the activation and context of 

antigen presentation by dendritic cells in order to shape the desired adaptive immune response. The first 

technology is a novel adjuvant for recombinant protein antigen (rP)-based vaccines comprising Glucopyranosyl 

Lipid A (GLA), a synthetic TLR4 agonist, formulated in a stable 2% oil-in-water emulsion (SE). Adjuvants can play 

an important role in vaccine therapies by stimulating the immune system’s response to the target antigen. GLA 

is the first ‘designer adjuvant’ and was developed by Immune Design co-founder Dr. Steve Reed. To date GLA-SE 

has been safely administered in over 300 human subjects. 

Our second vaccine platform is a novel lentivirus-based vector, ID-LV (Immune Design-Lentiviral Vector). The 

prototype of ID-LV was developed by Immune Design co-founder, Dr. David Baltimore. ID-LV is unique in that it 

can stimulate the body’s own dendritic cells (DCs), the “sentinels” of the immune system, to produce any, and 

importantly, multiple antigens of interest in the same product configuration, effectively orchestrating the human 

immune system to respond to targeted diseases. Immune Design’s ID-LV and GLA-SE vaccine technologies 

are immunologically synergistic, as documented in animal models, and thus, have the potential to be used both 

alone and in combination to create the next generation of vaccines for diseases with unmet medical need. 

MANAGEMENT 

Carlos Paya, MD, PhD, Chief Executive Officer 

Wayne Gombotz, PhD, Chief Development Officer 

J Paul Rickey, VP, Finance and Administration 



SPEAKERS 


ORGANISERS

CONTACTS 

Kevin FitzGerald 

Chief Operating Officer 

Ghaz Mahdizadeh 

EA 

ADDRESS 

London BioScience Innovation 

Centre 

2 Royal College Street 

London NW1 0NH 

TELEPHONE 

+44 020 7691 4908 

EMAIL 

Kevin.FitzGerald 

@its-innovation.com 

Ghaz.mahdizadeh 

@its-innovation.com 

YEAR FOUNDED 

2004 

Immune Targeting Systems 

www.its-innovation.com 


The Company is supported by leading investors including Novartis Venture Fund, HealthCap, Truffle Capital, SME 

Wholesale Finance and Esperante Ventures and has raised £14.5m to-date. The Company is currently seeking 

investors to participate in a series-B financing. 


Immune Targeting Systems is an emerging leader in the development of vaccine products that work by 

promoting T-cell responses against viruses and cancers (“T-cell vaccines”). The company’s lead product 

Flunisyn, currently in clinical development, is a novel T-cell vaccine which elicits potent cellular immune 

responses against multiple strains of influenza. The Company’s technology also supports a product portfolio 

which includes Hepsyn-B, an attractive therapeutic hepatitis B vaccine and T-cell vaccines against cancers. 

MANAGEMENT 

Kevin FitzGerald, PhD MBA, Chief Operating Officer 

• Serial life sciences entrepreneur with over twenty years’ experience within the biotechnology industry; 

• Scientific, commercial and strategic expertise; 

• CEO of F-star, founder & CEO of Isogenica and among the founding group of scientists at Cambridge Antibody Technology; 

• Capital-raising expertise (more than €30m raised to date); 

• Substantial business development experience (deals closed with Amgen, AstraZeneca, Boehringer Ingelheim, Centocor, GE 

Healthcare, Johnson & Johnson, Merck Serono, Pfizer, UCB-Celltech and Wyeth etc.). 



SPEAKERS 


ORGANISERS

CONTACTS 

John J. Trizzino 


Vicki Morgan 

VP, Business Development 

ADDRESS 

1344 Summer Street, Suite 412 

Halifax, Nova Scotia 

B3H 0A8 

CANADA 

TELEPHONE 

902-492-1819 

FAX 

902-492-0888 

EMAIL 

jtrizzino@imvaccie.com 

vmorgan@imvaccine.com 

YEAR FOUNDED 

2000 

Immunovaccine Inc. 

www.imvaccine.com 


Shares outstanding: 63.5M 

Recent Market Cap: $17.8M 

Recent share price: $0.28 

52 Week Range: $0.28 – $0.60 

Average Daily Volume: 35,500 

Cash & Other Cash Resources (31/12/11): $6.2M 


Immunovaccine is a biotechnology company focused on the application of its novel vaccine delivery platform to 

the development of vaccines for cancer therapy and infectious diseases. The Company’s DepoVax platform 

is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged 

period and has the potential to enhance immune responses. Immunovaccine has advanced its platform 

technology and proprietary cancer vaccine into Phase I clinical trials and has demonstrated both safety and 

immunogenicity potential. Immunovaccine is also capitalizing on the broad potential of its delivery platform 

by creating new DepoVax-based vaccines through multiple development collaborations. In addition to the 

Company’s human health vaccine strategy, it continues to capture value from animal health vaccine applications. 

Immunovaccine has several key partnerships in the animal health sector including an agreement with Pfizer 

Animal Health, which has licensed the Company’s delivery technology platform to develop vaccines for livestock. 

MANAGEMENT 

John J. Trizzino, CEO 

Vicki Morgan, VP, Business Development 

Kimberly Stephens, CFO 

Marc Mansour, Ph.D., CSO 


Albert Scardino, Chairman, Communications Strategist, Pulitzer Prize Recipient 

William Cochrane, MD, 2010 Inductee Canadian Medical Hall of Fame 

Wade Dawe, CEO of Brigus Gold 

James Hall, CA, Sr.VP of Investments GrowthWorks 

Stephanie Léouzon, Senior Advisor to Torreya Partners 

Wayne Pisano, Former President and CEO of Sanofi Pasteur 

Brad Thompson, CEO of Oncolytics 



SPEAKERS 


ORGANISERS

CONTACT 

Roel Q. J Schaapveld, PhD, MBA 


ADDRESS 

Hugo R. Kruyt building 

Padualaan 8 

3584 CH Utrecht 


TELEPHONE 

+31 30 253 2386 

FAX 

+31 30 253 9176 

EMAIL 

schaapveld 

@interna-technologies.com 

YEAR FOUNDED 

December 2006 

InteRNA Technologies B.V. 

www.interna-technologies.com 


Investors: • Aglaia Oncology Fund • PPM Oost 


InteRNA Technologies is a Dutch drug discovery and development company engaged in the development of novel 

breakthrough cancer therapies based on the unique functions of its proprietary miRNAs. 

InteRNA’s drug development programs aim at developing miRNA-based therapeutics that control genes 

connected in signal transduction pathways and biological processes that are known to play a role in cancer 

initiation, progression and metastasis. 

InteRNA identified the function of multiple miRNAs in a number of cancer indications through functional screens, 

using its proprietary lentiviral-based miRNA expression library, which is the largest currently available. 

With the Company’s proprietary miRNA expression database (generated through deep sequencing) and additional 

technologies (like RNAseq, bioinformatics, in vivo models) in place to identify the downstream regulated proteins 

for each miRNA drug candidate, the Company is well equipped to move its novel drug candidates with their 

biomarkers quickly towards the clinic. 

MANAGEMENT 

Roel Q.J. Schaapveld, PhD, MBA, Chief Executive Officer 



SPEAKERS 


ORGANISERS

CONTACTS 

Dr Sonia Benhamida 

Dr Scott Cuthill 

ADDRESS 


Ipsen 

65 Quai George Gorse 

92100 Boulogne Billancourt 

Paris 

France 


Ipsen Biopharm Limited 

190 Bath Road 

Slough 

Berkshire 

SL1 3XE 

TELEPHONE 


+33 1 583 35000 


+44 1 753 627700 

EMAIL 

sonia.benhamida@ipsen.com 

scott.cuthill@ipsen.com 

YEAR FOUNDED 

1929 

Ipsen Group 

www.ipsen.ltd.uk 


Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. 

Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its 

development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, 

uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is 

focused on innovative and differentiated technological patientdriven platforms, peptides and toxins. In 2011, R&D 

expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of 

close to 4,500 employees. 

Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and 

eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has 

implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-thecounter 

market in the United States under the symbol IPSEY. 

For more information on Ipsen, visit www.ipsen.com. 



SPEAKERS 


ORGANISERS

CONTACT 

Maaike Vogelezang 

Management Assistant 

ADDRESS 

ISA Pharmaceuticals BV 

Niels Bohrweg 11-13 

2333 CA Leiden 


TELEPHONE 

+31 71 33 22 310 

FAX 

+31 71 33 22 311 

EMAIL 

Info@isa-pharma.com 

YEAR FOUNDED 

2004 

ISA Pharmaceuticals BV 

www.isa-pharma.com 


Fundraising series B. 


ISA Pharmaceuticals is a clinical stage company developing novel therapeutic products for cancer and 

infectious diseases. ISA exploits its proprietary SLP® technology to achieve therapeutic effects in a number of 

indications. The most advanced clinical product under development is ISA-HPV-SLP®, a therapeutic vaccine 

for the treatment of patients suffering from Human Papilloma Virus type 16 (HPV16) associated malignant and 

premalignant disorders. 

ISA has further developed a unique adjuvant system which yields superior immune responses when mixed or 

conjugated to its target antigens. 

MANAGEMENT 

Gerard Platenburg, Managing director 

Mark Krul, Managing director 

Cornelis Melief, CSO 

Edwin Klumper, CMO 



SPEAKERS 


ORGANISERS

CONTACT 

Dr Heinz Schwer 

ADDRESS 

Lena-Christ-Str. 48 

82152 Martinsried/Planegg 

Germany 

TELEPHONE 

089 89927 152 

FAX 

089 89927 5152 

EMAIL 

Heinz.schwer@morphosys.com 

YEAR FOUNDED 

1992 

MorphoSys AG 

www.morphosys.com 


Report for the first six month of 2012: 

Group Revenues: 33.0 m Eur 

EBIT (1.9) m Eur 

Net (Loss)/Profit (1.0) m Eur 

EPS, diluted in Eur (0.04) 


MorphoSys has developed and established one of the world’s leading fully human antibody technologies. 

Numerous partnerships with well-known companies from the pharmaceutical and biotechnology sector, such as 

Boehringer Ingelheim, Daiichi Sankyo, Merck, Novartis, Pfizer and Roche illustrate our success. 

With the help of our proprietary, industry-leading antibody technologies, more than 400 employees at four 

locations worldwide are dedicated to engineering the medicines and diagnostics of tomorrow. The international 

teams collaborate closely to streamline and coordinate product research and development with all its 

accompanying processes. 

MANAGEMENT 

The Management Board and Supervisory Board of MorphoSys are committed to creating significant value for all 

employees, shareholders, customers and partners through a sustainable business strategy balancing short-term 

and long-term growth potential. 

The Board 

Dr Simon Moroney, CEO 

Dr Arndt Schottelius, CDO 

Jens Holstein, CFO 

Dr Marlies Sproll, CSO 



SPEAKERS 


ORGANISERS

CONTACT 

Tom Johnston 


ADDRESS 

Mucosis B.V. 

L.J. Zielstraweg 1 

9713 GX, Groningen 


TELEPHONE 

+31 (50) 8200050 (T) 

+31 (6) 55320948 (M) 

FAX 

+31 (50) 8200051 

EMAIL 

tom.johnston@mucosis.com 

YEAR FOUNDED 

2006 

Mucosis B.V. 

www.mucosis.com 


Series A: €3,000,000 (2007) 

Inn.Credit: €3,000,000 (2010) 

Current Investors: • Biogeneration Ventures • MedSciences Capital • N.V. NOM 


About Mucosis 

Mucosis B.V. is a Dutch biotechnology company with a proprietary platform technology, Mimopath, on which it 

develops mucosal vaccines with improved efficacy. Mucosis’s lead products are FluGEM, a vaccine to prevent 

influenza; PneuGEM, a vaccine to prevent diseases caused by pneumococcal bacteria; and SynGEM, a 

vaccine to prevent RSV viral infections. Mimopath-based vaccines can be administered needle-free in the 

nose and mouth, evoking a more natural immune response with a broader base of protection. 

About Mimopath technology 

The Mimopath technology is based on Lactococcus lactis, a safe bacterium commonly used in the food 

industry. Mucosis has developed a robust technique to formulate the L. lactis bacteria into non-living bacteriumlike 

particles (BLPs) that can be loaded with antigens from viral, bacterial, parasitic or tumor origin. The antigencovered 

BLPs form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These 

vaccines raise protective immunity by activation of both the innate and the adaptive immune system. 

MANAGEMENT 


Thomas Johnston, CEO 

Kees Leenhouts, CSO 

Roberto Grimaldi, CMO 

Jolande Schoemaker, QA-officer & Qualified Person 


John Lambert, Chairman 

Barry Buckland 

Annemieke Wouterse 

Willem Hazenberg 

Otto Postma 



SPEAKERS 


ORGANISERS

CONTACT 

Jeremy Warren 


ADDRESS 

Minton Park 

London Road 

Amesbury 

Wiltshire 

SP4 7RT 

United Kingdom 

TELEPHONE 

+44 1 980 676 060 

FAX 

+44 1 980 624 703 

EMAIL 

admin@nanosight.com 

YEAR FOUNDED 

2002 

NanoSight 

www.nanosight.com 


2005 2006 2007 2008 2009 2010 2011 

£k As filed As filed Audited Audited Audited Audited Audited 

Total Sales 243 247 472 820 1,610 2,249 3,775 

Gross Profit 81 91 282 507 1008 1464 2417 

Gross Margin 33% 37% 60% 62% 63% 65% 64% 

Total Overheads 291 473 510 748 1,368 1,446 1,861 

PBT -210 -382 -228 -241 -360 18 556 

Sales Growth Rate 2% 91% 74% 96% 40% 68% 


NanoSight’s unique role in potential early detection of cancer is developing rapidly. Our scientific focus 

continues to be the refinement of Nanoparticle Tracking Analysis. NTA is a unique methodology for detection 

and characterisation of nanoparticles in liquids. Applied to cell-derived biological nanoparticles (exosomes 

and microvesicles) it has emerging potential as a diagnostic platform for a Prostate, Oral, Liver and Gastric 

cancers, Diabetes, Pre-eclampsia, Parkinson’s disease, Autoimmune and Renal diseases. Our practical work 

is collaboration with research groups using our instruments to develop rigorous protocols for counting and 

speciation disease-specific exosomes. Recent publication of American Society for Testing Materials standard 

ASTM E2834 demonstrates our progress in refining NTA methodology. 

MANAGEMENT 

Dr Robert Carr, CTO & Founder 

Jeremy Warren, CEO 

John Knowles, Chairman & Founder 



SPEAKERS 


ORGANISERS

CONTACTS 

Aaron Powers 

President 

Dave Reusswig 

Vice President 

ADDRESS 

3820 Ohio Ave, Ste 8-14 

St Charles, IL 60174 

TELEPHONE 

630-400-2135 

FAX 

480-287-8984 

EMAIL 

aapowers@mac.com 

YEAR FOUNDED 

2007 

Northern Biotechnologies llc 

www.nothernbiotechnologies.com 


Northern Biotechnologies has raised $1.5M in round “a” private funding. Northern is seeking commercialization 

and investment partnerships to continue the development of additional anti-bacterial, antiviral and anti-fungal 

applications of our technology which require additional testing, proof of concept and commercialization partners. 


Northern Biotechnologies is pioneering the commercialization of an innovative, long lasting, therapeutic anti 

microbial technology that has significant applications in the Human Health Care arena. Infectious disease control 

and prevention can be revolutionized by integration of our cost saving technology. Issued Patents and proprietary 

production IP offer a stable platform for growth and partnership into all human related applications of the 

technology. A unique feature of the technology is its extended protection of 1-3 days through each application. 

Additionally, the physical method of pathogen destruction prevents formation of resistant strain types, in contrast 

to existing technologies that rely on metabolic action for kill. Testing shows high performance anti-bacterial, 

anti-fungal and antiviral functioning in various direct, topical, and wound care, nasal/ oral and related dosing 

mechanisms of the technology. We are in process with the first New Drug Application for antiseptic hand wash, 

and are looking for partners to pursue additional drug approvals in specific markets. 

Existing product branding in the Human market is Prefense hand sanitizer and wipes. In addition to human 

applications, Northern holds over twenty-five global patents for anti-microbial water filtration using our 

technology. We also hold EPA registrations for persistent antimicrobial filter media. Significant opportunity exists 

in the technology used as a multi surface sanitizer for all levels of food production. Other existing product lines 

and cash flow are in place from additional internally developed technologies including high performance filtration 

medias, biotech remediation and process technologies used in petroleum, agricultural, and industrial processing. 

Northern also holds nationally placed consumer and professional brand lines of “green probiotic” cleaning 

products based on our IP and manufacturing base. Additionally, our cGMP contract packaging division sells 

our proprietary formulations to many national brands in a variety of markets. Company management is made 

of a diverse team with the experience and drive required to steer strong growth and relationships with partner 

companies. 

MANAGEMENT 

Aaron Powers, President 

Dave Reusswig, Vice President 

Katan & Associates, Financial Consultants 



SPEAKERS 


ORGANISERS

CONTACTS 

Jack Barbut 


David Slack 

Head of Corporate & Business 

Development 

ADDRESS 

14 Chemin des Aulx 

1228 Plan-les-Ouate 

Geneva 

Switzerland 

TELEPHONE 

+41 22 839 71 41 

FAX 

+41 22 839 71 42 

EMAIL 

jbarbut@novimmune.com 

dslack@novimmune.com 

YEAR FOUNDED 

1999 

NovImmune SA 

www.novimmune.com 


Have raised 182M CHF from private investors including high-net worth individuals, corporate and 

private venture groups 


NovImmune is a life science enterprise with a proprietary next-generation antibody drug discovery platform 

and expertise in advancing drug candidates from bench to bedside. The Company is applying its capabilities to 

realize a vision of generating drugs that provide more robust benefit to patients by attacking the cause rather 

than symptoms of disease. NovImmune has established a balanced pipeline of first- and best-in-class preclinical 

and clinical drug candidates with a mix of both clinically validated and novel targets. 

• In 2009, received the European Biotechnica Award 

• In 2010, established Genentech/Roche partnership for NI-1401, anti-IL-17 drug candidate 

• In 2011, received Orphan Drug designation in Europe and the USA for, and in 2012 EUR 6 million FP7 

grant from the European Commission for development of NI-0501 for HLH 

• Pursuing additional partnerships for its next-generation antibody platform as well as development and 

commercialization of selected drug candidates 

• Potential to independently bring selected drugs to the market for focused applications 

MANAGEMENT 

Eduard Holdener, M.D., Chairman 

Jack Barbut, Sc.D., Chief Executive Officer 

Cristina de Min, M.D., Chief Medical Officer 

Marie Kosco-Vilbois, Ph.D., Chief Scientific Officer 

David Slack, Head of Corporate & Business Development 

Nathalie Muller, Director of Legal Affairs 



SPEAKERS 


ORGANISERS

CONTACTS 

General and Media Contact 

Emmanuelle Delabre 

Business Development 

Aram Mangasarian, PhD 


ADDRESS 

NOXXON Pharma AG 

Max-Dohrn-Strasse 8-10 

10589 Berlin 

Germany 

TELEPHONE 

+49 30 726 247 0 

Emmanuelle Delabre 

+49 30 726 247 100 

FAX 

+49 30 726 247 225 

EMAIL 

Noxxon@noxxon.com 

ibuchanan@noxxon.com 

edelabre@noxxon.com 

amangasarian@noxxon.com 

YEAR FOUNDED 

1997 

NOXXON Pharma AS 

www.noxxon.com 


Since 2007 NOXXON has closed two financing rounds and raised approximately €72m Euros from venture 

capital investors. NOXXON’s major investors include Sofinnova Partners, TVM Capital, DEWB, Edmond de 

Rothschild Investment Partners, NGN Capital, Seventure, IBB Beteiligungsgesellschaft, Dow and GoodVent. 


NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary 

therapeutics called Spiegelmers, the chemically synthesized, non-immunogenic alternative to antibodies. 

NOXXON has a diversified portfolio of clinical stage Spiegelmer® therapeutics: 

NOX-E36 is an anti-CCL2 (MCP-1) Spiegelmer® currently in a Phase IIa study in diabetics with albuminuria. 

CCL2 is involved in recruitment of immune cells to the kidney in diabetic patients, a process which is associated 

with progression of chronic kidney disease. 

NOX-A12 is an anti-CXCL12 (SDF-1) Spiegelmer® that has begun two Phase IIa studies in hematological 

oncology indications (chronic lymphocytic leukemia and multiple myeloma). CXCL12 acts via its two receptors, 

CXCR4 and CXCR7, to mediate tumor invasion, metastasis and resistance to chemotherapy. 

NOX-H94 is an anti-hepcidin Spiegelmer® currently completing Phase I safety studies as well as a Phase I 

human pharmacodynamic study to assess its ability to prevent inflammation-induced hypoferremia. Hepcidin 

is the key regulator of iron metabolism and mediator of iron restriction in anemia of chronic disease via its 

interaction with the iron export protein, ferroportin. 

The Spiegelmer platform provides the company with powerful and unique discovery capabilities, which have 

generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a 

well-financed mature biotech company with a strong syndicate of international investors, approx. 60 employees 

and a highly experienced management team 

MANAGEMENT 


Iain Buchanan, Chief Executive Officer 

Dr Matthias Baumann, Chief Medical Officer 

Dr Sven Klussmann, Chief Scientific Officer 

Aram Mangasarian, PhD, Chief Business Officer 

Supervisory Board 

Dr Walter Wenninger, Chairman of the Supervisory Board 



SPEAKERS 


ORGANISERS

CONTACT 

Oliver Middendorp 

CBO & Co-CEO 

ADDRESS 

Numab AG 

Einsiedlerstrasse 34 

CH-8820 Wädenswil 

Switzerland 

TELEPHONE 

+41 44 533 0471 

FAX 

+41 44 533 0470 

EMAIL 

o.middendorp@numab.com 

YEAR FOUNDED 

2011 

Numab 

www.numab.com 


Up to CHF 5 million seed money provided through industry collaboration. 


Numab is a Swiss biotech company focusing on the discovery and development of therapeutic antibodies. 

Numab is a young company lead by a Management with proven track record in the biotech industry (4 out of 5 

Management members have been long lasting employees in key positions at ESBATech). 

Numab applies a high-throughput selection system that increases the antibody discovery success rates 

by magnitudes and allows to efficiently identify best-in-class and/or first in class antibodies. The discovery 

engine is particularly well suited to detect antibodies against unconventional targets such as multi-spanning 

transmembrane proteins (e.g. GPCRs or ion channels). 

Numab is pursuing proprietary antibody programs in autoimmune diseases and pain, however, also applies its 

breakthrough technology to discover highly potent antibodies on behalf of its partners in the pharmaceutical 

industry. 

MANAGEMENT 

David Urech, PhD, CSO & Co-CEO 

Oliver Middendorp, PhD, CBO & Co-CEO 

Tea Gunde, PhD, Head of Pharmacology 

Sebastian Meyer, PhD, Head of Biochemistry 

Roland Helfenstein, Head of Finance and Administration 



SPEAKERS 


ORGANISERS

CONTACTS 

Martin Welschof 


Loretta Greene 

Executive Assistant & Administrator 

ADDRESS 

OPSONA Therapeutics Ltd 

Second Floor Ashford House 

Tara Street 

Dublin 2 

Ireland 

TELEPHONE 

+353 1 677 0223 

FAX 

+ 353 1 677 8949 

EMAIL 

mwelschof@opsona.com 

lgreene@opsona.com 

YEAR FOUNDED 

2004 

Opsona Therapuetics 

www.opsona.com 


Biotechnology Company 

0-20 Employees 

Private Company 

Latest Round of Funding – B Round 

Funding Total to date – $35M 


Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to 

key targets of the innate immune system associated with a wide range of major human diseases, including 

autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer’s disease and 

atherosclerosis. 

The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin one of 

Ireland’s leading academic institution with a core focus on immunology research. Opsona’s lead product, a fully 

human monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR2) has demonstrated activity in 

a number of animal models & recently was tested successfully in a phase 1 clinical trial in healthy volunteers. 

The Company plans to conduct a two-part multi-centered, double blinded and placebo controlled clinical study to 

evaluate the safety, tolerability and efficacy of OPN 305 in renal transplant patients at high risk of Delayed Graft 

Function(DGF) as the first clinical target indication for the development of OPN-305 to be initiated in 2012. 

The Company is supported by an international venture consortium including Novartis Venture Fund, Roche 

Venture Fund, Seroba-Kernel Life Sciences, Fountain Healthcare Partners, Inventages Venture Capital and 

Enterprise Ireland. 

MANAGEMENT 

Bernd Seizinger, Executive Chairman 

Martin Welschof, CEO 

Mary Reilly, VP Pharmaceutical Development & Operations 

Luke O’Neill, Co-Founder, Director and CSO 

Conor Dalton, Finance Director 

Dr Robert M Miller, Consultant Chief Medical Officer 



SPEAKERS 


ORGANISERS

CONTACT 

Janneke Meulenberg, PhD MBA, 


ADDRESS 

De Boelelaan 1118 

1081 HZ Amsterdam 


Postal address: 

PO Box 7057 

1007 MB Amsterdam 


TELEPHONE 

+31 204 441826 

FAX 

+31 204 442126 

EMAIL 

meulenberg 

@orca-therapeutics.com 

YEAR FOUNDED 

2005 

ORCA Therapeutics BV 

www.orca-therapeutics.com 


Current investor: Aglaia Oncology Seed Fund BV 

Financing Sought: 5 Million EURO 


ORCA Therapeutics B.V. (ORCA) is developing a pipeline of innovative anticancer therapies based on the 

highly promising approach of oncolytic viruses. ORCA’s value proposition is based on using its proprietary 

technologies in the field of Oncolytic Replication Competent Agents. ORCA’s lead product ORCA-010 is a new 

oncolytic adenovirus based on the Company’s proprietary T1 technology. ORCA-010 has up to ten thousand 

fold higher oncolytic potency as compared to current state of the art oncolytic adenoviruses in a variety of 

cancer cell lines and ORCA is currently developing ORCA-010 for its first study in man. 

MANAGEMENT 

Janneke Meulenberg, PhD MBA, CEO 

Victor van Beusechem, PhD, CSO 



SPEAKERS 


ORGANISERS

CONTACTS 

Carlos Buesa 


Emili Torrell 

Business Development Officer 

ADDRESS 

C/San Ferran 74 

08940 Cornella de Llobregat 

(Barcelona), SPAIN 

TELEPHONE 

+34 93 515 13 13 

FAX 

+34 93 377 40 28 

EMAIL 

cbuesa@oryzon.com 

etorrell@oryzon.com 

info@oryzon.com 

YEAR FOUNDED 

2000 

ORYZON 

www.oryzon.com 


Stage of funding 

5 Funding rounds from inception (15 M€ in total) + 15 M€ in Competitive Grants. Last funding (9M€) was 

accomplished in 2008. These funds were also matched with a set of competitive grants and long-term / nullvery 

soft rates public loans. 

Capital plans – IPO plans 

The Company will need a new round of funding (8-10M) in late 2012 early 2013 to keep the development of the 

programs to Phase I-II in full speed. The company is considering to get this funding either through C series or 

preIPO funding. 

Investors. The company has a French-Spanish VC firm NAJETI as main stakeholder from 2003. Other VCs 

having minor stakes are CORSABE, Invercat and Barcelona Empren. Several Spanish family offices and private 

minor investors are also present. 


Oryzon is a biomarker discovery company with a dual therapeutic pipeline in oncology and neurodegeneration. 

Founded in 2000, and venture backed from 2002, Oryzon has a strong focus in EPIGENETIC TARGETS with a 

special emphasis in Histone Lysine Demethylases being a global leader on Lysine Specific Demethylase-1 with 

a dominant IP position. LSD1 has been proposed as a target for oncology, viral diseases and neurodegeneration. 

Oryzon has two preclinical programs with different preclinical candidates LSD1i, one in ACUTE MIELOGENOUS 

LEUKAEMIA and the other in Huntington disease. Our inhibitors are highly potent in vitro (low nM) and in 

vivo (

CONTACTS 

Esteban Pombo-Villar 


Nicola Wootton 

ADDRESS 

94a Milton Park 

Abingdon 

Oxfordshire 

OX14 4RY 

United Kingdom 

TELEPHONE 

+44 1235 861770 (Head Office) 

+41 (0)61 225 4290 (Direct) 

FAX 

+44 1235 861771 

EMAIL 

epv@oxbt.co.uk 

nw@oxbt.co.uk 

YEAR FOUNDED 

2004 

Oxford BioTherapeutics Ltd 

www.oxbt.co.uk 


Private 


Oxford BioTherapeutics (OBT) is focused on the development of targeted antibody-based medicines for oncology. 

OBT’s strategy is to develop innovative antibody-based cancer drugs, with integrated diagnostics, against novel 

targets that it has discovered in its unique OGAP® proteomic database. Through its alliances with world leaders 

in antibody development OBT is in an unrivalled position to convert its novel targets into an exciting pipeline of 

first-in-class therapeutics for the treatment of cancer. OBT’s pipeline will deliver cost-effective medicines to fulfill 

the major unmet medical need of cancer patients. 

MANAGEMENT 

Christian Rohlff, CEO 

Esteban Pombo-Villar, COO 

Jon Terrett, CSO 

Tom Boone, Senior Vice President, Protein Sciences 



SPEAKERS 


ORGANISERS

CONTACTS 

Nick McCooke 


Prof Nick La Thangue 


Prof David Kerr, 

Chief Medical Officer 

ADDRESS 

Magdalen Centre 

Oxford Science Park 

Oxford 

OX4 4GA 

TELEPHONE 

Office: +44 1865 784000 

Mobile: +44 7900 214268 

FAX 

+44 1235 861771 

EMAIL 

nick.mccooke@oxfordbio.com 

YEAR FOUNDED 

2011 

Oxford Cancer Biomarkers 

www.oxfordbio.com 


$5M funding via equity investment from Quintiles 


Oxford Cancer Biomarkers (OCB) is a newly launched company developing tests that predict which cancer 

patients will respond favorably to existing and emerging cancer drugs allowing treatment to be tailored to 

individual patients. 

The company, which is a spin out from Oxford University, has a patent-protected and validated platform for 

discovering proteins that are novel chemosensitivity markers for specific drugs. 

OCB is developing its biomarkers tests both independently and in partnership with pharma and biotech 

companies. 

Setting the company apart from the crowd, OCB has already implemented a strategic relationship with Quintiles 

Inc that provides a route for accelerating its novel biomarkers into clinical trials, overcoming the inertia that can 

sometimes hamper the companion biomarker business model. 

The company has secured initial funding via a $5 million equity investment from Quintiles. 

OCB’s management team, led by Nick McCooke, former CEO of Solexa (the pioneer of next gen sequencing) and 

Pronota (protein biomarker diagnostic development), includes David Kerr, Professor of Cancer Medicine at the 

University of Oxford and a recent President of the European Society of Medical Oncology, and Nick La Thangue, 

Professor of Cancer Biology at the University of Oxford. 

MANAGEMENT 

Nick McCooke, CEO 

Nick is the former CEO of Pronota (developer of diagnostics based on novel protein biomarkers) and Solexa (the pioneer of next 

gen sequencing). 

David Kerr, CMO 

David is Professor of Cancer Medicine at the University of Oxford and a recent President of the European Society of Medical 

Oncology. 

Nick La Thangue, CSO 

Nick is Professor of Cancer Biology at the University of Oxford. His academic research is focused on the molecular 

mechanisms that give rise to the abnormal proliferation of tumour cells. 



SPEAKERS 


ORGANISERS

CONTACTS 

Dr Christof Böhler 


DDr Sven Rohmann 


ADDRESS 

Industriering 21 

9494 Ruggell 

Liechtenstein 

TELEPHONE 

+423 377 78 00 

FAX 

+423 377 78 99 

EMAIL 

info@pantec-biosolutions.com 

YEAR FOUNDED 

2005 

Pantec Biosolutions AG 

www.pantec-biosolutions.com 


Pantec is funded by private investors and one VC company. 

The company is seeking new investors alongside existing shareholders in a new financing round. 


Pantec Biosolutions is the leading company for stable and controlled dermal delivery of large weight 

biopharmaceuticals. Our goal is to replace injection based medication of biologicals in selected disease areas 

with the help of a breakthrough dermal delivery method. The proprietary combination of P.L.E.A.S.E.® (Precise 

Laser Epidermal System) microporation technology with intradermal drug delivery allows easy to use, safe, 

rapid and painless application of infertility hormones and other large molecular weight biopharmaceuticals. This 

platform significantly improves precise drug uptake in addition to reducing treatment duration and avoiding the 

need for injections. This technology has significant potential to unlock a high unmet need of treatments requiring 

large molecular weight biopharmaceuticals. 

The company’s focus is in combining laser of laser microporation with drug delivery in the dermatology and 

immunology space. 

In addition P.L.E.A.S.E.® can also be used “stand alone” as a new category fractional ablative laser device to 

break new ground in aesthetic dermatology. 

MANAGEMENT 

Dr Boehler Christof, CEO 

Mr Bragagna Thomas, CTO 

Dr Dr med. Rohmann Sven, CBO 

Dr. Clemens Norbert, Clinical Director as permanent consultant 

Dr Kalia Yogeshvar N, Chief Scientific Advisor 



SPEAKERS 


ORGANISERS

CONTACT 

Dr Erik Buntinx 


ADDRESS 

Alkerstraat 30A 

B3570 Alken 

Belgium 

TELEPHONE 

+32 11 480 750 

FAX 

+32 11 484 923 

EMAIL 

Erik.buntinx 

@pharmaneuroboost.com 

YEAR FOUNDED 

2006 

PharmaNeuroBoost 

www.pharmaneuroboost.com 


Pharmaneuroboost is a privately held R&D company dedicated to develop CNS drugs with a significant added 

value compared to standard of care products available based on a solid IP protected platform. 

Current developments involve PNB01, a fixed combination product of citalopram and low dose pipamperone in 

Major Depression (phase III) and PNB02, a fixed combination product of risperidone and low dose pipamperone 

in Schizophrenia (phase II). 

MANAGEMENT 

Dr Erik Buntinx, Chief Executive Officer 

Dr Remi Van den Broeck, Chief Development Officer 

Dr Ludo Haazen, Chief Medical Officer 

Prof Didier de Chaffoy de Courcelles, Chief Science Officer 



SPEAKERS 


ORGANISERS

CONTACT 

Jacques Näsström 


ADDRESS 

PledPharma AB 

Grev Turegatan 11 C 

114 46 Stockholm 

TELEPHONE 

+46 8 679 72 10 

FAX 

+46 8 663 57 25 

EMAIL 

jacques.nasstrom@pledpharma.se 

YEAR FOUNDED 

2006 

PledPharma AB 

www.pledpharma.se 


Cash and cash equivalents on June 30 was SEK 68 608k 


PledPharma is a Swedish specialty pharma company that develops a new medicine, PledOx®, for prevention 

of the severe side effects that patients develop as a consequence of chemotherapy treatment of cancer. Many 

times the treatment cannot be carried out as planned due to very difficult side effects. The current market for 

supportive cancer care is some SEK 72 billion. PledOx is a medicine within the patent protected substance class 

PLED, which protects the body’s normal cells against oxidative stress. Oxidative stress is a condition where an 

overabundance of harmful oxygen molecules (free oxygen radicals) has been formed. We are also evaluating 

opportunities with PLED substances for other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First 

North. Erik Penser Bankaktiebolag is the Certified Adviser. 

For more information, please visit www.pledpharma.se 

MANAGEMENT 

Jacques Näsström, CEO 

Marie Bengtson, Clinical Project Director 

Sven Jacobsson, CMC 

Johan Stuart, CFO 

Professor Per Jynge, Medical Advisor Cardiology 

Erik Kinnman, VP IR and Med. Advisor Neurology 

Malin Lundgren, Proj. Manager and Dir Regulatory 



SPEAKERS 


ORGANISERS

CONTACT 

Michael Altorfer, Ph.D. 

Head Corporate Development 

ADDRESS 

Hegenheimermattweg 125 

CH-4123 Allschwil 

Switzerland 

TELEPHONE 

+41 61 567 16 00 

FAX 

+41 61 567 16 01 

EMAIL 

info@polyphor.com 

michael.altorfer@polyphor.com 

YEAR FOUNDED 

1996 

Polyphor Ltd 

www.polyphor.com 


Polyphor secured cash inflows through operational revenues and capital increases, each of which contributed 

roughly 50% to the total amount of close to 200 Mio. CHF. 


Corporate overview 

Polyphor is a Swiss research-driven pharmaceutical company developing innovative products with high 

therapeutic benefit to the patient and providing high quality support to its industry partners engaged in drug 

discovery. 

Polyphor has established two complementary innovative, proprietary technology platforms with the aim to 

discover and develop new medicines for unmet medical needs. 

Polyphor’s MacroFinder® and PEMfinder® platforms were specifically developed for discovering potent and 

selective modulators of Protein-Protein Interactions and other challenging targets. 

Products: Broadly diversified clinical and pre-clinical development portfolio 

• POL6326 (CXCR4 antagonist) 

• POL7080 (Pseudomonas-selective antibiotic, novel mode of action) 

• POL6014 (elastase inhibitor) 

• GPCR platform (e.g. CXCR7, CCR10) 

• Protease platform 

Platforms: Two proprietary technology platforms 

• PEMfinder® 

• MacroFinder® 

Partnering: R&D collaborations with Pharma partners 

• Boehringer Ingelheim 

• Novartis 

Clinical Development Pipeline: 

Polyphor’s competitive edge is based on its technology platforms which sustain a diversified portfolio of clinical 

candidates in various therapeutic areas. 

POL6326 (Phase II) – a CXCR4 antagonist that mobilizes stem cells from the bone marrow to the circulating 

blood. This effect can be exploited in several ways: 

• Stem cell transplantation (autologous and allogeneic). 

• Tissue repair. 

• Chemosensitization (CXCR4 antagonist to enhance impact of established anti-cancer therapies). 

POL7080 (Phase II ready) – highly potent Pseudomonas-selective antibiotic with novel mode of action. 

Successfully completed Phase I clinical trial. POL7080 has been shown to be highly efficacious against a broad 

panel of clinical isolates, including MDR Pseudomonas strains: 

• Phase II clinical trial planned to start in Q1, 2013. 

MANAGEMENT 

Jean-Pierre Obrecht Ph.D., Co-founder & CEO 

Daniel Obrecht Ph.D., Co-founder & CSO 

Christoph Rentsch, CFO 

Michael Altorfer Ph.D., Head Corporate Development 

Klaus Dembowsky M.D., Ph.D., Chief Medical Officer 

Marc Thommen Ph.D., Head Technology Platform 

Peter Zbinden Ph.D., Head Internal Services 

Helmut Kessmann Ph.D., Head Business Development 



SPEAKERS 


ORGANISERS

CONTACTS 

Dr John Burt 


Dr Sally Waterman 


Dr Georg Buchner 

VP of Business Development 

ADDRESS 

The London Bioscience 

Innovation Centre 

2 Royal College Street 

Camden Town 

London 

NW1 0NH 

TELEPHONE 

+44(0) 207 6913580 

FAX 

+44(0) 207 691 3742 

EMAIL 

barbora.loblova@polytherics.com 

YEAR FOUNDED 

2002 

PolyTherics Ltd 

www.polytherics.com 


PolyTherics is a UK biotech company providing technology solutions enabling development of better 

biopharmaceuticals. PolyTherics has offers proprietary site-specific conjugation technologies for half-life 

extension of protein therapeutics, the creation of bispecific products and the efficient production of stable, 

homogeneous antibody-drug conjugates, including antibody fragment-drug conjugates. PolyTherics partners 

include Nuron Biotech (TheraPEG interferon ß), Celtic Pharma Holdings/Pro Bono Bio (TheraPEG variants of 

Factor VIIA and Factor IX) and Spirogen (for the development of novel ADC reagents). 

MANAGEMENT 

Dr John Burt, Chief Executive Officer 

Dr Sally Waterman, Chief Operating Officer 

Dr Georg Buchner, VP of Business Development 

Dr Steve Brocchini, Chief Scientific Officer 

Dr Antony Godwin, Director of Science & Technology 

Dr Ji-Won Choi, Director of Scientific Evaluation 

Dr Jeff Edwards, Director of Alliance Management 

Tim Brown, Finance Manager 



SPEAKERS 


ORGANISERS

CONTACT 

Matthew B. Lehman 


ADDRESS 

Prima BioMed, US 

303 Twin Dolphin Drive 

Suite 600 

Redwood City CA 94063 

TELEPHONE 

650-632-4370 

FAX 

650-632-4384 

EMAIL 

Matt.lehman 

@primabiomed.com.au 

YEAR FOUNDED 

2005 

Prima BioMed 

www.primabiomed.com.au 


Prima BioMed is a global biotechnology company headquartered in Australia. As a leader in personalized biotherapeutic 

products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop 

innovative treatment options for patients and maximize value to shareholders. Prima’s lead product is CVac, 

an autologous dendritic cell product currently in clinical trials for ovarian cancer. 

MANAGEMENT 

Matthew Lehman, Chief Executive Officer 

Ian Bangs, Chief Financial Officer 

Dr Neil Frazer, Chief Medical Officer 

Dr Sharron Gargosky, Chief Technical Officer 

Marc Voigt, Chief Business Officer 



SPEAKERS 


ORGANISERS

CONTACTS 

Jan Öhrström 


Arnoud Dijkstra 


L Diepgrond 

ADDRESS 

Zernikedreef 9 

2333 CK, Leiden 


TELEPHONE 

+31 888 669 665 

FAX 

+31 715 181 340 

EMAIL 

j.ohrstrom@profibrix.com 

a.dijkstra@profibrix.com 

l.diepgrond@profibrix.com 

YEAR FOUNDED 

2005 

ProFibrix BV 

www.profibrix.com 


Completed B round and added EUR 15Mill in May 2011. 


ProFibrix leverages its expertise in fibrinogen technology to develop and market innovative products for the 

hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and 

tissue healing. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the field 

of hemostasis. Fibrocaps, the proposed name of the company’s lead biologic, is being studied to help stop 

bleeding during surgery and after trauma injury. A dry powder based on a mixture of fibrinogen and thrombin, 

Fibrocaps is a ready-to-use preparation designed to be stable at room temperature and applied in different 

formats, including sprays and bandages. Fibrocaps is currently enrolling patients into a final pivotal Phase 3 

study and aiming at submitting a BLA/MAA in mid-2013. 

MANAGEMENT 

Jan Öhrström, CEO 

Jaap Koopman. CSO 

Arnoud Dijkstra, CBO 

Martijn Meijer, VP Finance 

Eliane Schutte, CDO 

Paul Frohna, CMO 

Linda Zuckerman, VP Preclinical 



SPEAKERS 


ORGANISERS

ADDRESS 

Otto-Hahn-Strasse 15 

D- 44227 Dortmund 

Germany 

TELEPHONE 

+49 231 9742 6300 

FAX 

+49 231 9742 6301 

EMAIL 

stefan.muellner@protagen.com 

YEAR FOUNDED 

1997 

Protagen AG 

www.protagen.com 


Completed five rounds of financing totalling 15,3 Mio Euro (Years 2004-2010). 


The PROTAGEN GROUP is a leading provider of solutions for the pharmaceutical and biotech industries, 

supporting drug development towards personalized medicines and GMP compliant protein characterization 

services of outstanding quality. 

The PROTAGEN GROUP consists of PROTAGEN AG with a clear focus on diagnostics, and PROTAGEN Protein 

Services GmbH (PPS) providing GMP compliant protein analysis. PROTAGEN AG has developed the proprietary 

UNIarray® platform to support patient stratification and the development of Companion Diagnostics (CDx) using 

the diagnostic power of autoantibody signatures in blood. We combine our outstanding know-how in biostatistics 

and expertise in Protein arrays and Luminex technology for the development of novel diagnostic assays. Our 

R&D focus is on chronic diseases, e.g. neurodegenerative disorders, endometriosis, autoimmune diseases 

such as Rheumatoid Arthritis, Systemic Lupus Erythematosus and Multiple Sclerosis as well as selected cancer 

indications, e.g. Prostate-, Breast-, Ovarian-, Colon- and Pancreatic Cancer. 

PROTAGEN Protein Services GmbH (PPS) is a reliable partner for GMP compliant characterization of 

biotherapeutics (NBEs) and biosimilar comparability, including stability and release testing. PPS combines unique 

expertise in bioinformatics for protein mass spectrometry with a long track record in protein chemistry and 

protein analytics in order to provide the best quality available. In addition, we provide customer support for all 

relevant regulatory issues to match with current regulatory requirements (FDA, EMA, KFDA) for protein drugs. 

MANAGEMENT 

Dr Stefan Müllner, CEO 

Dr Peter Schulz-Knappe, CSO 



SPEAKERS 


ORGANISERS

CONTACTS 

Dr Ricardo Biondi 


Dr Rolf Witte 


ADDRESS 

Universitätskliniken, Haus 1 

Theodor-Stern-Kai 7 

60590 Frankfurt / Main 

Germany 

EMAIL 

rolf.witte@psites.de 

ricardo.biondi@psites.de 

YEAR FOUNDED 

2011 

PSites Pharma GmbH 

www.psites.de 


PSites develops allosteric protein kinase inhibitors for a new non-ATP competitive regulatory binding site, the so 

called PIF pocket. This allows a much higher specificity and therefore less adverse side effects. 

MANAGEMENT 

Dr Rolf Witte, Chief Executive Officer 

Dr Ricardo Biondi, Chief Scientific Officer 



SPEAKERS 


ORGANISERS

CONTACT 

Dr Roman Schenk 


ADDRESS 

Lakeside B07b 

9020 Klagenfurt 

AUSTRIA 

TELEPHONE 

+43 463 210 131 

FAX 

+43 463 210 131 

EMAIL 

info@recardio.eu 

YEAR FOUNDED 

2011 

RECARDIO GmbH 

www.pledpharma.se 


RECARDIO (Regenerative CARDIOvascular Therapy) is an innovative Austria based life science company founded 

in 2011. It is focusing on regenerative therapeutic modalities for the treatment of cardiovascular diseases. After 

establishing proof-of-principle in vivo, it is developing multiple therapeutic leads as the future regenerative 

medication for patients with various cardiovascular diseases, with the potential of improving their cardiac 

function, quality of life and survival. 

MANAGEMENT 

RECARDIO has an experienced management team with longlasting and significant experience and reputation in 

cardiology, stem cell therapy and the biotech industry and is complemented by an exclusive and knowledgeable 

Scientific & Clinical Supervisory Board and Board of Directors. 



SPEAKERS 


ORGANISERS

CONTACT 

Dr Richard Goodfellow 


ADDRESS 

Scancell Ltd 

Dept Clinical Oncology 

City Hospital 

Hucknall Road 

Nottingham NG5 1PB 

EMAIL 

richardgoodfellow@scancell.co.uk 

Scancell 

www.scancell.co.uk 


Scancell is developing novel therapeutic vaccines for the treatment of cancer and based on its groundbreaking 

ImmunoBody® and Moditope technology platforms. Scancell’s first cancer vaccine SCIB1 is a DNA vaccine 

being developed for the treatment of melanoma and is in Phase 2 clinical trials. 

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, 

stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts 

of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and 

the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific 

cells. 

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic 

cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing 

them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming 

and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to 

overcome these limitations. 

The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also 

be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases. 

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 

that destroy tumours without toxicity. The Directors believe that the Moditope platform could have a profound 

effect on the way that cancer vaccines are developed. 



SPEAKERS 


ORGANISERS

CONTACTS 

Dr Hans Fliri 

Chairman 

Simon Bury 

Business Development Director – 

Discovery 

ADDRESS 

Selcia Limited 

Fyfield Business & Research Park, 

Fyfield Road, 

Ongar, 

Essex 

CM5 0GS 

UK 

TELEPHONE 

+44 1277 367000 

FAX 

+44 1277 367099 

EMAIL 

simon.bury@selcia.com 

contact@selcia.com 

YEAR FOUNDED 

2001 

Selcia Limited 

www.selcia.com 


Selcia Ltd., headquartered in Ongar, Essex, UK and with a branch in Hopkinton, Massachusetts, operates 

two divisions, Selcia Discovery and Selcia Radiochemistry. Whilst Radiochemistry specializes in 14C GMP 

radiolabelling, Selcia Discovery provides integrated small molecule drug discovery to pharmaceutical and biotech 

clients. Besides general medicinal chemistry and biology capabilities applicable across all target classes, Selcia 

Discovery has a particular strength in three unique and highly synergistic technologies: (1) medicinal chemistry 

on complex natural products, (2) capillary electrophoresis -based fragment and natural product screening, (3) 

peptidyl-prolyl isomerase targets (cyclophilins, FKBPs, Pin1, together called PPIases). Whilst relatively neglected 

by pharmaceutical companies in the past, understanding of the involvement of PPIases in many diseases is 

currently emerging. All PPIase inhibitors presently in clinical use or in development are natural products, natural 

product derivatives or have structures inspired by natural products. 

The combination of these technologies has enabled Selcia to deliver several clinical PPIase inhibitors to 

clients, but has also generated IP for Selcia, which was recently demerged into a new company, Mitopharm 

Ltd. Mitopharm is in advanced license negotiations for a breakthrough drug in the field of acute and chronic 

neurodegenerative diseases. Other applications in the fields of chronic inflammatory diseases, oncology, COPD, 

and virus infections will be developed by Mitopharm either via investment or via joint R&D programs with 

pharmaceutical companies. 

MANAGEMENT 

Simon Saxby, CEO 

Dr Clive Cornell, COO 

Simon Bury, Business Development Director – Discovery 



SPEAKERS 


ORGANISERS

CONTACT 

Richard Jones 


ADDRESS 

Shield Therapeutics, 

Rotterdam House, 

116 Quayside, 

Newcastle upon Tyne 

NE1 3DY 

TELEPHONE 

+44 (0) 191 206 4046 

FAX 

+44 (0) 870 458 6523 

EMAIL 

info@shieldtherapeutics.com 

YEAR FOUNDED 

2008 

Shield Therapeutics 

www.shieldtherapeutics.com 


Shield Therapeutics, founded in 2008, is an independent specialty pharmaceutical company focused on the 

development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address 

areas of high unmet medical need. Shield is currently conducting two global pivotal Phase 3 studies of its lead 

asset, ST10, for the treatment of iron deficiency anaemia associated with Ulcerative Colitis and Crohn’s disease 

and is now also commencing a Phase 3 study of ST10 for the treatment of iron deficiency anaemia in patients 

with chronic kidney disease. 

MANAGEMENT 

Carl Sterritt, CEO 

Richard Jones, CFO 



SPEAKERS 


ORGANISERS

CONTACTS 

Dr Raúl Insa 


Dra Nuria Gavaldá 

R&R Manager 

ADDRESS 

Barcelona Science Park 

Baldiri Reixac, 4 

08028- Barcelona 

Spain 

TELEPHONE 

+34 93 402 0150 

+34 69 062 3263 

FAX 

+34 93 403 4510 

EMAIL 

insa@sombiotech.com 

YEAR FOUNDED 

2006 

SOM Biotech 

www.sombiotech.com 


Sources of Financing 

Founders: €109.000 

FFFs: €261.000 

VC firm: €100.000 

Institutional: €500.000 

Grants & loans: 

Investment in R&D 

€1.392.600 

2010 €201.000 

2011 €653.000 

2012 (expected) €800.000 

Funding capital required: €10.000.000 

Funding application: To secure the two most advanced products to Phase IIa p.o.c. in humans. 

Expected sales: > €60Mill in 2015 


SOM Biotech has developed a proprietary Drug Repurposing technology platform for discovery of new 

therapeutic indications for given drugs, which we are offering to partners for expanding their drug pipeline. 

During the last 34 months we have validated 41 new indications, with 18 positive hits (43%), of which 3 cover 

clear medical need indications: 

SOM0777 for the treatment of Glioma, already licensed to Argon Pharma and Draconis Pharma. 

SOM0226 for the treatment of TTR-Amyloidosis. Orphan Disease. Phase II planned for 1Q 2013. 

SOM0606 for the topical treatment of Psoriasis, in preclinical development. Phase II expected for 4Q 2013. 

25 more repurposing programs per year are running to file the advanced company pipeline. 

MANAGEMENT 

Raúl Insa, MD, PhD, MBA., Chief Executive Officer 

Ignasi Belda, PhD., Founder & Member of the Board 

Ramon Morera, BS, MBA., Part-time Chief Financial Officer 

Joaquim Trias, PhD., Advisor & Member of the Board 

Núria Gavaldà, PhD., R&D Manager 

Núria Reig, PhD., IP & Project Coordinator 

Hermann Mucke, PhD., Member of the Board of Advisors 



SPEAKERS 


ORGANISERS

ADDRESS 

Am Klopferspitz 19 

82152 Martinsried/Munich 

TELEPHONE 

+49 30 90 50 68-0 

FAX 

+49 30 90 60 68-68 

EMAIL 

info@suppremol.com 

YEAR FOUNDED 

2002 

Suppremol 

www.suppremol.com 


Delivering novel therapeutics for the treatment of autoimmune diseases 

SuppreMol, a privately held biopharmaceutical Company, is developing novel proteins to treat autoimmune 

diseases. SuppreMol has developed a novel therapeutic concept for the treatment of autoimmune diseases that 

relies on naturally produced Fc gamma receptors (FcgRs). The Company was founded in 2002 as a spin-off from 

the Max Planck Institute of Biochemistry. 

The Company is developing SM101 for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic 

Lupus Erythematosus (SLE) in Phase II clinical trials. SM101 is designed to be a specific, early onset, long lasting 

and well tolerated treatment for autoimmune diseases such as ITP, SLE, Rheumatoid Arthritis (RA) and Multiple 

Sclerosis (MS). 

Further building its platform of selective immunoregulators, SuppreMol is working on antibody programs 

targeting Fc receptors and other immunomodulatory molecules for alternative treatment strategies in 

autoimmune conditions. 

MANAGEMENT 

Prof Dr Peter Buckel, CEO 

Dr Robert Phelps, Head of BD and Licensing 

Dr Peter Sondermann, CSO 

Sascha Tillmanns, Medical Director 



SPEAKERS 


ORGANISERS

CONTACT 

Dr Johanna Holldack, MD 


ADDRESS 

TELORMEDIX SA 

Via della Posta 10 

CH-6934 Bioggio 

Switzerland 

TELEPHONE 

+41 (0)91 610 7000 

FAX 

+41 (0)91 610 7031 

EMAIL 

Telormedix@telormedix.com 

YEAR FOUNDED 

2007 

Telormedix 

www.telomedix.com 


Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune 

system in treating autoimmune diseases and cancer. Telormedix is particularly interested in the role of Toll-like 

Receptor 7 (TLR7) for the topical treatment of cancer. 

The Company’s lead product, TMX-101, is currently in a Phase I/II clinical trial for the treatment of Non- 

Muscle Invasive Bladder Cancer (NMIBC) and has showed a good safety profile in humans. TMX-101 is a new 

formulation of a clinically-active small molecule compound with a known and favourable safety profile and a 

specific immunotherapeutic target. Telormedix has optimized TMX-101 specifically for the localised treatment of 

bladder cancer, the fifth most prevalent cancer and a disease of significant unmet medical need. TMX-101 will 

be the first targeted therapy dedicated to bladder cancer and the first to modulate the innate immune system for 

this indication. 

The second product, TMX-202, is a small molecule for the topical treatment of skin and bladder cancers that 

has already provided significant preclinical results. Within the TMX-20X series, the Company also has another 

product called TMX-201, which is being developed for use as a vaccine adjuvant. Proof of concept has recently 

been established in relevant animal models. An additional product, TMX-302, is part of a pipeline programme 

targeting autoimmune diseases. 

MANAGEMENT 

Johanna Holldack, MD, CEO 

Roberto Maj, PharmD, Founder/Head of Drug Development 

Alcide Barberis, PhD, Head of Research and Collaborations 

Filippo Riva, MBA, CFO 

Raffaella Pozzi, PharmD, Head of Clinical Operations 

Nadia Passini, PhD, Project Management Director 



SPEAKERS 


ORGANISERS

CONTACT 

Curt Bilby, PhD 

President and CEO 

ADDRESS 

7000 North MoPac Expressway 

2nd Floor 

Austin, TX 78731 

TELEPHONE 

512 514 6760 

FAX 

512 287 4241 

EMAIL 

cbilby@terapio.com 

YEAR FOUNDED 

2006 

Terapio Corporation 

www.terapio.com 


$6.7M Series A 

$1M seed capital 

$3.6M in federal funds 

Terapio is seeking a lead or syndicate investors to participate with Santé Ventures in Terapio’s Series B financing. 

Terapio plans at least $10M in Series B financing where Santé Ventures, the Series A lead investor, will 

participate on a pro rata basis. The use of proceeds for Series B will be primarily used for drug development, 

preclinical and nonclinical programs, and regulatory activities required to fund the company to the valuation 

inflection point associated with completing the pivotal nonhuman primate efficacy trial under the FDA Animal 

Rule. 


Launched in 2007 and backed by Santé Ventures, Terapio is a biopharmaceutical company developing clinical 

applications based on the naturally-occurring RLIP76 protein. RLIP76 is a membrane-associated cellular 

transport protein that is an integral part of the cell’s normal process of removing toxic metabolites formed by 

oxidative insults. However, in cases of elevated oxidative stress, such as occurs with exposure to radiation and 

chemical toxins, the endogenous RLIP76 system can be overwhelmed, leading to cell death. Supplementing 

cellular levels of RLIP76 through exogenous administration of Terapio’s liposomal formulation of the RLIP76 

protein promotes protection by relieving this cellular stress and allows recovery by tissue cells. This mechanism 

of action has broad applicability to a variety of additional clinical indications, including the treatment of the toxic 

side effects of therapeutic radiation and chemotherapy in oncology patients and CNS diseases – a key part of 

Terapio’s commercial pipeline. 

For biodefense applications, Terapio has accumulated a large body of data demonstrating that the protein is 

effective in protecting and rescuing animals exposed to otherwise lethal exposures of whole body radiation. 

Therefore, the company is pursuing the prevention and treatment of Acute Radiation Syndrome (ARS) as a lead 

indication. No effective countermeasures for ARS exist today, making this a highly unmet need. 

Terapio has performed multiple 30-day survival studies with the RLIP76 protein in animal models of ARS and 

demonstrated that administered either before and/or after exposure to lethal doses of radiation results in greater 

than 90% survival of treated animals, versus 20% survival of controls. 

MANAGEMENT 

Curt Bilby, PhD, President and CEO 

Casey Cunningham, MD, co-founder and Chief Medical Officer 

Henry Hebel, Vice President of Drug Development 

Elizabeth Leffel, PhD, MPH, Vice President of Preclinical and Nonclinical Programs 



SPEAKERS 


ORGANISERS

CONTACT 

Eduardo Bravo (speaker) 

Managing Director and 


ADDRESS 

TiGenix NV 

Haasrode Researchpark 1724 

Romeinse straat 12 bus 2 

3001 Leuven 

Belgium 

TELEPHONE 

+32 16 396 060 

FAX 

+32 16 397 970 

EMAIL 

eduardo.bravo@tigenix.com 

YEAR FOUNDED 

2000 

TiGenix NV 

www.tigenix.com 


TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and an 

advanced clinical stage pipeline of adult stem cell programs. 

The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the first and only approved 

cell-based product in Europe. The product has received full national reimbursement in Belgium and the 

Netherlands and is already being commercialized in 5 European countries. 

TiGenix’s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem 

cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, 

they are being developed in close consultation with the European Medicines Agency. The company has initiated a 

Phase III clinical trial in complex perianal fistulas in patients with Crohn’s disease, has concluded recruitment in 

a Phase IIa trial in rheumatoid arthritis, and successfully concluded a Phase I trial to investigate the potential of 

intra-lymphatic administration of eASCs for autoimmune disorders. 

TiGenix is based out of Leuven (Belgium), and has operations in Madrid (Spain), and Sittard-Geleen (the 

Netherlands). 

MANAGEMENT 

Eduardo Bravo, Managing Director and Chief Executive Officer (CEO). 

Gil Beyen BVBA, Managing Director and Chief Business Officer (CBO) 

Claudia D’Augusta, Chief Financial Officer (CFO) 

Wilfried Dalemans, Chief Technical Officer (CTO) 



SPEAKERS 


ORGANISERS

CONTACT 

Willem van Weperen 


ADDRESS 

Niels Bohrweg 11 

2333 CA Leiden 


TELEPHONE 

+31 71 332 2252 

FAX 

+31 84 831 3409 

EMAIL 

vanweperen@tobbb.com 

YEAR FOUNDED 

2004 

to-BBB technologies 

www.tobbb.com 


Seed 2004-2006: ±€1M 

Series-A 2007: ±€4M 

Series-B 2011: ±€6M 

Accum grants/credits: ±€5M 


to-BBB is a clinical stage blood-brain barrier company in the Netherlands with a proprietary technology 

(G-Technology®) to safely enhance brain drug delivery. The company is performing a phase I/II study with lead 

product 2B3-101, which focuses on brain metastases of Breast Cancer and glioblastoma. 

to-BBB is also developing 2B3-201 for neuroinflammation in MS, neuropathic pain and ALS, which will be in the 

clinic in 2013. Furthermore, the company is exploring additional product propositions in stroke, Alzheimer’s and 

orphan brain diseases. 

The business model of to-BBB is based on partnerships with pharma/biotech companies. The company has 

entered into several research collaborations with academic and pharma partners on brain drug delivery. 

In 2011 to-BBB completed a series-B round of ±€6M and over the years the company generated substantial 

non-dilutive funding. The company expects to be cash positive based on license income after a last equity round 

in 2013. 

MANAGEMENT 

Willem van Weperen, MSc, MBA, Chief Executive Officer 

Pieter Gaillard, PhD, Chief Scientific Officer/founder: 

Fredrik Lonnqvist, MD, PhD, Assoc. Prof., Chief Medical Officer 



SPEAKERS 


ORGANISERS

CONTACTS 

Piers Morgan 


Aicha Diba 

Legal Affairs 

Marsha Lemmers 

Administrative Assistant 

ADDRESS 

Meibergdreef 61 

1105 BA Amsterdam 


TELEPHONE 

+31 (0) 20 5667509 

Aicha Diba 

+31 (0) 20 5668014 

Marsha Lemmers 

+31 (0) 20 5662402 

FAX 

+31 (0) 20 5667509 

EMAIL 

p.morgan@uniqure.com 

a.diba@uniqure.com 

m.lemmers@uniqure.com 

YEAR FOUNDED 

04.05.2012 

uniQure 

www.uniqure.com 


Amounts in € x 1,000 

31.12.2011* 31.12.2010* 

Total other income 2,192 1,448 

Total operating costs (19,038) (20,517) 

Operating result (17,300) (19,069) 

Result for year (17,300) (19,118) 

Cash 3,100* 17,859 

*Adjusted pro forma 


uniQure is a world leader in the research and early development of human gene based therapies. uniQure 

has a product pipeline of several gene therapies in development: hemophilia B, acute intermittent porphyria, 

Parkinson’s disease and Sanfilippo. uniQure is located on the premises of the Academic Medical Center, 

University of Amsterdam, employs a staff with extensive scientific and industry experience, is the world leader for 

manufacturing of AAV-based products on a commercial scale, meeting cGMP requirements, and has extensive 

experience in the regulatory processes for gene therapies. 

MANAGEMENT 

Joern Aldag, CEO 

Carlos Camozzi, CMO 

Piers Morgan, CFO 

Harald Petry, VP, R&D 

Hans Preusting, VP, Bus Dev 

Piers Morgan, CFO 

Mr. Morgan joined AMT in December 2009 as Chief Financial Officer. He has over ten years experience as CFO with 

biotechnology companies, including Phytopharm plc, BioAlliance Pharma SA, and Arrow Therapeutics Ltd. Prior to this period, 

he gained ten years experience in investment banking, working in Mergers & Acquisitions, and Equity Capital Markets with 

Close Brothers and Ernst & Young Corporate Finance. Currently he is Non-executive Chairman of Trino Therapeutics Ltd. He 

qualified as a Chartered Accountant in London with PricewaterhouseCoopers 



SPEAKERS 


ORGANISERS

CONTACT 

Vincent Lefaiconnier 

Chief Commercial Officer 

ADDRESS 

Vexim 

75 rue Saint Jean 

31130 Balma 

France 

TELEPHONE 

+33 4 61 48 48 38 

FAX 

+33 5 61 48 95 19 

EMAIL 

v.lefauconnier@vexim.fr 

YEAR FOUNDED 

2006 

Vexim 

www.vexim.fr 


Half-year 2012 sales: €1.1m (+93% over 12 months) 

Full-year 2011 sales: €1.2m 

2011 net income: -€5.1m 


Based in Balma, near Toulouse (France), Vexim is a medical device specialist created in February 2006. The 

company has specialised in the creation and marketing of mini-invasive solutions for treating spinal pathologies. 

Benefitting from the financial support of its longstanding shareholders, Truffle Capital and Banexi Venture, and 

from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable 

of repairing a deformed or fractured vertebra and correcting the anatomy of the spinal column. The Company 

currently has 35 staff. It has its own sales teams in France, Germany and Italy, as well as distributors in Spain, 

Portugal, Italy, Turkey, Argentina and South Africa. The company’s 2011 sales amounted to €1.2m and its 2011 

gross margin was 58.3%. Vexim was successfully listed on NYSE Alternext in May 2012, raising €11m. The 

company’s 1st half 2012 sales achieved €1.1m, almost equaling the whole 2011 financial year performance. 

MANAGEMENT 

Vincent Gardès, Chief Executive Officer 

Vincent Lefauconnier, Chief Commercial Officer 



SPEAKERS 


ORGANISERS

CONTACT 

Jakob Knudsen 


ADDRESS 

Blokken 45 

3460 Birkerød 

Denmark 

TELEPHONE 

+45 22 261 355 

EMAIL 

jk@virogates.com 

YEAR FOUNDED 

2001 

Virogates 

www.virogates.com 


ViroGates A/S is committed to improve the screening and monitoring of patients in a hospital setting and healthy 

individuals in risk of developing life style related diseases. 

ViroGates has developed an ELISA (enzyme-linked immunosorbent assay) based suPAR (soluble urokinase 

Plasminogen Activator Receptor) test that, in clinical settings, has shown to predict mortality and disease 

progression. More than 120.000 patients have to date been tested with suPARnostic® and studies have been 

reported in more than 80 peer reviewed articles. ViroGates has recently (2012) launched its suPARnostic Quick 

Triage test based on lateral flow technology. The Quick Triage products provide results in 20 minutes. 

ViroGates product portfolio consists of three fully developed products with CE-IVD approvals. The ELISA Standard 

kit marketed for clinical research and the ELISA Flex kit marketed for routine use at central laboratories in 

addition to the ELISA products, ViroGates has recently (2012) launched its suPARnostic Quick Triage test based 

on lateral flow technology. The Quick Triage product provide results in 20 minutes. 

Sales and marketing is carried out through ViroGates’ network of distributors. ViroGates has more than 20 

distribution partners worldwide 

MANAGEMENT 

Jakob Knudsen, Chief Executive Officer 



SPEAKERS 


ORGANISERS

CONTACT 

Dr Arin Ghasparian 


ADDRESS 

Virometix AG 

Winterthurerstrasse 190 

8057 Zurich 

Switzerland 

TELEPHONE 

+41 44 63 56117 

FAX 

+41 44 63 56833 

EMAIL 

arin.ghasparian@virometix.com 

YEAR FOUNDED 

2006 

Virometix AG 

www.virometix.com 


Virometix is a privately held young innovative Swiss Biotech company developing a new class of vaccines, 

which should overcome limitations of current biological vaccines in terms of safety, efficacy, speed, stability and 

manufacturing cost. Virometix Synthetic Virus-Like Nanoparticle (SVLP) technology platform offers the following 

value propositions: 

Safety. Virometix SVLP-based vaccines avoid the use of life pathogens and the safety concerns associated with 

the biological manufacturing processes used for conventional vaccines. 

Quality. SVLPs are based on a proprietary lipopeptide self-assembly process that leads to atomically defined 

nanoparticles with a constant size and number of lipopeptide monomers per particle, which increases the 

specificity and quality of the elicited immune response and assures lot-to-lot consistency. 

Efficacy. SVLPs efficiently deliver antigens to antigen presenting cells for optimal B- and T-cell responses and 

induce antibodies that bind with very high affinity to the native target antigen. 

Convenience. SVLPs do not require sonication, refolding, extrusion or similar processes. SVLPs can be prepared 

by simply dissolving freeze-dried lipopeptide monomers in a buffer suitable for injection shortly before use. 

Virometix develops vaccines for infectious diseases and cancer. Two vaccines are in early preclinical 

development. Virometix offers collaborative research and licensing partnerships for selected vaccines and 

disease areas. 

MANAGEMENT 

Arin Ghasparian, CEO and co-founder 

John A. Robinson, CSO and co-founder 



SPEAKERS 


ORGANISERS

CONTACTS 

Dr Sonja Reingruber 


Prof Dr Peter Petzelbauer (CSO) 


ADDRESS 

Xiber Science GmbH 

Perlhofgasse 2/1 

2372 Giesshuebl 

Austria 

TELEPHONE 

+43 699 170 54086 

Prof Dr Peter Petzelbauer (CSO) 

+43 699 170 54087 

EMAIL 

s.reingruber@xiberscience.com 

peter.petzelbauer 

@meduniwien.ac.at 

YEAR FOUNDED 

December 2009 

Xiber Science 

www.xiberscience.com 


Financial need: ~ 4 Mio € 

Shareholder Investment: 100 k € 

Public grants approved: 570 k € 

Public grants pending: 1,3 Mio € 

LOI over VC–investment: 1 Mio € 


Xiber is a biopharmaceutical start–up company. Xiber develops new peptide drugs to improve outcome of critical 

care & transplant patients. Xiber’s peptide drugs preserve organ function & prevent Organ failure. Xiber will enter 

market by two niche indications: Acute Lung Injury & Lung Transplantation – with a total market volume of 630 

Mio. USD. 

In 2015 Xiber will complete the preclinical development for both indications. A phase I clinical trial will start with 

the beginning of 2016. 

Xiber’ developmental program is driven by a small core team of highly qualified executives, supported by network 

of academic collaborators and contract research partners in a virtual development environment. 

After completion of the phase I trial Xiber aims to partner with an appropriate Pharma or Biotech company. 

Xiber is a spin-off of the Medical University of Vienna. The majority of the shares is owned by the founders S. 

Reingruber & P. Petzelbauer. The University holds a non-controlling interest and rewards its shares by providing 

cooperation, infrastructure, facility services and management support. 

MANAGEMENT 

Sonja Reingruber, PhD, CEO 

Molecular Biologist Certified for Regulatory Affairs & Clinical Trial Management; over 10 years experience in Biotech from 

start-up to licence deal. Expert for acquisition of public grants & funds 

Peter Petzelbauer, MD, CSO 

Prof. of Microvascular Research MedUni Vienna; over 10 years experience in Biotech & translational research; international 

scientific network, holder of 10 patents 

Michael Hoffmann, Ms, CFO 

Business Economist; more than 10 years in Biotech management positions; Expert for early stage financing. 



SPEAKERS 


ORGANISERS

Supporting Organisations 

BioTOP Berlin-Brandenburg 

www.biotop.de 

BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning biotechnology 

in the German capital region. 

It is our objective to coordinate all regional activities in biotechnology by networking with all key players and to 

initiate specific projects in order to turn Berlin-Brandenburg into a globally leading life science cluster. 

The services provided by BioTOP include: 

• Technology transfer science - industry 

• Initiation and support of networks 

• Support for technology-oriented start-ups 

• Funding support for innovative projects 

• Providing information on biotechnology 

• Building and coordination of scientific and interdisciplinary networks 

• Establishing contacts between experts from all disciplines 

• Design and organization of events 

• Public relations work for the biotech region Berlin-Brandenburg 

For more information, including a database with comprehensive profiles of all companies and scientific work 

groups, please visit our website at www.biotop.de. 

Dr. Kai Bindseil 

BioTOP Berlin-Brandenburg 

Fasanenstr. 85 

10623 Berlin - Germany 

Tel: +49 30 318 622 11 

Fax + 49 30 318 622 22 



SPEAKERS 


ORGANISERS


Citigate Dewe Rogerson 

www.citigatedr.co.uk 

Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and 

corporate communications across the UK, Europe, North America and Asia. 

Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector 

and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic 

science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting 

from the company’s overall strength and from the cross-fertilisation of ideas across sectors. 

The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies 

at all stages in development. As well as core skills in financial calendar work, transactions support, financial 

PR and media relations, the team has extensive experience in branding, design and new media consultancy. 

Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging 

businesses in the UK, France, Germany, the Netherlands, and Scandinavia. 

Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public 

and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; 

METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera 

Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China 

MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - 

£35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million). 

Citigate Dewe Rogerson 

3 London Wall Buildings 

London Wall 

London EC2M 5SY 

Tel: +44 (0)-207-638-9571 



SPEAKERS 


ORGANISERS

Life Sciences 


College Hill 

www.collegehill.com/lifesciences 

College Hill Life Sciences provides a full service communications consultancy focused on science-based 

sectors. Within the life science field we have established a leadership position by working in partnership with our 

clients to deliver high quality communications that build corporate value and promote leading edge products, 

technologies and services). 

London 

Sue Charles 

The Registry, Royal Mint Court, London EC3N 4QN, UK 

T: +44 (0)20 7457 2020 F: +44 (0)20 7866 7900 

Email: lsinfo@collegehill.com 

Manchester 

Dr Eileen Paul / Chris Fisher 

Meadowside, Mountbatten Way, Congleton, CW12 1DN, UK 

Tel: +44 (0)1260 296500 Fax: +44 (0)1260 296501 


Munich 

Dr Douglas Pretsell 

Augustenstraße 79, 80333 Munich, Germany 

Tel: +49 (0)89 57 00 18 06 Fax: +49 (0)89 52 38 80 06 


San Francisco 

Erik Clausen 

201 Spear Street, Suite 1100, San Francisco CA 94105, USA 

Tel: +1 (415) 230 5385 




SPEAKERS 


ORGANISERS


Life Science Austria www.lifescienceaustria.at 

Life Science Austria - LISA - is a program acting as a hub for people from all over the 

world who are interested in the life science sector in Austria. Together with its associates 

in the Austrian regions, LISA is the first point of contact for anyone with questions about 

scientific collaboration, setting up an operation, or funding and sponsoring projects and 

businesses in Austria. 

Working with all existing life science clusters in the Austrian regions – ecoplus, human. 

technology.styria, Life Science Austria Vienna Region, Health Technology Cluster, and 

Life Science Cluster Tirol - LISA is able to build on their expertise and services. The 

aims of LISA and its partners are: contribute to the success of life science enterprises in 

Austria by helping to introduce scientific discoveries to the market, assist in the search 

for funding, and provide general business consultancy and support to ensure healthy 

commercial development. 

Austria Wirtschaftsservice GesmbH (aws), is responsible for running this program on 

behalf of the Austrian Federal Ministry of Economics, Family and Youth (BMWFJ). 

Austria Wirtschaftsservice Gesellschaft mbH, Ungargasse 37, 1030 Wien, Austria 

Tel.: +43 (1) 501 75 - 0 • Fax: +43 (1) 501 75 - 900 • Email: office@awsg.at 



SPEAKERS 


ORGANISERS


Novartis 

www.novartis.com 

Novartis provides healthcare solutions that address the evolving needs of patients and 

societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet 

these needs: innovative medicines, eye care products, cost-saving generic pharmaceuticals, 

consumer health products, preventive vaccines and diagnostic tools. Novartis is the only 

company with leading positions in each of these areas. 

Novartis International AG 

CH-4002 Basel 

Switzerland 

Tel: +41 61 324 11 11 

Fax: +41 61 324 80 01 



SPEAKERS 


ORGANISERS


Swiss Biotech Association www.swissbiotech.org 

SwissBiotech – One Nation – One Biotech Cluster 

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, 

Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with 

the SWX Swiss Exchange which holds a leading position in terms of life-science listings 

and services. 

The National Industry Association named Swiss Biotech Association Represents more 

than 150 companies to date and acts as the operational arm for the marketing alliance. 

Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles 

the biotech industry with its key research institutions and companies. 

Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top 

biotech locations in the world. This will be achieved by presenting a comprehensive 

picture of the drivers of biotechnology including research, education, economics, finance 

and industry. The bases for success in biotechnology are the critical mass of research 

institutes and accelerated technology transfer. The early integration of industry and 

well-trained workforce is another critical success factor for rapid economic growth. More 

than 40 technology parks throughout the country support the increasingly important and 

successful TechTransfer process. 

Further inquiries: 

SwissBiotech, Executive Office 

Tel. +41 (0)44 455 56 78 

info@swissbiotech.org 



SPEAKERS 


ORGANISERS


Tiberend Strategic Advisors, Inc. 

www.tiberendstrategicadvisors.com 

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for 

life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and 

private emerging growth companies. 

1. To enhance valuation 

2. To build visibility for partnerships and strategic alliances 

Tiberend Strategic Advisors, Inc. 

35 W. 35th Street, 5th Floor, 

New York, NY 10001-2205 

Tel: 212.827.0020 

Fax: 212.827.0028 Fax 



SPEAKERS 


ORGANISERS


Torreya Partners LLC www.torreyapartners.com 

Torreya Partners LLC is a leading boutique advisory firm that provides strategic advice 

and assistance with Mergers & Acquisitions, Partnering and Financings to life science 

companies worldwide. Torreya Partners provides the long-term thinking and objective 

advice required for life science companies to create lasting value. We take great pride 

in handling complex financial and strategic matters for some of the most sophisticated 

private and public life science companies in the world. Our reputation has been built on 

quality advice, excellence in deal execution and good outcomes for our clients. We bring 

the caliber of people and quality of relationships found in some of the largest investment 

banks along with the attentive, detailed service you expect from a boutique advisory firm. 

Torreya Partners has offices located in New York, Philadelphia and San Francisco. 



SPEAKERS 


ORGANISERS

Organisers 

Sachs Associates 


Sachs Associates Ltd is a London-based company, which organises and produces securities and emerging 

markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated 

to the highest quality standards in conferencing and, as a result, produces only a limited number of events each 

year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, 

and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on 

the practical benefi ts accruing from conference participation, the exchange of ideas and information, and the 

facilitating of business transactions. 

The benefits of conference participation with Sachs Associates may be summarised as follows: 

Multimedia Exposure 

Sachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well 

focused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out 

through video streaming and extensive events coverage through major international financial news agencies, 

including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long established 

relationships with other financial press organisations globally, which allow further effective distribution on 

behalf of its clients. 

Eminent Speakers 

Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of 

the most eminent speakers from the public and private sectors. Through its reputation and its long-established 

local relationships, the Company has attracted the very senior political and economic personalities as speakers 

at its events. 

Sponsorship and Marketing Opportunities for forthcoming events 

Sachs Associates has developed an extensive knowledge of the key individuals operating within the European 

and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the 

forefront of the industry and provides a powerful tool by which to increase the position of your company in this 

market. 

Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients. 

All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out 

of attending our industry driven events. 

The following sponsorship and marketing opportunities are available at future conferences: 

• Conference Sponsor – including workshops and social events 

• Exhibition stands 

• Distribution of Promotional Material 

If your company is interested in exhibiting or sponsorship opportunities please call 

Zoe Harris on +44 203 463 4890. 


SPEAKERS 


ORGANISERS

B I O T E C H I N E U R O P E I N V E S T O R F O R U M 

We look forward to seeing you at: 

6th Annual 

EUROPEAN LIFE SCIENCE CEO FORUM 

PARTNERING & INVESTING in 

Biotech & Pharma Industry 

5th-6th March 2013 • Zurich 

Annual 

Cancer Bio Partnering Forum 

Promoting Public & Private Sector, Collaboration & 

Investment in Drug Development 

21st-22nd May 2013 • Boston 

13th Annual 

BIOTECH IN EUROPE FORUM 

30th September -1st October 2013 • Zurich 

1st Floor Holborn Gate 

330 High Holborn 

London 

WC1V 7QT 

Tel: +44 203 463 4890 

Fax: +44 (0)20 7405 4411 



SPEAKERS 


ORGANISERS

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?